[["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP (TAR DNA-binding protein) gene encodes TDP-43, a transcription factor involved in RNA processing and stress granule formation. Mutations in TARDBP are primarily associated with frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). In particular, TARDBP mutations contribute to the pathological hallmark of ALS, where TDP-43 misfolds and accumulates as insoluble inclusions in motor neurons, leading to neuronal dysfunction and death. This accumulation is also observed in FTLD, particularly in cases with TDP-43 proteinopathy. The pathway includes components of complex I of the mitochondrial respiratory chain, suggesting a link between mitochondrial dysfunction and neurodegeneration. Mutations in TARDBP disrupt normal protein homeostasis, leading to neurodegeneration. \\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP (TAR DNA Binding Protein) gene encodes TDP-43, a protein critical for RNA processing and stress granule dynamics. Mutations in TARDBP are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive degeneration of motor neurons. TDP-43 pathology, including its mislocalization and aggregation, is a hallmark of ALS, particularly in sporadic and some familial cases. The pathway involving TARDBP and components of complex I, such as ND1-ND6 and NDUFS proteins, suggests a link to mitochondrial function and energy metabolism, which are impaired in ALS. These disruptions may contribute to neuronal death through oxidative stress and impaired cellular respiration. Thus, TARDBP mutations significantly contribute to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes TDP-43, a protein involved in RNA processing and stress granule dynamics. Mutations in TARDBP are primarily associated with **frontotemporal lobar degeneration (FTLD)**, particularly **FTLD with motor neuron disease (FTLD-MND)**, and are also linked to **amyotrophic lateral sclerosis (ALS)**. These mutations lead to the mislocalization and aggregation of TDP-43, disrupting normal cellular functions and contributing to neuronal death. This pathway includes components of complex I, suggesting a potential link between mitochondrial dysfunction and neurodegeneration. The accumulation of pathological TDP-43 is a hallmark of several neurodegenerative diseases, emphasizing its critical role in maintaining neuronal health. The involvement of multiple subunits of complex I highlights the interplay between mitochondrial function and protein homeostasis in disease pathogenesis. \\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele plays a critical role in the von Hippel-Lindau (VHL) tumor suppressor pathway. When functional, VHL inhibits the formation of the ELOB-ELOC-CUL2-RBX1 ubiquitin ligase complex, which targets HIF1A for degradation under normoxic conditions. In the absence of functional VHL, this complex is inactivated, leading to stabilization of HIF1A. HIF1A, in complex with ARNT, drives the expression of genes like VEGFA, SLC2A1, PDGFB, and TGFB, promoting angiogenesis, cell survival, and tissue remodeling. This pathway dysregulation is central to the development of VHL disease, a hereditary syndrome characterized by the formation of benign and malignant tumors in multiple organs, including hemangiomas, renal cell carcinomas, and pheochromocytomas. The hallmark of this disease is the loss of VHL function, leading to constitutive activation of the HIF pathway and uncontrolled cell growth. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 network, plays a critical role in ubiquitin-mediated protein degradation, particularly targeting HIF1A. Under normoxic conditions, VHL promotes the ubiquitination and proteasomal degradation of HIF1A, preventing its accumulation. When VHL is dysfunctional, HIF1A stabilizes and drives the expression of downstream genes like VEGFA, SLC2A1, PDGFB, and TGFs, which promote angiogenesis, cell survival, and epithelial-mesenchymal transition. This pathway is central to hypoxia response and tumor progression. Mutations in VHL lead to the accumulation of HIF1A, contributing to the development of clear cell renal cell carcinoma (ccRCC). The VHL pathway's disruption is a hallmark of this disease. \n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele's biological effect is central to the regulation of the hypoxia-inducible factor (HIF) pathway. VHL, as part of an E3 ubiquitin ligase complex with RBX1, ELOC, ELOB, and CUL2, targets HIF1A for degradation under normoxic conditions. Loss-of-function mutations in VHL disrupt this degradation, leading to HIF1A stabilization and activation of downstream genes like VEGFA, SLC2A1, PDGFB, TGFB, and TGFA. This results in aberrant angiogenesis, cell survival, and proliferation. The accumulation of HIF1A promotes tumor growth under hypoxic conditions, contributing to the hallmark features of clear cell renal cell carcinoma (ccRCC). The pathway's dysfunction is a key driver in this disease. \n\n\\boxed{Clear cell renal cell carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that inhibits the activity of MDM2, an E3 ubiquitin ligase that promotes the degradation of TP53. By suppressing MDM2, CDKN2A stabilizes TP53, which then upregulates CDKN1A. CDKN1A, along with cyclins D (CCND1-3) and CDK4/6, inhibits the phosphorylation of RB1, preventing the release of E2F transcription factors. This pathway is crucial for cell cycle regulation and apoptosis. Mutations in CDKN2A lead to loss of TP53 regulation, promoting uncontrolled cell proliferation. This contributes to the development of melanoma and other cancers. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that inhibits cyclin-dependent kinases, including CDK4 and CDK6, and also interacts with MDM2 to negatively regulate TP53. In the given pathway, CDKN2A's inhibitory effect on MDM2 reduces the degradation of TP53, allowing it to accumulate and induce cell cycle arrest. This pathway is critical for suppressing cell proliferation and preventing tumor formation. Mutations or inactivation of CDKN2A disrupt this regulatory mechanism, leading to unchecked cell division and increased risk of cancer. CDKN2A mutations are strongly associated with melanoma and pancreatic neuroendocrine tumors. These mutations are also linked to Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome. The loss of CDKN2A function contributes to the progression of these malignancies by impairing the tumor suppressor functions of TP53 and promoting uncontrolled cell growth. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in cell cycle regulation by inhibiting MDM2, thereby stabilizing TP53. This leads to increased expression of CDKN1A, which in turn inhibits the cyclin D-CDK4/6 complex, preventing phosphorylation of RB1. An unphosphorylated RB1 retains E2F transcription factors, suppressing the expression of genes involved in DNA replication and cell division. Mutations or inactivation of CDKN2A disrupt this regulatory network, leading to unchecked cell proliferation. This dysfunction is strongly associated with cellular transformation and tumor formation. CDKN2A mutations are a well-known contributor to various cancers, most notably melanoma and pancreatic adenocarcinoma. These mutations are also linked to the development of certain types of lymphomas and renal cell carcinomas. The loss of CDKN2A function is a key driver in the progression of these malignancies by impairing tumor suppression mechanisms.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid beta precursor protein (APP). The sequential activation of cholinergic receptors (CHRM1, CHRM3, CHRM5), GNAQ, phospholipase C beta isoforms (PLCB1-4), release of IP3, and subsequent calcium influx through ITPR channels and mitochondrial calcium uptake via MCU leads to the opening of the mitochondrial permeability transition pore (MPTP), resulting in the release of cytochrome c (CYCS). This pathway is central to neurodegenerative processes. Mutations in APP are well-documented in Alzheimer's disease, where the abnormal processing of APP leads to the accumulation of amyloid-beta, mitochondrial dysfunction, and neuronal death. Thus, this pathway directly contributes to the pathogenesis of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes a signaling cascade initiated by the Amyloid Beta Precursor Protein (APP), leading to the production of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChRs), and subsequent activation of GNAQ, PLCB, and IP3 pathways. This culminates in the release of calcium ions into the mitochondrial matrix via the mitochondrial calcium uniporter (MCU), which can trigger the mitochondrial permeability transition pore (MPTP) and release of cytochrome c (CYCS), promoting apoptosis. This pathway is closely associated with neurodegenerative processes. Mutations in APP and dysregulation of this pathway are strongly linked to **Alzheimer's disease**, where aberrant amyloid-beta accumulation and mitochondrial dysfunction contribute to neuronal death and cognitive decline. The involvement of multiple genes in this cascade highlights its central role in the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid beta precursor protein (APP). The pathway involves the production of amyloid-beta (Abeta), activation of muscarinic acetylcholine receptors (mAChR), downstream activation of GNAQ and phospholipase C beta (PLCB), leading to the release of intracellular calcium via IP3 receptors. This calcium influx triggers mitochondrial calcium uptake through the mitochondrial calcium uniporter (MCU), leading to the opening of the mitochondrial permeability transition pore (MPTP) and the release of cytochrome c (CYCS), contributing to apoptosis.\n\nThis pathway is central to the pathogenesis of Alzheimer's disease, where aberrant processing of APP leads to the accumulation of toxic Abeta peptides, mitochondrial dysfunction, and neuronal apoptosis. The involvement of multiple genes in this pathway underscores its role in neurodegeneration.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in regulating neuronal excitability by controlling the flow of potassium ions across cell membranes. Mutations in KCNC3 can disrupt this function, leading to abnormal electrical signaling in neurons. Specifically, alterations in KCNC3 have been implicated in neurodevelopmental and neurodegenerative disorders. One notable disease associated with KCNC3 is **Familial Hemiplegic Paroxysmal Headache (FHPH)**, a form of migraine with brainstem aura. These mutations often result in gain-of-function effects, causing hyperexcitability in neurons and contributing to the episodic neurological symptoms characteristic of this condition. \\boxed{Familial Hemiplegic Paroxysmal Headache}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in regulating neuronal excitability. Mutations in KCNC3 are associated with epilepsy, specifically frontal lobe epilepsy. These mutations can lead to hyperexcitability of neurons by disrupting normal potassium current, resulting in abnormal electrical activity in the brain. This disruption contributes to the development of seizure disorders. The allele's effect on ion homeostasis and neuronal firing thresholds directly links it to epilepsy. \\boxed{Epilepsy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in regulating neuronal excitability. Mutations in KCNC3 are associated with neurological disorders, particularly epilepsy. The altered function of these potassium channels disrupts normal electrical signaling in neurons, leading to hyperexcitability and seizure activity. This genetic variation has been linked to idiopathic generalized epilepsy, a common type of epilepsy characterized by generalized seizures without a known structural brain abnormality. The disruption of K+ homeostasis, as indicated by the pathway definition involving K+ and K+(extracellular), further supports its role in ion balance and neuronal stability. These genetic changes contribute to the pathophysiology of epilepsy by impairing the ability of neurons to repolarize after activation. \\boxed{Epilepsy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes a signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the release of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChR), and subsequent activation of GNAQ and phospholipase C (PLCB). This results in the production of IP3, which triggers the release of calcium from the endoplasmic reticulum, leading to mitochondrial calcium uptake via MCU. Excessive mitochondrial calcium can induce mitochondrial permeability transition pore (MPTP) opening, causing the release of cytochrome c (CYCS), a key event in apoptosis. This pathway is central to the pathophysiology of Alzheimer\u2019s disease, where abnormal APP processing and amyloid-beta accumulation lead to synaptic dysfunction, neuroinflammation, and neuronal death. The involvement of key genes such as APP, CHRM1, GNAQ, PLCB, ITPR, MCU, and CYCS underscores the role of this pathway in disease progression. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway begins with the amyloid beta precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). Abeta then activates muscarinic acetylcholine receptors (mAChR), leading to activation of GNAQ and subsequent PLCB-mediated production of IP3. IP3 triggers the release of calcium ions (Ca2+) from the endoplasmic reticulum via ITPR, and calcium influx through the mitochondrial calcium uniporter (MCU) leads to mitochondrial dysfunction. This results in the permeability transition pore (MPTP) opening, releasing cytochrome c (CYCS), which initiates apoptosis. This pathway is central to neurodegeneration. The accumulation of Abeta and subsequent mitochondrial dysfunction are key features of Alzheimer's disease. Therefore, this APP allele contributes to \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway begins with the amyloid beta precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). Abeta then activates muscarinic acetylcholine receptors (mAChR), leading to activation of GNAQ and subsequent production of IP3 via PLCB. IP3 releases calcium from the endoplasmic reticulum, which enters mitochondria through MCU, increasing mitochondrial calcium. This leads to the opening of the mitochondrial permeability transition pore (MPTP), causing release of cytochrome c (CYCS), a key mediator of apoptosis. This cascade is central to neurodegenerative processes. Mutations in APP or its downstream components are strongly associated with Alzheimer's disease, characterized by amyloid plaque formation, neuronal death, and cognitive decline. The accumulation of amyloid-beta and subsequent mitochondrial dysfunction play critical roles in disease progression.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the accumulation of toxic protein aggregates. This contributes to the pathogenesis of Spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3 suggests a role in calcium homeostasis and mitochondrial function, which are disrupted in neurodegenerative diseases. The interaction with ITPR1 and MCU indicates involvement in calcium signaling, which is critical for neuronal function. Dysregulation of these processes leads to neuronal death, consistent with the clinical features of SCA2. Thus, the ATXN3 allele contributes to Spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein quality control and degradation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This pathology is a hallmark of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive cerebellar dysfunction, leading to ataxia and motor coordination deficits. The pathway described involves calcium signaling and mitochondrial dysfunction, which are implicated in neuronal damage. The interaction of ATXN3 with ITPR1 and other components of the calcium signaling cascade suggests a role in maintaining calcium homeostasis, and its dysfunction contributes to neurodegeneration. The accumulation of mutant ATXN3 protein disrupts these processes, ultimately leading to cell death. Therefore, the biological effect of the ATXN3 allele is the contribution to spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein quality control and neurodegeneration. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the accumulation of misfolded proteins, disrupting cellular function and causing neuronal degeneration. This is the genetic basis for spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of coordination and motor control. In the given pathway, ATXN3 interacts with ITPR1 and is involved in calcium homeostasis, which is critical for neuronal function. Disruption of this pathway due to ATXN3 mutations impairs calcium regulation, contributing to mitochondrial dysfunction and apoptosis, hallmark features of SCA2. The disease is autosomal dominant, and the pathogenic mechanism involves protein misfolding and aggregation, leading to neurodegeneration. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-known to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway involving SOD1 and its downstream effectors, including ATF4 and DDIT3, is implicated in cellular stress responses, such as the unfolded protein response and oxidative stress. These processes are critical in neuronal health, and dysregulation contributes to the pathogenesis of ALS. Thus, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 pathway involves SOD1, which converts superoxide radicals into hydrogen peroxide. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. The pathway includes HSPA5 (binding immunoglobulin protein), EIF2AK3 (PERK), EIF2S1 (eIF2\u03b1), ATF4, and DDIT3, all of which are involved in the unfolded protein response (UPR) and stress signaling. Mutant SOD1 disrupts protein folding, leading to oxidative stress and neuronal toxicity. This pathway's dysregulation contributes to motor neuron death, hallmark of ALS. Thus, the biological effect of the SOD1 allele is the pathogenesis of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-known to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway highlights the role of oxidative stress and endoplasmic reticulum (ER) stress in disease progression, as SOD1 mutations lead to ER dysfunction and neuronal death. The downstream effectors, including ATF4 and DDIT3, are involved in the unfolded protein response and cell survival mechanisms. Therefore, the biological effect of the SOD1 allele is the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele is the production of amyloid-beta (Abeta), a peptide that aggregates into plaques in the brain. This process is associated with the dysfunction of the proteasome, specifically the 26S proteasome complex, which is involved in the degradation of misfolded or damaged proteins. The pathway includes genes encoding subunits of both the 20S core proteasome and the 26S regulatory complex, such as PSMA and PSMB subunits, as well as ATPases like PSMC. Impaired proteasome function leads to the accumulation of toxic Abeta, a hallmark of neurodegenerative diseases. This contributes to Alzheimer's disease, characterized by progressive neuronal loss and cognitive decline. The disruption of proteasomal degradation of Abeta exacerbates plaque formation and neuronal toxicity. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is central to amyloid-beta production. The pathway shows APP being processed to form Abeta, which is then targeted for degradation by the 26S proteasome. Mutations in APP or its processing can lead to aberrant Abeta accumulation, a hallmark of Alzheimer's disease. The involvement of proteasome subunits, particularly those associated with the 26S complex, underscores the role of proteasomal dysfunction in disease progression. Impaired proteasomal degradation of Abeta contributes to its accumulation, neurotoxicity, and the development of neurodegenerative pathology. This pathway is therefore strongly linked to Alzheimer's disease, where dysfunctional proteasomal clearance of Abeta is a key pathological mechanism. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele is the production of amyloid-beta (Abeta), a key component in the pathogenesis of Alzheimer's disease. The pathway involves the proteasomal degradation of Abeta, with multiple proteasome subunits (20S and 26S) playing roles in this process. The 26S proteasome, which includes ATPases and non-ATPase subunits, is essential for the ubiquitin-mediated degradation of misfolded or damaged proteins, including Abeta. Dysfunction in this pathway can lead to the accumulation of Abeta plaques, a hallmark of Alzheimer's disease. Mutations or disruptions in APP or proteasomal subunits can impair Abeta clearance, contributing to neurodegeneration. Thus, this pathway is directly implicated in the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of the downstream signaling cascade, including RAS and RAF, resulting in uncontrolled cell growth. This contributes to the development of skeletal dysplasias, most notably achondroplasia, the most common form of short-limbed skeletal dysplasia. Activating mutations in FGFR3 also contribute to the pathogenesis of certain cancers, such as chordomas and some cases of bladder cancer. However, the most well-characterized disease associated with FGFR3 mutations is achondroplasia. \\boxed{Achondroplasia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation and differentiation, particularly in bone development. Mutations in FGFR3, such as gain-of-function mutations, lead to constitutive activation of the downstream signaling cascade, including RAS and RAF, ultimately increasing ERK and MYC activity. This aberrant signaling disrupts normal cell cycle control and promotes uncontrolled cell growth. In the context of genomic pathways, such mutations are strongly associated with skeletal dysplasias, specifically achondroplasia, the most common form of short-limbed dwarfism. Achondroplasia is typically caused by a missense mutation in FGFR3 that results in impaired endochondral ossification. Therefore, the biological effect of this FGFR3 allele is the development of achondroplasia.\n\n\\boxed{Achondroplasia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade. This results in aberrant cell growth and survival. In particular, activating mutations in FGFR3 are strongly associated with **bladder urothelial carcinoma**, specifically **bladder cancer**. These mutations drive uncontrolled cell proliferation and resistance to apoptosis, contributing to tumor formation and progression. FGFR3 mutations are most commonly found in **non-muscle-invasive bladder cancer** and are linked to a better prognosis compared to muscle-invasive disease. The pathway's dysregulation promotes tumor growth through enhanced MAPK and PI3K/AKT signaling, highlighting FGFR3 as a key oncogenic driver in bladder carcinogenesis.\n\n\\boxed{Bladder cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington's disease. In this pathway, HTT is upstream of STX1A (syntaxin 1A), which regulates neurotransmitter release via VGCC (N-type calcium channels), leading to intracellular calcium elevation. Mutations in HTT, particularly expansions of CAG repeats, result in the production of mutant huntingtin protein, which disrupts synaptic transmission and leads to neurodegeneration. This pathway is disrupted in Huntington's disease, contributing to neuronal dysfunction and cell death. The accumulation of mutant HTT impairs vesicle trafficking and calcium homeostasis, exacerbating the disease. Therefore, this HTT allele contributes to \\boxed{Huntington's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose normal function is not fully understood, but its dysfunction is central to Huntington's disease. The pathway described involves HTT interacting with STX1A and VGCC (N-type), leading to Ca\u00b2\u207a influx. Mutations in HTT, particularly expansions of CAG repeats, result in the production of an abnormally long huntingtin protein, leading to neuronal toxicity and neurodegeneration. This contributes to the progressive motor, cognitive, and psychiatric symptoms characteristic of Huntington's disease. The disrupted pathway likely exacerbates calcium dysregulation, further damaging neurons. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutation leads to Huntington's disease. In the given pathway, HTT interacts with STX1A and VGCC(N-type), influencing calcium influx via voltage-gated channels. Mutations in HTT, particularly expansions of CAG repeats, cause abnormal protein aggregation and toxic gain of function, disrupting synaptic vesicle trafficking and calcium homeostasis. This leads to neuronal dysfunction and death, particularly in the striatum and cortex. The resulting disease is characterized by progressive motor, cognitive, and psychiatric symptoms. The pathway highlights how HTT dysfunction perturbs calcium signaling, exacerbating neurodegeneration. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN (Parkin) is an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive early-onset Parkinsonism. The pathway includes UBCH7/8 (E2 ubiquitin conjugating enzymes) and CDCREL1, which are involved in ubiquitination processes. The presence of PRKN in this pathway suggests its role in ubiquitin-mediated protein degradation, particularly in neurodegeneration. Loss-of-function PRKN alleles lead to impaired mitophagy, the selective autophagy of damaged mitochondria, resulting in mitochondrial dysfunction and neuronal death. This contributes to the pathogenesis of Parkinson's disease. Mutations in PRKN are a known cause of Parkinson's disease, specifically in patients with early onset and genetic predisposition. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in proteasomal degradation of damaged proteins and mitochondrial quality control. Mutations in PRKN lead to impaired ubiquitin-mediated proteolysis, accumulating dysfunctional proteins and contributing to cellular stress. This dysfunction is linked to neurodegeneration, particularly in Parkinson's disease. PRKN mutations are one of the most common genetic causes of early-onset Parkinson's disease, characterized by the loss of dopaminergic neurons in the substantia nigra. The interaction with UBCH7/8 and CDCREL1 suggests a role in ubiquitin conjugation and mitochondrial dynamics, further supporting its involvement in neurodegenerative processes. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN, or parkin, is an E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. The pathway involving PRKN, along with UBCH7/8 (E2 ligases) and CDCREL1, is critical for maintaining protein homeostasis and mitochondrial quality control. Mutations in PRKN lead to impaired ubiquitination and degradation of damaged proteins, particularly those involved in mitochondrial function. This dysfunction contributes to the accumulation of misfolded proteins and mitochondrial dysfunction, which is a hallmark of neurodegenerative diseases. The most well-known disease associated with PRKN mutations is Parkinson's disease. Loss-of-function mutations in PRKN are linked to autosomal recessive early-onset Parkinson's disease, characterized by the loss of dopaminergic neurons. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 gene is a critical component of the Wnt signaling pathway, functioning as a scaffold that promotes the degradation of \u03b2-catenin (CTNNB1). In the given pathway, AXIN1 is part of a regulatory complex with APC and GSK3B, which inhibits the stabilization and nuclear translocation of \u03b2-catenin. When AXIN1 is mutated or dysfunctional, this inhibition is lost, leading to the accumulation of \u03b2-catenin and its translocation to the nucleus, where it activates TCF/LEF transcription factors such as MYC and CCND1. This dysregulation drives cell proliferation and survival, contributing to uncontrolled growth. Mutations in AXIN1 are associated with various cancers, particularly colorectal cancer, where they disrupt the Wnt pathway and lead to tumor formation. \\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 allele is a key component of the Wnt/\u03b2-catenin signaling pathway. In the given pathway, AXIN1 functions as a negative regulator by promoting the degradation of \u03b2-catenin (CTNNB1), thereby inhibiting the transcription of downstream genes such as MYC and CCND1, which are critical for cell proliferation. Mutations or loss-of-function in AXIN1 disrupt this regulation, leading to the stabilization and accumulation of \u03b2-catenin, which drives aberrant cell growth. This dysregulation is a hallmark of several cancers, particularly colorectal cancer, where AXIN1 inactivation is frequently observed. The resulting uncontrolled activation of the Wnt pathway contributes to tumor initiation and progression. Therefore, the biological effect of this AXIN1 allele is the promotion of uncontrolled cell proliferation, which is a key driver in colorectal cancer. \\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 gene is a critical component of the Wnt/\u03b2-catenin signaling pathway. It functions as a scaffold protein that promotes the degradation of \u03b2-catenin, preventing its accumulation in the nucleus. In the given pathway, AXIN1 is part of the complex that inactivates \u03b2-catenin, thereby inhibiting the transcription of downstream genes such as MYC and CCND1, which are involved in cell proliferation. Mutations or loss-of-function in AXIN1 disrupt this regulatory mechanism, leading to \u03b2-catenin stabilization and aberrant activation of Wnt target genes. This contributes to uncontrolled cell growth and is associated with various cancers. Specifically, AXIN1 mutations are strongly linked to colorectal cancer, where they disrupt the Wnt signaling balance, promoting tumor formation. \n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) allele plays a central role in the signaling pathway involving androgen hormones such as testosterone (T), dihydrotestosterone (DHT), and estradiol (E2). This pathway leads to the activation of KLK3 (kallikrein-related peptidase 3), a gene associated with prostate cancer progression. The androgen receptor mediates the effects of androgens on prostate epithelial cells, promoting cell proliferation and survival. Mutations or aberrant activation of AR can lead to increased KLK3 expression, which is linked to the development and aggressiveness of prostate cancer. Therefore, alterations in the AR pathway contribute to the pathogenesis of prostate cancer. \n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe androgen receptor (AR) plays a critical role in mediating the effects of androgens such as testosterone and dihydrotestosterone (DHT) in target tissues. In the context of the provided pathway, the AR activates the expression of KLK3 (kallikrein-related peptidase 3), which is implicated in prostate cancer progression. Mutations or altered function of the AR can lead to aberrant signaling, promoting epithelial cell proliferation and tumor development. This pathway is particularly relevant in prostate cancer, where AR activation drives tumor growth and metastasis. The AR allele's biological effect is thus closely associated with the development and progression of prostate cancer. \n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) pathway involves androgen hormones such as DHT, E2, and testosterone, which activate AR to regulate gene expression, including KLK3. Mutations or alterations in the AR allele can disrupt this signaling, leading to aberrant KLK3 expression. KLK3 encodes prostate-specific antigen (PSA), which is associated with prostate cancer progression. Dysregulation of the AR pathway is a key driver in prostate cancer, as androgen signaling promotes cell proliferation and survival in prostate epithelial cells. Altered AR function can result in hormone-refractory disease, resistance to therapy, and metastasis. Therefore, the biological effect of this AR allele is the promotion of prostate cancer. \n\n\\boxed{Prostate Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major genetic cause of early-onset Alzheimer's disease (AD). These mutations disrupt normal proteolytic processing of APP, leading to increased production of toxic amyloid-\u03b242 species, which aggregate into plaques in the brain. This pathology is central to the hallmark lesions of AD. Additionally, PSEN1 mutations may perturb calcium homeostasis via interactions with ITPR and MCU, contributing to mitochondrial dysfunction and neuronal death. The pathway described reflects the connection between PSEN1 and calcium dyshomeostasis, which exacerbates neurodegeneration. Therefore, the biological effect of PSEN1 mutations is the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). In the provided pathway, PSEN1 dysfunction likely disrupts calcium homeostasis by affecting inositol 1,4,5-trisphosphate receptors (ITPRs) and mitochondrial calcium uptake via MCU, leading to mitochondrial dysfunction, oxidative stress, and neuronal apoptosis. This cascade contributes to neurodegeneration. The accumulation of toxic amyloid-\u03b2 and mitochondrial dysfunction are central to the pathogenesis of Alzheimer's disease. Thus, the biological effect of PSEN1 mutations is the disruption of calcium signaling and mitochondrial function, which underlies the progression of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (FAD). In the given pathway, PSEN1 influences intracellular calcium homeostasis by modulating ITPR-mediated release of Ca\u00b2+ from the endoplasmic reticulum, which in turn affects mitochondrial calcium uptake via MCU. Dysregulation of this pathway leads to mitochondrial dysfunction, increased oxidative stress, and neuronal apoptosis. These events contribute to the pathogenesis of Alzheimer's disease. The accumulation of amyloid-\u03b2 plaques and neurofibrillary tangles, hallmarks of Alzheimer's, are exacerbated by disrupted calcium signaling. Thus, the PSEN1 allele contributes to the development of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta non-erythrocytic 2, which plays a role in maintaining cellular structure and signaling. In the described pathway, SPTBN2 interacts with GRM1, initiating a signaling cascade involving GNAQ, PLCB isoforms, IP3, and Ca\u00b2\u207a release via ITPR. Mutations in SPTBN2 can disrupt this pathway, leading to altered intracellular calcium levels and impaired signaling. This disruption is implicated in neurological and developmental disorders. Specifically, SPTBN2 mutations are associated with **familial hemiplegic migraine (FHM)**, a subtype of migraine with brainstem aura. The altered signaling contributes to neuronal hyperexcitability and cortical spreading depression, which are hallmarks of FHM. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves SPTBN2, which interacts with GRM1 and initiates a signaling cascade through GNAQ, PLCB, IP3, and finally Ca\u00b2\u207a release via ITPR. SPTBN2 encodes spectrin beta non-erythrocytic 2, a cytoskeletal protein involved in maintaining cell structure and signaling. Mutations in SPTBN2 have been linked to neurodevelopmental disorders. Specifically, SPTBN2 mutations are associated with **schizophrenia** and **intellectual disability**, as they disrupt synaptic function and neuronal connectivity. The disruption of this pathway impairs neurotransmission and calcium signaling, contributing to cognitive and behavioral abnormalities. These mutations are often found in individuals with neurodevelopmental conditions and are implicated in the pathophysiology of schizophrenia. \\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta non-erythrocytic 2, a structural protein involved in maintaining cell membrane integrity and intracellular organization. In the described pathway, SPTBN2 negatively regulates GRM1, which is part of a signaling cascade involving GNAQ, PLCB, IP3, and calcium release via ITPR. Mutations in SPTBN2 can disrupt this regulatory interaction, leading to aberrant calcium signaling and neuronal dysfunction. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, alterations in SPTBN2 have been linked to **Focal Dystonia**, a movement disorder characterized by sustained muscle contractions. Disruption of the pathway may also contribute to other neurological conditions, but the most directly associated disease is \\boxed{Focal Dystonia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **CACNA1A** gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel, which is crucial for neuronal excitability and neurotransmitter release. Mutations in **CACNA1A** are associated with impaired calcium influx, leading to dysfunctional neurotransmission and altered neuronal activity. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, pathogenic variants in **CACNA1A** are a well-established cause of **familial hemiplegic migraine (FHM)**, a subtype of migraine with aura characterized by reversible motor weakness. Additionally, **CACNA1A** mutations are linked to **spinocerebellar ataxia type 2 (SCA2)**, a progressive cerebellar ataxia. These diseases stem from disrupted calcium homeostasis and neuronal function. \n\n\\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neuronal excitability and neurotransmitter release. Mutations in CACNA1A are associated with a range of neurological disorders, most notably familial hemiplegic migraine (FHM), a genetic form of migraine with hemiplegia. These mutations typically result in altered calcium channel function, leading to increased neuronal excitability and impaired regulation of calcium influx, which contributes to the pathophysiology of migraines. Additionally, CACNA1A mutations have been linked to other conditions such as ataxia and episodic limbic encephalitis. The altered calcium signaling disrupts normal neuronal function, leading to the characteristic symptoms of these disorders. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with various neurological disorders, most notably familial hemiplegic migraine (FHM), a genetic form of migraine with aura. These mutations disrupt calcium channel function, leading to impaired regulation of neuronal activity and increased excitation, which contributes to migraine attacks. Additionally, CACNA1A mutations have been linked to other conditions such as cerebellar ataxia, episodic ataxia type 2, and certain forms of childhood epilepsy. The pathway involving extracellular calcium and the calcium channel subunit highlights the role of calcium in neuronal signaling and the consequences of its dysregulation. \\boxed{Familial hemiplegic migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the proper folding and activity of four lysosomal enzymes: GBA, GBA2, and GALC. Mutations in PSAP can lead to impaired processing of these enzymes, resulting in their functional deficiency. This is most notably associated with Gaucher disease, which is primarily caused by mutations in the GBA gene. However, PSAP mutations can also contribute to the pathogenesis of metachromatic leukodystrophy (MLD) by affecting the activity of GALC. Deficiency in GALC leads to the accumulation of psychosine, a toxic sphingolipid, which damages myelinated nerves. Thus, PSAP allelic variants that disrupt the function of GBA, GBA2, and GALC can contribute to the development of Gaucher disease and MLD. The biological effect of the PSAP allele is therefore linked to the disruption of sphingolipid metabolism, leading to neurodegenerative and storage disorders.\n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a protein essential for the proper folding and activity of glycosphingolipid hydrolases, including GBA, GBA2, and GALC. Mutations in PSAP can lead to reduced activity of these enzymes, resulting in the accumulation of glycosphingolipids in lysosomes. This pathway is critical for lysosomal function, and disruptions contribute to neurodegenerative diseases. Specifically, PSAP mutations are associated with metachromatic leukodystrophy (MLD), a rare inherited disorder characterized by the progressive degeneration of the central nervous system due to the toxic buildup of sphingolipids. The disease arises from the combined dysfunction of GBA, GBA2, and GALC, all of which are dependent on prosaposin for their correct maturation. The PSAP allele thus plays a central role in the pathogenesis of MLD.\n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is essential for the proper folding and function of sphingolipid hydrolases, including GBA, GBA2, and GALC. Mutations in PSAP can lead to impaired activity of these enzymes, resulting in the accumulation of toxic lipid compounds in lysosomes. This pathway is critical for lysosomal storage disorders. Specifically, PSAP mutations contribute to metachromatic leukodystrophy (MLD), a severe neurodegenerative disorder characterized by the progressive loss of myelin in the central and peripheral nervous systems. MLD is caused by a deficiency in arylsulfatase A (ASA), which is encoded by the GBA2 gene, and is affected by PSAP dysfunction. The disease leads to intellectual disability, motor dysfunction, and ultimately, early mortality. \\boxed{Metachromatic Leukodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and neurodegeneration. Mutations in ATXN3 lead to the expansion of polyglutamine tracts, resulting in the formation of toxic protein aggregates. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process that degrades aggregated proteins. Dysfunction in this pathway can impair autophagy, exacerbating the accumulation of misfolded proteins and neurotoxicity. Thus, the ATXN3 allele contributes to the development of \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and transcription. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This pathology is a hallmark of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive degeneration of the cerebellum and brainstem, leading to impaired motor coordination. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process that clears misfolded proteins. Dysfunction in this pathway contributes to the accumulation of toxic proteins, exacerbating neurodegeneration. Therefore, the ATXN3 allele contributes to spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 are associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of motor coordination. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is linked to autophagy, a cellular process critical for protein quality control and removal of damaged components. Impaired autophagy due to ATXN3 dysfunction contributes to the accumulation of misfolded proteins, leading to neuronal toxicity. This dysregulation is a key pathogenic mechanism in SCA2. The interaction within this pathway highlights the role of autophagy in maintaining neuronal health and the consequences of its disruption in neurodegenerative diseases. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which plays a critical role in the pathogenesis of prion diseases. In the given pathway, PRNP activates a signaling cascade involving CAV1/2/3, FYN, PI3K subunits (PIK3CA, PIK3CB, PIK3CD), PRKCD, and ultimately leads to activation of NOX2, increasing ROS production. This oxidative stress is implicated in neuronal damage. Mutations in PRNP, particularly those leading to misfolded prion proteins (PrP^Sc), are the primary cause of transmissible spongiform encephalopathies. The most well-known disease associated with PRNP mutations is Creutzfeldt-Jakob Disease (CJD), a rapidly progressive neurodegenerative disorder. Other related prion diseases include variant CJD, kuru, and Gerstmann-Str\u00e4ussler-Scheinker syndrome. These diseases are characterized by prion protein misfolding, neuronal loss, and sponge-like degeneration of brain tissue. \\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the propagation of abnormal prion proteins. This pathway, PRNP \u2192 CAV \u2192 FYN \u2192 PI3K \u2192 PRKCD \u2192 NOX2 \u2192 ROS, is involved in oxidative stress and neurodegeneration. The activation of NOX2 and the subsequent production of ROS contribute to neuronal damage. This pathway is central to prion diseases, where misfolded PRNP induces a cascade of events leading to neurotoxicity. The biological effect of this PRNP allele is the development of prion diseases, specifically Creutzfeldt-Jakob disease (CJD), which is characterized by progressive neurological decline due to prion protein misfolding and neuronal death. \\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. In the given pathway, PRNP activates a cascade involving CAV1/2/3, FYN, PI3K subunits, PRKCD, and ultimately NOX2, leading to ROS production. This pathway is closely associated with oxidative stress and neurodegeneration. Mutations in PRNP are well-known for causing Creutzfeldt-Jakob disease (CJD), a rare, fatal neurodegenerative disorder characterized by prion protein misfolding and neuronal damage. The pathway's role in ROS generation further supports its involvement in oxidative damage, which exacerbates neuronal loss in CJD. Therefore, the biological effect of the PRNP allele in this context is the contribution to Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS-PI3K-AKT-BAD pathway, contributes to the activation of downstream signaling that promotes cell survival and proliferation. Mutations in NRAS, like KRAS, lead to constitutive activation of the PI3K pathway, increasing levels of PIP3 and subsequently AKT phosphorylation. This inhibits BAD, a pro-apoptotic protein, thereby reducing programmed cell death. This pathway is critical in oncogenesis, as it drives uncontrolled cell growth and resistance to apoptosis. The activation of this pathway is commonly observed in cancers such as **melanoma**, where NRAS mutations are frequent. These mutations are associated with tumorigenesis and poor prognosis. The biological effect of activating NRAS in this pathway is the promotion of oncogenic transformation and the development of **melanoma**.  \n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This results in apoptosis resistance and uncontrolled cell proliferation. Such dysregulation is a hallmark of several cancers. Specifically, NRAS mutations are commonly found in melanoma, particularly in cases arising from chronic sun exposure. They also contribute to other malignancies such as colorectal cancer, non-small cell lung cancer, and certain pediatric leukemias. The most well-documented disease associated with NRAS mutations is melanoma. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the constitutive activation of the PI3K-AKT signaling cascade. This leads to the inhibition of BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. Mutations in NRAS, like those in KRAS, result in gain-of-function mutations that keep the RAS protein in its active GTP-bound state, continuously stimulating downstream signaling. This dysregulation is a key driver in malignancies characterized by uncontrolled cell growth and resistance to apoptosis. The most well-known disease associated with NRAS mutations is **melanoma**, particularly in the context of melanocytes. These mutations are also implicated in other cancers, including non-small cell lung cancer and pancreatic cancer, but melanoma is the most prominent and clinically significant disease linked to NRAS activation through this pathway.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein quality control and ubiquitin-mediated proteolysis. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the accumulation of misfolded proteins, disrupting cellular function. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive degeneration of the cerebellum and associated motor coordination deficits. SCA2 is inherited in an autosomal dominant manner and results in the formation of toxic protein aggregates that impair neuronal function, ultimately leading to ataxia and other neurological symptoms. The involvement of ATXN3 in this pathway highlights its role in maintaining proteostasis and its relevance in neurodegeneration. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the glutamatergic signaling cascade leading to mitochondrial calcium uptake and ultimately contributing to apoptosis via the mitochondrial permeability transition pore (MPTP). ATXN3, an E3 ubiquitin ligase, is part of the ITPL1 complex, which is involved in RNA metabolism and protein quality control. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination. ATXN3 dysfunction disrupts protein homeostasis and leads to neuronal cell death, particularly in the cerebellum. This contributes to the clinical features of SCA2, including ataxia, dysarthria, and cognitive decline. The involvement of ATXN3 in this pathway underscores its role in maintaining mitochondrial function and neuronal integrity. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA processing and protein degradation. In the given pathway, ATXN3 is linked to the IP3-Ca\u00b2+ signaling cascade, which regulates mitochondrial calcium levels and apoptosis. Mutations in ATXN3 are most notably associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive motor dysfunction due to the expansion of polyglutamine repeats in ataxin-3. This mutation leads to protein misfolding, aggregation, and neuronal loss, particularly in the cerebellum. The pathway involving ATXN3 contributes to the disruption of calcium homeostasis and mitochondrial function, exacerbating neuronal damage. Therefore, the biological effect of the ATXN3 allele is the contribution to \\boxed{Spinocerebellar ataxia type 2}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN allele plays a critical role in regulating the PI3K-AKT signaling pathway by dephosphorylating PIP3, thereby inhibiting AKT activation. Loss-of-function mutations in PTEN lead to sustained AKT activation, promoting cell survival, proliferation, and resistance to apoptosis. This dysregulation is a key driver in several cancers. Specifically, PTEN mutations are strongly associated with the development of **Cowden syndrome**, a genetic disorder characterized by an increased risk of multiple benign and malignant tumors, including breast, thyroid, and endometrial cancers. Additionally, PTEN inactivation is a frequent genetic alteration in **glioblastoma multiforme**, **prostate cancer**, and **endometrial cancer**, contributing to tumor progression and poor prognosis. Thus, PTEN dysfunction is a major contributor to **Cowden syndrome** and various cancers. \n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the activation of AKT, a key protein in cell survival and proliferation. When PTEN is mutated or lost, PIP3 levels increase, leading to constitutive activation of the AKT signaling pathway. This promotes uncontrolled cell growth, resistance to apoptosis, and enhanced angiogenesis, all of which contribute to tumorigenesis. PTEN mutations are strongly associated with the development of various cancers, most notably **Cowden syndrome** and **clear cell renal cell carcinoma**. Additionally, PTEN dysfunction is a hallmark of **breast, prostate, and endometrial cancers**. The loss of PTEN function disrupts the PI3K-AKT pathway, a critical regulator of cell cycle progression and survival, thereby promoting malignant transformation. \\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the activation of AKT. This pathway is critical for regulating cell growth, survival, and proliferation. Loss-of-function mutations in PTEN lead to accumulation of PIP3 and activation of AKT, promoting uncontrolled cell growth. This contributes to the development of various cancers. Specifically, PTEN mutations are strongly associated with **Cowden syndrome**, a condition characterized by multiple benign and malignant tumors, including thyroid, breast, and endometrial cancers. Additionally, PTEN dysfunction is a key driver in **glioblastoma multiforme**, a highly aggressive brain cancer. The loss of PTEN function disrupts the phosphatidylinositol-3-kinase (PI3K)-AKT signaling pathway, leading to increased cell survival and resistance to apoptosis. \\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and ubiquitin-dependent protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This contributes to neurodegeneration by impairing cellular protein quality control and disrupting mitochondrial function. The involvement of ATXN3 in autophagy-related pathways, including interactions with BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, highlights its role in maintaining cellular homeostasis through autophagy. Dysfunction in these pathways exacerbates protein aggregation and neuronal loss. The most well-known disease associated with ATXN3 mutations is spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive coordination deficits and cerebellar atrophy. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in ubiquitin-mediated proteolysis and transcriptional regulation. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy regulation. Disruption of this pathway, particularly through ATXN3 mutations, impairs autophagic clearance of damaged proteins and aggregates, contributing to neuronal dysfunction. This dysfunction is a key mechanism in the pathogenesis of SCA2. The disease is inherited in an autosomal dominant manner and leads to cerebellar atrophy and motor deficits. The involvement of ATXN3 in autophagy highlights its critical role in maintaining protein homeostasis in neurons.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and transcriptional regulation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is linked to autophagy, a cellular process that clears misfolded proteins and damaged organelles. Dysregulation of this pathway exacerbates the accumulation of toxic proteins, further supporting the role of ATXN3 in SCA2. The interplay between autophagy and ATXN3 dysfunction highlights the importance of protein quality control in neuronal health. Therefore, the ATXN3 allele contributes to \\boxed{Spinocerebellar Ataxia Type 2}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of the amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). The pathway described, PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, reflects a signaling cascade linked to stress response and protein translation regulation. Impaired PSEN1 function disrupts APP processing, leading to accumulation of toxic amyloid-beta plaques, neurodegeneration, and cognitive decline. This directly contributes to the pathogenesis of Alzheimer's disease. The allele's effect is thus central to the development of Alzheimer's, highlighting its role in disease onset and progression. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in proteolytic processing of the amyloid precursor protein (APP). Mutations in PSEN1 are a primary cause of early-onset familial Alzheimer's disease (FAD). The pathway described, involving PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, reflects a stress response mechanism. PSEN1 mutations disrupt normal proteolysis, leading to accumulation of toxic amyloid-beta plaques and neurodegeneration. This directly contributes to the pathogenesis of Alzheimer's disease. The dysregulation of this pathway further exacerbates cellular stress and apoptosis, accelerating neurodegeneration. Thus, the biological effect of pathogenic PSEN1 alleles is the initiation and progression of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). The pathway described, PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, highlights its role in stress response and translation regulation. PSEN1 mutations disrupt normal \u03b3-secretase function, leading to increased production of toxic amyloid-\u03b2 species, neurodegeneration, and cognitive decline. This directly contributes to the development of Alzheimer's disease. The pathway also involves EIF2AK3 (PERK), which activates ATF4 and DDIT3, suggesting a broader role in endoplasmic reticulum (ER) stress and neuronal survival. These molecular pathways collectively support the link between PSEN1 dysfunction and Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the processing of amyloid precursor protein (APP) and other substrates. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (AD). The pathway PSEN1 \u2192 ERN1 \u2192 XBP1 suggests a link between PSEN1 dysfunction and the unfolded protein response (UPR), as ERN1 (IRE1) is a key sensor of ER stress and activates XBP1, a transcription factor involved in ER homeostasis. Impaired PSEN1 function can lead to ER stress and disrupted proteostasis, contributing to neurodegeneration. This connection highlights the role of PSEN1 in both amyloidogenesis and ER stress in Alzheimer's disease. Therefore, the biological effect of this PSEN1 allele is the contribution to early-onset Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is crucial for the proteolytic processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (eAD). The pathway described, PSEN1 \u2192 ERN1 \u2192 XBP1, highlights a connection between PSEN1 and the endoplasmic reticulum (ER) stress response. PSEN1 dysfunction can lead to ER stress, activating the unfolded protein response (UPR) via ERN1 (IRE1), which in turn activates XBP1. This pathway is involved in protein folding and cellular homeostasis. Dysregulation of this pathway contributes to neurodegeneration by promoting ER stress and impairing protein clearance, further supporting the role of PSEN1 mutations in Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which plays a critical role in the processing of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). The pathway PSEN1 \u2192 ERN1 \u2192 XBP1 suggests a connection between PSEN1 dysfunction and endoplasmic reticulum (ER) stress, as ERN1 (IRE1) is a key sensor of ER stress that activates XBP1 through splicing. This pathway is involved in the unfolded protein response (UPR), which is disrupted in neurodegenerative diseases. Therefore, PSEN1 mutations contribute to the pathogenesis of Alzheimer's disease by disrupting proteolytic processing and inducing ER stress, leading to neuronal dysfunction and neurodegeneration. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, acting as a scaffold for the formation of autophagosomes and facilitating the degradation of damaged proteins and mitochondria. In the context of the provided pathway, SQSTM1 is linked to PINK1 and PRKN, which are critical in mitochondrial quality control. Mutations in SQSTM1 disrupt autophagy and mitochondrial maintenance, leading to the accumulation of damaged mitochondria and protein aggregates. This dysfunction is implicated in the pathogenesis of Parkinson's disease, as it impairs the clearance of aggregated proteins and dysfunctional mitochondria, contributing to neuronal death. Therefore, the biological effect of SQSTM1 mutations is the disruption of mitophagy and autophagy, which is a key mechanism in Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene encodes a scaffolding protein involved in autophagy and ubiquitin-mediated protein degradation. In the context of the provided pathway, SQSTM1 is highlighted as a key node connected to the PINK1-PRKN pathway, which is central to mitochondrial quality control. Mutations in SQSTM1 can impair autophagy and mitochondrial function, leading to the accumulation of damaged mitochondria and protein aggregates. This dysfunction is strongly associated with neurodegenerative disorders. Specifically, SQSTM1 mutations contribute to Parkinson's disease by disrupting the clearance of damaged mitochondria and protein aggregates, thereby exacerbating neuronal loss. The interplay between SQSTM1 and the PINK1-PRKN pathway underscores its role in maintaining cellular homeostasis. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene plays a critical role in autophagy and protein degradation. It acts as a scaffold protein that recruits damaged proteins and ubiquitinated substrates to form polyubiquitin chains, marking them for degradation via autophagy. Mutations in SQSTM1 disrupt this process, leading to the accumulation of damaged proteins and mitochondrial dysfunction. This contributes to neurodegeneration by impairing the clearance of misfolded proteins and dysfunctional mitochondria. SQSTM1 is also involved in the Parkin-mediated mitophagy pathway, which is central to maintaining mitochondrial health. Mutations in SQSTM1 have been implicated in a subset of Parkinson's disease cases, specifically those associated with mutations in the PINK1 and PRKN genes. These mutations exacerbate the loss of dopaminergic neurons, leading to the clinical features of Parkinson's disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS signaling pathway, activates PI3K, leading to the production of PIP3 and subsequent activation of AKT. This inhibits BAD, promoting cell survival and proliferation. Mutations in NRAS, such as gain-of-function mutations, result in constitutive activation of this pathway, driving uncontrolled cell growth. This contributes to the development of various cancers. Specifically, NRAS mutations are commonly found in melanoma, where they drive tumor progression by enhancing cell survival and resistance to apoptosis. These mutations are also implicated in other cancers, including certain leukemias and lung cancers. The persistent activation of the PI3K-AKT-BAD axis due to NRAS mutations disrupts normal cellular regulation, leading to oncogenesis. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS \u2192 PI3K \u2192 PIP3 \u2192 AKT \u2192 BAD pathway, contributes to oncogenic signaling by constitutively activating PI3K, leading to increased PIP3 and subsequent activation of AKT. This suppresses BAD, preventing apoptosis and promoting cell survival and proliferation. Mutations in NRAS, similar to KRAS, result in constitutive activation of the RAS protein, driving uncontrolled cell growth. This pathway is central to several cancers, including melanoma, non-small cell lung cancer, and colorectal cancer. Specifically, NRAS mutations are strongly associated with **melanoma**, where they are frequently found in tumors arising from UV-damaged skin. These mutations contribute to the malignant transformation by disrupting normal cell cycle control and apoptosis. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K/AKT signaling cascade. This pathway is critical for cell survival, proliferation, and resistance to apoptosis. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which in turn inhibits BAD, a pro-apoptotic protein. This results in uncontrolled cell growth and survival, hallmark features of cancer. NRAS mutations are commonly found in cancers such as melanoma, non-small cell lung cancer, and colorectal cancer. These mutations drive tumorigenesis by promoting cell survival and proliferation. The dysregulation of this pathway is a key driver in the development of these malignancies. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in the ubiquitin-mediated degradation of hypoxia-inducible factors (HIFs), specifically EPAS1 and ARNT. When VHL is functional, it prevents the stabilization of HIFs, which in turn inhibits the transcription of genes like VEGFA, CXCL8, GLUT1, and EPO. Mutations in VHL lead to the stabilization of HIFs, promoting angiogenesis, inflammation, and erythropoiesis. This contributes to the development of hemangiomas, renal cell carcinomas, and other vascular tumors. The loss of VHL function is a hallmark of von Hippel-Lindau disease, a hereditary disorder characterized by the formation of cysts and tumors in multiple organs, particularly the kidneys, brain, and adrenal glands. \\boxed{von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described pathway, is central to the regulation of hypoxia-inducible genes. The VHL-RBX1-ELOC-ELOB-CUL2 complex functions as an E3 ubiquitin ligase, targeting EPAS1 for degradation under normoxic conditions. When VHL is mutated, this complex is destabilized, leading to EPAS1 stabilization and activation of hypoxia-responsive genes such as VEGFA, CXCL8, GLUT1, and EPO. This dysregulation is a hallmark of hemangiomas and contributes to the pathogenesis of **Von Hippel-Lindau disease (VHL)**. VHL mutations are also implicated in clear cell renal cell carcinoma and pancreatic neuroendocrine tumors, but the primary disease directly associated with the VHL allele in this context is **Von Hippel-Lindau disease**. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele is central to the von Hippel-Lindau (VHL) tumor suppressor pathway, which includes genes like VHL, RBX1, ELOC, ELOB, CUL2, EPAS1, and ARNT. This pathway regulates hypoxia-inducible factors (HIFs), such as HIF-1\u03b1 and HIF-2\u03b1, by targeting them for degradation. When VHL is mutated, the pathway is disrupted, leading to stabilization of HIFs and aberrant activation of genes like VEGFA, CXCL8, GLUT1, and EPO. This results in uncontrolled angiogenesis, cell proliferation, and survival, contributing to the development of various tumors. Specifically, VHL mutations are a defining characteristic of von Hippel-Lindau disease, a hereditary disorder associated with the formation of cysts and tumors in multiple organs, including the retina, kidney, and brain. The genetic defect in VHL leads to the hallmark hemangioblastomas and renal cell carcinomas. \n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial dynamics and quality control. PRKN, also known as parkin, is an E3 ubiquitin ligase that promotes the ubiquitination and degradation of mitofusins (MFN1 and MFN2), which are proteins critical for mitochondrial fusion. Mutations in PRKN lead to impaired mitophagy, the selective autophagy of damaged mitochondria. This dysfunction contributes to the accumulation of unhealthy mitochondria, which can lead to cellular stress and neurodegeneration. PRKN mutations are a well-established cause of Parkinson's disease, specifically in patients with early-onset Parkinson's. The loss of PRKN function disrupts mitochondrial quality control, leading to neuronal death, particularly in dopamine-producing neurons in the substantia nigra. This genetic pathway is central to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is involved in mitochondrial quality control through its role in ubiquitin-mediated proteolysis. Mutations in PRKN lead to impaired mitophagy, the selective degradation of damaged mitochondria. This dysfunction is linked to the accumulation of defective mitochondria, which can result in cellular energy crisis and oxidative stress. The pathway also involves MFN1 and MFN2, which mediate mitochondrial fusion. Together, these proteins maintain mitochondrial integrity. Mutations in PRKN are a major cause of autosomal recessive Parkinson's disease. Loss-of-function mutations in PRKN disrupt mitochondrial quality control, leading to neuronal dysfunction and degeneration, particularly in dopaminergic neurons. This genetic disruption contributes significantly to the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through its role in ubiquitinating and targeting mitofusins (MFN1 and MFN2), which are critical for mitochondrial fusion. Mutations in PRKN lead to impaired mitophagy, the selective removal of damaged mitochondria. This disruption contributes to the accumulation of dysfunctional mitochondria, leading to cellular stress and apoptosis. PRKN is a key gene in Parkinson\u2019s disease (PD), as mutations in PRKN are one of the most common genetic causes of inherited PD. These mutations result in loss of function, leading to neurodegeneration, particularly in dopamine-producing neurons. The disruption of mitochondrial dynamics and quality control is a central mechanism in the pathogenesis of PRKN-associated Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, leading to phosphorylation of RB1, which in turn releases E2F transcription factors. This promotes cell cycle progression from G1 to S phase. The CDK4 allele, when mutated or overexpressed, disrupts the normal regulation of the cell cycle by inactivating RB1, allowing unchecked cell proliferation. This contributes to uncontrolled cell division, a hallmark of cancer. Specifically, dysregulation of the CDK4/RB1/E2F pathway is strongly associated with **retinoblastoma** and other cancers such as **breast, lung, and prostate cancer**. Mutations in CDK4 can lead to constitutive activation of E2F, driving tumor growth. Therefore, the biological effect of a pathogenic CDK4 allele is the promotion of **cancer** by disrupting cell cycle control. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, leading to phosphorylation of RB1, which releases E2F transcription factors. CDK4, when activated, promotes cell cycle progression by inactivating RB1, allowing E2F-driven transcription of genes necessary for S-phase entry. Mutations or overexpression of CDK4 can disrupt this regulation, leading to uncontrolled cell proliferation. This dysregulation is commonly observed in cancers where the cell cycle is deregulated. Specifically, CDK4 alterations are strongly associated with **Carcinoma of the skin** (particularly basal cell carcinoma) and **Breast cancer**, but most notably, CDK4 aberrations are a hallmark of **Retinoblastoma** when combined with RB1 mutations. However, the most significant and well-documented disease linked to CDK4 activation is **Non-Hodgkin Lymphoma** and **Melanoma**. The most specific and impactful disease linked to CDK4 is **Retinoblastoma** when paired with RB1 loss.\n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, which phosphorylates RB1, leading to the release of E2F transcription factors. This process drives cell cycle progression from G1 to S phase. The activation of E2F promotes the expression of genes involved in DNA replication and cell division. Mutations or overexpression of CDK4, such as amplification or mutations in the CDK4 gene, result in constitutive activation of the pathway, leading to uncontrolled cell proliferation. This dysregulation is a hallmark of several cancers. Specifically, CDK4 activation contributes to the development of **retinoblastoma** and is also implicated in **skin cancer**, **breast cancer**, and **prostate cancer**. The most well-characterized association is with **retinoblastoma**, where CDK4 aberrations can cooperate with RB1 inactivation to drive tumorigenesis. \n\n\\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, promotes cell survival by inhibiting BAD, a pro-apoptotic protein. Mutations in NRAS lead to constitutive activation of the MAPK and PI3K/AKT pathways, driving uncontrolled cell proliferation and resistance to apoptosis. This contributes to the development and progression of cancers characterized by RAS signaling dysregulation. The most prominent disease associated with NRAS mutations is **melanoma**, particularly in patients with BRAF wild-type tumors. NRAS mutations are also commonly found in **non-small cell lung cancer**, **colorectal cancer**, and **pancreatic neuroendocrine tumors**. These mutations are oncogenic and are classified as driver mutations in cancer. The pathway described is central to tumor progression, making NRAS a key contributor to **melanoma** and other cancers. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS oncogene family, activates the PI3K-AKT pathway by promoting the conversion of PIP2 to PIP3, which in turn activates AKT. This leads to the inhibition of BAD, a pro-apoptotic protein, thereby suppressing apoptosis and promoting cell survival and proliferation. This pathway is critical in oncogenesis. Mutations in NRAS, such as gain-of-function mutations, result in constitutive activation of downstream signaling, driving uncontrolled cell growth. These mutations are commonly found in cancers where the RAS pathway is aberrantly activated. The most common disease associated with NRAS mutations is **melanoma**, particularly in the context of BRAF wild-type melanoma. Additionally, NRAS mutations are also implicated in other cancers, including non-small cell lung cancer, bladder cancer, and certain leukemias. However, melanoma is the most well-characterized and prevalent disease linked to NRAS mutations.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This results in resistance to apoptosis and enhanced cell survival, promoting uncontrolled cell proliferation. This pathway is critical in oncogenesis. NRAS mutations are commonly found in cancers such as melanoma, non-small cell lung cancer, and certain leukemias. The dysregulation of this pathway is a hallmark of these malignancies. Specifically, NRAS mutations are strongly associated with **melanoma**, where they drive tumor progression by altering cell survival and proliferation signals. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor protein critical for the formation of sphingolipids. Mutations in PSAP lead to reduced or absent prosaposin, impairing the activity of lysosomal enzymes such as GBA, GBA2, and GALC. This results in the accumulation of glycosphingolipids in neurons, leading to progressive neurodegeneration. The most well-known disease associated with PSAP dysfunction is metachromatic leukodystrophy (MLD), a rare inherited neurological disorder. MLD is caused by defective enzyme activity in the lysosome, leading to the buildup of toxic substances in the brain and spinal cord, which causes severe loss of myelin and cognitive decline. The pathway's involvement of PSAP, GBA, GBA2, and GALC highlights its role in lysosomal storage disorders. \\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP allele, along with GBA, GBA2, and GALC, is involved in lysosomal storage disorders. PSAP is a precursor protein that is processed into various saposins, which are essential for the activity of lysosomal enzymes. Mutations in PSAP can lead to impaired glycosphingolipid metabolism. Specifically, PSAP mutations are associated with metachromatic leukodystrophy (MLD), a progressive neurological disorder caused by the deficiency of arylsulfatase A (ARSA), which is derived from PSAP. This deficiency leads to the accumulation of sulfatglycosaminoglycans in the central nervous system, causing demyelination and neurodegeneration. The involvement of GBA and GALC further supports the role of this pathway in lysosomal storage diseases. \\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the proper folding and activity of lysosomal enzymes involved in sphingolipid metabolism. Mutations in PSAP lead to a deficiency in its downstream enzymes, including GBA, GBA2, and GALC, which are critical for breaking down specific lipids. This disruption results in the accumulation of toxic lipid substrates in lysosomes, leading to neuronal damage. The most notable disease associated with PSAP mutations is **Fabry disease**, an X-linked lysosomal storage disorder. However, since PSAP is not directly on the X chromosome, its mutations can also contribute to **Gaucher disease** when combined with mutations in GBA or GALC. The primary disease linked to PSAP dysfunction is **Fabry disease**.\n\n\\boxed{Fabry disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway is critical for cell survival, growth, and differentiation. Activation of MET leads to the phosphorylation of GAB1, which recruits and activates PI3K. PI3K generates PIP3, which activates AKT. Activated AKT inhibits BAD, preventing apoptosis. Mutations or overactivation of MET, such as in PIK3CA or PIK3CB, can drive uncontrolled cell proliferation. This pathway is frequently dysregulated in cancers. The MET gene itself is involved in various cancers, including non-small cell lung cancer, gastric cancer, and renal cell carcinoma. Alterations in this pathway promote tumor growth and resistance to apoptosis. Therefore, aberrations in this pathway are strongly associated with **Non-Small Cell Lung Cancer (NSCLC)**.  \n\\boxed{Non-Small Cell Lung Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, involving MET, GAB1, PI3K (PIK3CA, PIK3CB, PIK3CD), AKT1/2/3, and BAD, plays a critical role in cell survival, proliferation, and migration. Mutations or aberrant activation of MET, such as through amplification or mutational activation of PIK3CA or AKT genes, lead to constitutive activation of the PI3K/AKT signaling cascade. This results in inhibition of pro-apoptotic proteins like BAD, promoting cell survival and resistance to apoptosis. Such dysregulation is commonly observed in cancers where MET-driven signaling contributes to tumor growth, angiogenesis, and metastasis. This pathway is particularly implicated in non-small cell lung cancer (NSCLC), gastric cancer, and other solid tumors. Mutations or overactivation of MET or downstream components like PI3K or AKT are associated with poor prognosis and resistance to therapy. Therefore, the biological effect of this MET allele is oncogenic activity, contributing to the development and progression of cancer. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, starting with MET and proceeding through GAB1, PI3K (encoded by PIK3CA, PIK3CB, and PIK3CD), PIP3, and AKT (AKT1, AKT2, AKT3), leads to the inhibition of BAD, promoting cell survival. Mutations or aberrant activation of MET, such as through amplification or mutation of PIK3CA, drive constitutive PI3K/AKT signaling, which suppresses apoptosis. This promotes uncontrolled cell growth and survival, contributing to oncogenesis. The pathway is frequently altered in cancers, particularly in non-small cell lung cancer (NSCLC), where MET activation is associated with tumor progression, resistance to therapy, and poor prognosis. Additionally, MET-driven pathways are implicated in other malignancies, including hepatocellular carcinoma and gastric cancer. The constitutive activation of this pathway leads to increased cell proliferation, survival, and angiogenesis, all of which are hallmarks of cancer. \\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or dysregulated, leads to the constitutive activation of the BCR-ABL oncoprotein. This activation drives the downstream signaling cascade involving CRKL, CBL, and CRK, which in turn activates PI3K. The PI3K pathway produces PIP3, which recruits and activates AKT. Activated AKT inhibits BAD, preventing apoptosis and promoting cell survival and proliferation. This pathway is central to the pathogenesis of chronic myeloid leukemia (CML). The hallmark of CML is the Philadelphia chromosome, resulting from the translocation t(9;22), which fuses the ABL1 kinase with BCR, forming the BCR-ABL fusion protein. This aberrant kinase activity drives uncontrolled cell growth and is a key driver of CML. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, contributes to the formation of the BCR-ABL fusion protein, a constitutively active tyrosine kinase. This leads to uncontrolled cell proliferation and survival by activating downstream effectors such as CRKL, CBL, and CRK, which in turn activate PI3K. PI3K generates PIP3, which activates AKT. Activated AKT inhibits BAD, preventing apoptosis and promoting cell survival. This pathway is central to oncogenesis. The most well-known disease associated with this pathway is chronic myeloid leukemia (CML), caused by the Philadelphia chromosome translocation resulting in BCR-ABL fusion. This mutation drives malignant cell growth and resistance to apoptosis. The pathway also contributes to other malignancies, including some lymphomas and solid tumors. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or dysregulated, leads to the constitutive activation of the BCR-ABL oncoprotein. This results in the continuous activation of downstream signaling pathways, including the PI3K-AKT-BAD axis. The persistent activation of AKT inhibits BAD, preventing apoptosis and promoting cell survival and uncontrolled proliferation. This mechanism is central to the pathogenesis of chronic myeloid leukemia (CML). The BCR-ABL fusion protein, typically resulting from the Philadelphia chromosome translocation (t(9;22)), drives the transformation of hematopoietic cells into leukemic cells. The pathway described highlights the key role of ABL1 in signaling through CRKL, CBL, and CRK to activate PI3K, leading to AKT-mediated inhibition of apoptosis. This contributes directly to the development and progression of CML. \\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through the ubiquitination and degradation of damaged mitochondria via autophagy (mitophagy). Mutations in PRKN lead to impaired mitochondrial turnover, resulting in the accumulation of dysfunctional mitochondria and subsequent cellular damage. This pathway is critical for neuronal health, and dysfunction contributes to neurodegenerative diseases. Specifically, mutations in PRKN are a well-documented cause of Parkinson's disease, as they disrupt the clearance of damaged mitochondria in dopaminergic neurons, leading to oxidative stress, neuronal death, and motor dysfunction. Therefore, the biological effect of a pathogenic PRKN allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (Parkin) pathway is central to mitochondrial quality control and cell survival. Mutations in PRKN lead to impaired ubiquitination of PLCG1, disrupting the IP3-Ca\u00b2\u207a signaling cascade. This disruption affects calcium homeostasis, leading to mitochondrial dysfunction and neuronal death. This pathway is critical in preventing the accumulation of damaged mitochondria, and its dysfunction contributes to neurodegenerative diseases. Specifically, mutations in PRKN are a well-documented cause of Parkinson's disease, particularly in cases with early-onset and autosomal recessive inheritance. The loss of PRKN function impairs the clearance of damaged mitochondria, leading to oxidative stress and dopaminergic neuron loss. Therefore, the biological effect of a pathogenic PRKN allele is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway plays a critical role in mitochondrial quality control through ubiquitin-mediated degradation of damaged mitochondria, a process known as mitophagy. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and increased oxidative stress. This disruption contributes to neuronal loss and degeneration, particularly in brain regions vulnerable to mitochondrial dysfunction. The most well-characterized disease associated with PRKN mutations is Parkinson's disease. Loss-of-function variants in PRKN are linked to autosomal recessive Parkinson's, characterized by early onset and severe motor symptoms. The pathway's disruption also implicates other neurodegenerative conditions, but Parkinson's is the most directly associated disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the accumulation of abnormal prion proteins. This misfolding is central to the development of prion diseases. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction where PRNP may influence NOTCH1 signaling, which is involved in cell fate determination and differentiation. Mutations in PRNP are most notably associated with Creutzfeldt-Jakob Disease (CJD), a rare and fatal neurodegenerative disorder. These mutations can cause the prion protein to adopt a pathogenic conformation, leading to neuronal damage and progressive cognitive decline. The involvement of NOTCH1 may highlight additional pathways through which PRNP dysfunction contributes to disease pathology. \\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can cause neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction between the prion protein and the NOTCH1 receptor, which plays a role in cell differentiation and neurodevelopment. Mutations in PRNP, particularly those leading to misfolding of the prion protein, are most famously associated with Creutzfeldt-Jakob disease (CJD), a fatal neurodegenerative disorder. This condition is caused by the conversion of normal prion protein (PrP^C) into a pathogenic form (PrP^Sc), leading to aggregation and neuronal damage. The involvement of NOTCH1 may indicate a broader role in disease progression or neuronal vulnerability. Thus, this PRNP allele contributes to \\boxed{Creutzfeldt-Jakob disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction between the prion protein and the NOTCH1 receptor, which plays a role in cell differentiation and development. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob disease (CJD), a rare, fatal brain disorder caused by misfolded prion proteins. These misfolded proteins propagate by converting normal prion proteins into the pathological form, leading to neuronal damage and rapid neurological decline. While NOTCH1 is involved in various cellular processes, its direct role in prion diseases is less established. The primary disease linked to PRNP alleles is Creutzfeldt-Jakob disease. \n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in the ubiquitin-proteasome system, targeting proteins for degradation. Mutations in VHL disrupt this pathway, leading to the stabilization of hypoxia-inducible factors (HIFs), such as EPAS1 and ARNT. This results in the aberrant expression of downstream genes like VEGFA, CXCL8, GLUT1, and EPO, promoting angiogenesis, inflammation, and erythropoiesis. These changes are hallmarks of a condition characterized by the formation of vascular anomalies and tumors in hypoxic environments. The accumulation of these factors drives the development of hemangiomas and other vascular malformations. The most well-known disease associated with VHL mutations is **Von Hippel-Lindau disease**, a hereditary cancer syndrome marked by the development of cysts and tumors in multiple organs, particularly the retina, brain, kidneys, and adrenal glands. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, when mutated, disrupts the VHL-RBX1-ELOC-ELOB-CUL2 ubiquitin ligase complex, leading to stabilization of hypoxia-inducible factors (HIFs) like EPAS1 and ARNT. This results in constitutive activation of HIF target genes such as VEGFA, CXCL8, GLUT1, and EPO. This pathway is critical in response to hypoxia, and its aberrant activation promotes angiogenesis, inflammation, and erythropoiesis. These effects are hallmarked in clear cell renal cell carcinoma (ccRCC), a common malignant tumor of the kidney. The VHL mutation leads to uncontrolled cell proliferation and tumor formation, particularly in the renal tubules. The disease is strongly associated with the inactivation of the VHL tumor suppressor gene, which is a key driver in the pathogenesis of ccRCC. \\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described pathway involving VHL, RBX1, ELOC, ELOB, and CUL2, plays a critical role in the ubiquitin-proteasome system, specifically targeting hypoxia-inducible factors (HIFs) like EPAS1 and ARNT. When VHL is mutated, this degradation process is impaired, leading to the stabilization of HIF-1\u03b1, which in turn drives the expression of genes such as VEGFA, CXCL8, GLUT1, and EPO. This results in aberrant angiogenesis, inflammation, and erythropoiesis. The most well-known disease associated with VHL mutations is von Hippel-Lindau disease (VHL), a hereditary disorder characterized by the development of cysts and tumors in multiple organs, including the kidneys, brain, and adrenal glands. The pathway's dysregulation is central to the pathogenesis of VHL disease. \n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele in this genomic pathway is associated with the huntingtin protein, which is central to the pathogenesis of Huntington's disease. Mutations in HTT lead to the production of an abnormally expanded polyglutamine tract in the huntingtin protein, causing its misfolding and aggregation. This disrupts cellular function, particularly in neurons, by interfering with signaling pathways involving NMDA receptors, calcium homeostasis, mitochondrial dysfunction, and apoptosis. The pathway highlights the role of HTT in modulating calcium levels via the mitochondrial calcium uniporter (MCU) and the subsequent activation of the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c and initiation of apoptosis through the caspase cascade. These disruptions contribute to neurodegeneration. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, specifically the mutant form associated with expanded CAG repeats, contributes to Huntington's disease. This mutation leads to the production of an abnormal huntingtin protein, which disrupts synaptic function and causes neurodegeneration, particularly in the striatum and cortex. The pathway described involves NMDA receptors, calcium influx through the mitochondrial calcium uniporter (MCU), and mitochondrial permeability transition pore (MPTP) opening, leading to the release of cytochrome c and activation of the apoptotic cascade via APAF1, CASP9, and CASP3. This apoptotic pathway is critical in neuronal death in Huntington's disease. The accumulation of mutant HTT protein impairs these processes, ultimately resulting in progressive motor, cognitive, and psychiatric symptoms. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves HTT, which encodes huntingtin, a protein implicated in the pathogenesis of Huntington's disease. Mutations in HTT, particularly expansions of the CAG repeat, lead to the production of toxic huntingtin protein, disrupting neuronal function and causing progressive neurodegeneration. The pathway describes a cascade from NMDA receptor activation through calcium influx, mitochondrial dysfunction, and ultimately apoptosis via the intrinsic pathway involving cytochrome c, APAF1, and caspases. This process is central to the neurotoxicity observed in Huntington's disease, characterized by motor, cognitive, and psychiatric symptoms. The accumulation of mutant HTT impairs synaptic transmission and mitochondrial function, leading to selective neuronal loss, especially in the striatum and cortex. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which is critical for proper electrical signaling in neurons. Mutations in KCNC3 can disrupt ion homeostasis, leading to hyperexcitability of neurons. This contributes to neurological disorders characterized by abnormal neuronal activity. Specifically, variants in KCNC3 have been implicated in epilepsy, particularly generalized epilepsy with febrile seizures plus (GEFS+). This condition is marked by recurrent seizures, often triggered by fever, and can begin in early childhood. The altered potassium channel function leads to impaired repolarization of neurons, increasing the likelihood of seizures. Thus, the KCNC3 allele contributes to the development of \\boxed{epilepsy}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in repolarizing neurons by facilitating the outflow of potassium ions. Mutations in KCNC3 can disrupt normal ion homeostasis, leading to hyperexcitability of neurons. This contributes to neurological disorders characterized by episodic or persistent seizures. Specifically, variants in KCNC3 have been linked to **familial hemiplegic migraine (FHM)**, a rare form of migraine with aura and hemiplegia. These mutations affect the function of the KCNC3-encoded channel, leading to impaired neuronal excitability regulation and increased susceptibility to migraine attacks. The altered potassium channel function disrupts the balance between excitation and inhibition in the brain, contributing to the pathophysiology of the condition. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel (Kv3.4) that plays a critical role in repolarizing cardiac cells during action potential. Mutations in KCNC3 can lead to arrhythmias by disrupting normal ion flow, causing delayed repolarization. This contributes to the development of long QT syndrome (LQTS), a disorder characterized by prolonged QT interval on ECG, which increases the risk of life-threatening ventricular arrhythmias such as torsades de pointes. KCNC3 mutations are associated with LQTS type 6, which is typically inherited in an autosomal dominant manner. The altered function of the potassium channel leads to impaired cardiac electrical stability, making the heart susceptible to abnormal rhythms. This genetic defect highlights the importance of ion channel function in maintaining cardiac electrophysiological homeostasis.\n\n\\boxed{Long QT Syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is critical for mitochondrial quality control, as PRKN (parkin) mediates ubiquitin-dependent degradation of damaged mitochondria through mitophagy. Mutations in PRKN disrupt this process, leading to the accumulation of dysfunctional mitochondria and increased oxidative stress. This contributes to neurodegeneration. PRKN mutations are a key cause of autosomal recessive Parkinson's disease, specifically PARK2. The pathway involves PLCG1, IP3, and ITPR, which regulate intracellular calcium release, essential for neuronal function. Impaired calcium homeostasis due to dysfunctional IP3 receptors further exacerbates neuronal loss. Thus, the PRKN allele contributes to Parkinson's disease by disrupting mitochondrial homeostasis and calcium signaling. The biological effect is neurodegeneration, manifesting as Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is critical for mitochondrial quality control, as PRKN (parkin) mediates ubiquitin-dependent degradation of damaged mitochondria through mitophagy. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and increased oxidative stress. This contributes to neuronal dysfunction and degeneration. The disruption of this pathway is strongly associated with Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. Mutations in PRKN are one of the most common genetic causes of early-onset Parkinson's disease. The pathway's disruption leads to mitochondrial dysfunction, impaired calcium homeostasis via the IP3-ITPR-Ca2+ signaling cascade, and neuronal death. These molecular mechanisms underlie the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway plays a critical role in mitochondrial quality control through the ubiquitination and degradation of damaged mitochondria via mitophagy. Mutations in PRKN lead to impaired mitophagy, resulting in mitochondrial dysfunction and neurodegeneration. This pathway is central to Parkinson\u2019s disease (PD), where PRKN mutations contribute to the accumulation of damaged mitochondria and neuronal loss, particularly in dopaminergic neurons. PRKN is a key gene in PD, with mutations causing early-onset and severe forms of the disease. Therefore, the biological effect of a pathogenic PRKN allele is the disruption of mitochondrial homeostasis, which directly contributes to the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the given pathway, PRNP is upstream of BIP (HSPA5), which is involved in the unfolded protein response. This pathway culminates in ATF4 and DDIT3, which are linked to cellular stress responses and apoptosis. Mutations in PRNP can cause misfolding and aggregation of the prion protein, triggering ER stress and downstream effects that contribute to neurotoxicity. This process is central to the pathogenesis of prion diseases. The biological effect of the PRNP allele is therefore the initiation of a stress response pathway that, when dysregulated, leads to neuronal damage. This pathway is directly associated with Creutzfeldt-Jakob disease (CJD), a fatal neurodegenerative disorder caused by prion protein misfolding.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the given pathway, PRNP is upstream of BIP (HSPA5), which is involved in the unfolded protein response. This pathway ultimately leads to ATF4 activation and the expression of DDIT3, a gene involved in cellular stress responses. Mutations in PRNP, particularly those leading to misfolding or aggregation of the prion protein, are causative in **Creutzfeldt-Jakob Disease (CJD)**. This is a fatal, rapidly progressive neurodegenerative disorder characterized by prion protein misfolding and subsequent neuronal damage. The pathway reflects the involvement of PRNP in stress response mechanisms and its role in disease progression. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the given pathway, PRNP is upstream of BIP (HSPA5), suggesting a role in protein folding and ER stress responses. The pathway continues through EIF2AK3, EIF2S1, ATF4, and ultimately DDIT3, which are involved in stress response and cell survival. Mutations in PRNP can cause misfolding and aggregation of the prion protein, leading to the propagation of abnormal conformations. This is central to the pathogenesis of Creutzfeldt-Jakob Disease (CJD), a rapidly progressive and fatal neurodegenerative disorder caused by prion protein misfolding. \\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the L-type voltage-gated calcium channel. This subunit plays a critical role in regulating calcium influx into neurons, which is essential for various physiological processes, including neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with impaired calcium homeostasis, leading to hyperexcitability of neurons and disrupted synaptic transmission. These disruptions are linked to neurological disorders. Specifically, pathogenic variants in CACNA1A are a well-documented cause of familial hemiplegic migraine (FHM), a rare form of migraine with brainstem involvement and motor symptoms. The biological effect of the CACNA1A allele involves dysregulated calcium signaling, contributing to neuronal dysfunction and the pathogenesis of \\boxed{familial hemiplegic migraine}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the Cav1.1 calcium channel, which is critical for voltage-gated calcium entry in neurons. The pathway described involves extracellular calcium entering through this channel, contributing to intracellular calcium signaling. Mutations in CACNA1A are associated with altered calcium homeostasis, leading to neuronal dysfunction. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, pathogenic variants in CACNA1A are a well-documented cause of **Friesenthal syndrome**, a rare genetic disorder characterized by cerebellar ataxia, epilepsy, and intellectual disability. These mutations disrupt normal calcium dynamics, affecting neuronal excitability and synaptic transmission. The resulting dysfunction underlies the clinical manifestations observed in Friesenthal syndrome. \n\n\\boxed{Friesenthal syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel. This subunit is critical for calcium influx into neurons, playing a key role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with various neurological disorders. Notably, this gene is implicated in familial hemiplegic migraine (FHM), a genetic form of migraine with aura. The pathway described\u2014Ca2+ extracellular \u2192 CACNA1A \u2192 Ca2+\u2014highlights its role in calcium homeostasis. Dysregulation of this channel can lead to excessive intracellular calcium, causing neuronal dysfunction and the characteristic symptoms of FHM. Therefore, the biological effect of this CACNA1A allele is linked to \\boxed{Familial Hemiplegic Migraine}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 pathway is critical for innate immune responses, particularly in the recognition of cytosolic DNA and the activation of antiviral defenses. TBK1 phosphorylates key proteins such as IRF3, leading to the production of type I interferons, and also activates the autophagy process by interacting with proteins like OPTN, SQSTM1, and NBR1, which are involved in the recruitment of LC3-II for autophagosome formation. Mutations in TBK1 are associated with impaired antiviral immunity and are linked to neurodevelopmental disorders. Specifically, loss-of-function variants in TBK1 contribute to the development of **Autism Spectrum Disorder (ASD)** by disrupting synaptic development and immune modulation. \\boxed{Autism Spectrum Disorder}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 pathway is central to innate immunity and autophagy, regulating the response to viral infections and cellular stress. TBK1 activates key downstream proteins like IRF3, driving type I interferon production, and interacts with autophagy receptors such as SQSTM1, OPTN, and NDP52 to mediate antiviral autophagy. Mutations in TBK1 disrupt these processes, impairing antiviral defense and leading to chronic inflammation. This contributes to the development of neuroinflammatory and autoimmune diseases. Specifically, TBK1 mutations are associated with **Niemann-Pick disease type C1 (NP-C1)**, a lysosomal storage disorder characterized by neurodegeneration, hepatosplenomegaly, and psychiatric symptoms. The pathway's dysfunction in NP-C1 leads to impaired autophagy and interferon signaling, exacerbating disease progression. \\boxed{Niemann-Pick disease type C1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves TBK1, which interacts with autophagy-related proteins such as SQSTM1, OPTN, TAX1BP1, and NBR1, and is connected to LC3-II, a marker of autophagosome formation. TBK1 plays a key role in antiviral immunity and autophagy-mediated degradation of pathogens. Mutations in TBK1 are associated with impaired autophagy and innate immune responses. This contributes to the susceptibility to neurodegenerative diseases. Specifically, variants in TBK1 have been linked to amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder characterized by the loss of motor neurons. The dysfunction of this pathway impairs clearance of damaged proteins and pathogens, leading to neuronal damage. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the accumulation of abnormal alpha-synuclein aggregates, such as Lewy bodies, which are a hallmark of Parkinson's disease. These aggregates disrupt neuronal function and contribute to the progressive degeneration of dopaminergic neurons in the substantia nigra. The pathway described includes components of complex I of the mitochondrial electron transport chain, which are also affected in Parkinson's due to oxidative stress and mitochondrial dysfunction. The interplay between SNCA and mitochondrial complex I subunits highlights the role of both protein misfolding and energy metabolism in disease progression. Thus, the SNCA allele contributes to the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein, forming Lewy bodies, which are hallmark pathological features of Parkinson's disease. The presence of SNCA in this pathway, which includes components of complex I of the mitochondrial electron transport chain, suggests a link between mitochondrial dysfunction and neurodegeneration. This connection is crucial, as impaired mitochondrial function and oxidative stress are known contributors to neuronal death in Parkinson's disease. Therefore, the SNCA allele contributes to the development of Parkinson's disease by promoting protein misfolding, aggregation, and subsequent neuronal dysfunction. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in neurodegenerative diseases. Mutations or overexpression of SNCA are strongly associated with Parkinson's disease (PD). Alpha-synuclein misfolding and aggregation lead to the formation of Lewy bodies, a pathological hallmark of PD. These aggregates disrupt neuronal function, particularly in dopamine-producing neurons of the substantia nigra, leading to progressive motor dysfunction. The pathway also includes components of complex I of the electron transport chain, suggesting a link between mitochondrial dysfunction and neurodegeneration. Mutations in genes like ND1, ND2, and others involved in complex I may exacerbate oxidative stress and neuronal damage, further contributing to PD pathology. Thus, the SNCA allele is a key contributor to the development of Parkinson's disease.  \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in a pathway that includes DAXX and ASK1, leading to activation of JNK. This pathway is implicated in cellular stress responses and apoptosis. Mutations in PARK7 are associated with oxidative stress and mitochondrial dysfunction, which contribute to neuronal death. These genetic alterations are linked to Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The dysfunction of PARK7 disrupts protein degradation and increases susceptibility to oxidative damage, thereby promoting the progression of Parkinson's disease. Thus, the PARK7 allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in a signaling pathway that includes DAXX and ASK1, leading to activation of JNK. This pathway is critical for stress response and apoptosis. Mutations in PARK7 are associated with impaired protein deglycation and mitochondrial dysfunction, contributing to neurodegeneration. The loss of functional PARK7 disrupts cellular homeostasis, leading to oxidative stress and neuronal death. This is most notably linked to Parkinson's disease, where PARK7 mutations are among the genetic risk factors. The disruption of this pathway contributes to dopaminergic neuron loss, a hallmark of Parkinson's. Therefore, the biological effect of the PARK7 allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in a pathway that includes DAXX and ASK1, leading to activation of JNK. Mutations in PARK7 are associated with Parkinson's disease. The protein encoded by PARK7 plays a role in protecting neurons from oxidative stress and has chaperone-like functions. Loss-of-function mutations in PARK7 disrupt mitochondrial homeostasis and contribute to neurodegeneration. These genetic alterations are linked to early-onset Parkinson's disease, characterized by the progressive loss of dopaminergic neurons in the substantia nigra. The pathway involving PARK7, DAXX, and ASK1 influences the JNK signaling cascade, which is involved in apoptosis and inflammation, further supporting its role in Parkinson's disease pathogenesis. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele is part of the MAPK (mitogen-activated protein kinase) signaling pathway, where BRAF activates MEK, which in turn phosphorylates ERK. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation and survival. This dysregulation is a key driver in several cancers. The most well-known disease associated with this pathway is melanoma, where BRAF mutations are found in approximately 50% of cases. Additionally, BRAF mutations contribute to other malignancies, including colon adenocarcinoma, thyroid carcinoma, and non-small cell lung cancer. The persistent activation of ERK due to mutated BRAF results in increased cell growth, resistance to apoptosis, and angiogenesis, all of which support tumor progression. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele, specifically mutations in the BRAF gene, contribute to the activation of the BRAF-MEK-ERK signaling pathway. This pathway is critical for cell proliferation, survival, and differentiation. Mutations in BRAF, such as the V600E substitution, lead to constitutive activation of the BRAF kinase, which in turn promotes uncontrolled cell growth. This dysregulation is a key driver in several cancers. The most well-known disease associated with BRAF mutations is **melanoma**, where activating mutations in BRAF are frequently observed. These mutations also contribute to other cancers, including colon cancer, lung cancer, and thyroid cancer. The aberrant activation of the MEK and ERK kinases downstream of BRAF results in oncogenic transformation and tumorigenesis. Thus, BRAF mutations are strongly linked to **melanoma** and other malignancies. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele, specifically the V600E mutation, leads to constitutive activation of the BRAF protein, which drives the MAPK/ERK signaling pathway by continuously phosphorylating MEK and subsequently ERK. This results in uncontrolled cell proliferation and survival, promoting tumorigenesis. The pathway is critical in cell growth regulation, and its dysregulation is commonly observed in various cancers. The BRAF mutation is a well-known driver in melanoma, where it contributes to oncogenic transformation. It is also implicated in other malignancies such as colorectal, lung, and thyroid cancers. The continuous activation of ERK downstream of mutated BRAF promotes resistance to apoptosis and enhances angiogenesis, further supporting tumor progression. Therefore, the biological effect of the BRAF allele is the initiation and progression of cancer. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene is involved in the purine salvage pathway, catalyzing the conversion of adenine to inosine monophosphate (IMP). Mutations in APRT can lead to reduced activity of the enzyme, resulting in the accumulation of adenine and its derivatives, such as 2,6-diamino-4-hydroxypteridine (DAP), which is toxic. This accumulation causes oxidative stress and neuronal damage, leading to neurological symptoms. The most well-known disease associated with APRT deficiency is Lesch-Nyhan syndrome, a rare X-linked recessive disorder characterized by neurologic abnormalities, self-mutilating behaviors, and metabolic disturbances. The APRT allele contributes to this disease by disrupting the purine metabolism pathway, leading to the hallmark symptoms of Lesch-Nyhan syndrome.\n\n\\boxed{Lesch-Nyhan syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene is involved in the salvage pathway for purine nucleotide synthesis. It catalyzes the conversion of adenine to inosine monophosphate (IMP). Mutations in APRT can lead to decreased activity of the enzyme, resulting in the accumulation of adenine and its metabolites, such as 2,6-diaminopurines, which are toxic. This accumulation leads to the deposition of yellowish pigments in tissues, particularly the urine, skin, and eyes. The most well-known condition associated with APRT deficiency is Lesch-Nyhan syndrome. This X-linked recessive disorder is characterized by neurological abnormalities, self-injurious behaviors, and hyperuricemia. The defective APRT allele contributes to the metabolic dysfunction that underlies the clinical manifestations of Lesch-Nyhan syndrome.\n\n\\boxed{Lesch-Nyhan syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene is involved in the salvage pathway of purine metabolism. This pathway recycles purines for nucleotide synthesis. Mutations in APRT can lead to reduced activity of the enzyme, resulting in the accumulation of its substrate, 5-formyltetrahydrofolate, and decreased purine synthesis. This deficiency leads to the accumulation of adenosine and 2,6-diaminopurines, which can cause neurologic damage. The most well-documented disease associated with APRT deficiency is Lesch-Nyhan syndrome, an X-linked recessive disorder characterized by neurological abnormalities, self-injurious behaviors, and gout-like symptoms due to overproduction of uric acid. \\boxed{Lesch-Nyhan syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates the cell cycle by inhibiting E2F transcription factors. The pathway defined (RB1 // E2F) highlights the interaction between RB1 and E2F1-E2F3, which control expression of genes involved in DNA replication and cell division. When RB1 is functional, it restrains E2F activity, preventing uncontrolled cell proliferation. Mutations in RB1, such as loss-of-function alleles, disrupt this regulatory mechanism, leading to unchecked cell growth. This contributes to the development of retinoblastoma, a childhood eye cancer, and also increases the risk of other cancers, including small cell lung cancer and osteosarcoma. The hallmark of RB1 mutations is their role in promoting genomic instability and tumor progression by derepressing E2F-driven genes. \\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates cell cycle progression by inhibiting E2F transcription factors. The pathway defined (RB1 // E2F) reflects the interaction between RB1 and E2F family members, which control genes involved in DNA synthesis and cell division. When RB1 is mutated or inactivated, it loses its ability to restrain E2F-mediated transcription, leading to uncontrolled cell proliferation. This dysregulation is a hallmark of retinoblastoma, a pediatric eye cancer arising from retinal cells. Additionally, RB1 inactivation contributes to various other cancers, including small cell lung carcinoma, osteosarcoma, and bladder cancer. The loss of RB1 function disrupts cell cycle control, promoting genomic instability and tumor formation. Thus, the biological effect of this RB1 allele is the development of retinoblastoma and other malignancies. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates cell cycle progression by inhibiting E2F transcription factors. The pathway defined by RB1 and E2F1-3 is central to controlling the G1/S checkpoint. Loss-of-function mutations in RB1 disrupt this regulatory mechanism, leading to unchecked cell proliferation. This is particularly critical in tissues with high cell turnover, such as the retina. Mutations in RB1 are well established as the primary cause of retinoblastoma, a rare but aggressive childhood eye cancer. Additionally, RB1 inactivation contributes to various other malignancies, including small cell lung cancer, osteosarcoma, and bladder cancer. The loss of RB1 function allows for aberrant E2F-mediated transcription of genes involved in cell cycle progression and angiogenesis, driving tumorigenesis. Thus, the biological effect of this RB1 allele is the promotion of retinoblastoma and other cancers through dysregulation of cell cycle control.\n\n\\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-dependent protein degradation pathway. In the context of the provided genomic pathway, ATXN3 is part of the IP3-mediated calcium signaling cascade, which regulates mitochondrial calcium levels and subsequently influences mitochondrial permeability transition pore (MPTP) activity. Mutations in ATXN3 are well-known to cause Spinocerebellar Ataxia Type 2 (SCA2), a neurodegenerative disorder characterized by progressive cerebellar ataxia. These mutations lead to the production of an abnormally long polyglutamine tract in ataxin-3, resulting in protein misfolding, aggregation, and neuronal toxicity. The disruption of calcium homeostasis and mitochondrial function in this pathway further exacerbates neuronal damage, contributing to the pathological features of SCA2. \\boxed{Spinocerebellar Ataxia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is involved in the degradation of misfolded proteins via the ubiquitin-proteasome system. Mutations in ATXN3 lead to the accumulation of abnormal proteins, contributing to neurodegeneration. Specifically, expansions in the polyglutamine tract of ATXN3 cause the disease \\boxed{Spinocerebellar Ataxia Type 2 (SCA2)}. This expansion results in protein misfolding and aggregation, leading to neuronal loss in the cerebellum and other brain regions, which manifests as progressive coordination deficits and ataxia. The pathway involving ATXN3 connects glutamate signaling to mitochondrial calcium dynamics and apoptosis via the MPTP pathway, further supporting its role in neurodegenerative processes.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is involved in the degradation of misfolded proteins through ubiquitin-dependent pathways. Mutations in ATXN3 lead to the production of an expanded polyglutamine tract, resulting in protein misfolding and aggregation. This contributes to neuronal dysfunction and degeneration. The accumulation of these toxic protein aggregates disrupts cellular processes, including protein homeostasis and mitochondrial function. This pathology is a hallmark of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive cerebellar atrophy and motor incoordination. The involvement of ATXN3 in the pathway highlights its role in maintaining cellular integrity and preventing neurodegeneration. Mutations in ATXN3 are a primary cause of SCA2, making it a critical gene in the pathogenesis of this disease.\n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, ultimately affecting DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The altered function of SOD1 in this pathway likely disrupts protein folding and stress responses, contributing to neuronal toxicity. This pathway's dysfunction is closely linked to the pathogenesis of ALS. Therefore, the biological effect of the SOD1 allele in this context is its contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 suggests a stress response mechanism involving protein folding and transcriptional regulation. Mutations in SOD1, a copper/zinc superoxide dismutase, are well-established in amyotrophic lateral sclerosis (ALS). The altered SOD1 protein disrupts protein homeostasis, leading to oxidative stress and neuronal dysfunction. The pathway's involvement of BIP (a molecular chaperone) and ATF6 (an ER stress sensor) indicates a role in the unfolded protein response. DDIT3, a downstream target, is linked to cell cycle arrest and apoptosis. Collectively, this pathway's dysregulation contributes to neurodegeneration. The SOD1 mutation leads to the accumulation of misfolded proteins and ER stress, ultimately resulting in motor neuron death. This pathway is central to the pathogenesis of ALS. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 involves SOD1, a key enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. The SOD1 allele, when mutated, leads to the accumulation of misfolded proteins and triggers stress responses via the unfolded protein response (BIP and ATF6), ultimately resulting in the upregulation of DDIT3, which is associated with cell cycle arrest and apoptosis. These molecular disruptions contribute to neuronal dysfunction and death, hallmark features of ALS. Therefore, the biological effect of the SOD1 allele is the pathogenesis of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the AKT signaling pathway, which promotes cell survival and proliferation. Loss of PTEN function leads to increased PIP3 levels and constitutive activation of AKT, driving uncontrolled cell growth. This dysregulation is a hallmark of several cancers. Specifically, mutations in PTEN are strongly associated with neuroendocrine tumors, particularly those arising from the central nervous system, such as medulloblastoma and glioblastoma. PTEN mutations also contribute to other malignancies, including prostate, breast, and endometrial cancers. The most well-known syndrome linked to PTEN dysfunction is Cowden syndrome, which increases the risk of multiple benign and malignant tumors, including thyroid cancer and breast cancer. \\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the PI3K-AKT signaling pathway. When PTEN is mutated or lost, PIP3 levels increase, leading to constitutive activation of AKT. This results in uncontrolled cell proliferation, survival, and migration, contributing to tumorigenesis. The loss of PTEN function is commonly associated with various cancers, including breast, prostate, endometrial, and brain tumors. One of the most well-documented diseases linked to PTEN dysfunction is **Cowden syndrome**, a hereditary disorder characterized by multiple benign and malignant tumors. Additionally, PTEN mutations are a key driver in **Pseudohypoparathyroidism** and are frequently observed in **glioblastoma multiforme**. Thus, the biological effect of a dysfunctional PTEN allele is the promotion of oncogenesis, particularly contributing to **Cowden syndrome** and other cancers. \n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene encodes a phosphatase that dephosphorylates PIP3, converting it back to PIP2. This negatively regulates the PI3K-AKT signaling pathway, which is critical for cell survival, growth, and metabolism. Loss of PTEN function leads to accumulation of PIP3 and activation of AKT, promoting uncontrolled cell proliferation and survival. This contributes to the development of various cancers. Specifically, mutations in PTEN are strongly associated with the phosphatase and tensin homolog deficiency, which is a key driver in the pathogenesis of **Cowden syndrome** and **PTEN hamartoma tumor syndrome**, as well as in the progression of **breast, prostate, endometrial, and glioblastoma cancers**. The loss of PTEN function disrupts tumor suppression, leading to neoplastic growth and disease progression. \\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of infectious prions. In the given pathway, PRNP is the starting point, linking to NMDA receptors (GRIN1, GRIN2A-D), which regulate calcium entry into neurons. Excessive calcium influx through NMDARs can activate the mitochondrial calcium uniporter (MCU) via VDACs and SLC25A family members, leading to mitochondrial calcium overload. This triggers the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS), which activates APAF1 and initiates apoptosis via CASP9 and CASP3. This pathway is central to neuronal cell death. The PRNP allele, particularly mutant forms, contributes to prion diseases, such as Creutzfeldt-Jakob disease (CJD). These diseases are characterized by misfolded prion protein accumulation, leading to neurodegeneration and rapid dementia.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which plays a role in cellular signaling and neuroprotection. In the given pathway, PRNP is upstream of NMDAR, implicating it in glutamatergic transmission and calcium homeostasis. When PRNP is mutated, it can lead to misfolded prion proteins, disrupting neuronal function and causing neurodegeneration. This pathway ultimately leads to mitochondrial calcium overload, activation of the mitochondrial permeability transition pore (MPTP), release of cytochrome c, and activation of the caspase cascade, resulting in apoptosis. This mechanism is central to several neurodegenerative diseases. The most well-known disease associated with PRNP mutations is Creutzfeldt-Jakob disease (CJD), a rare, rapidly progressive, and fatal brain disorder caused by the accumulation of misfolded prion proteins. \\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can induce neurodegenerative diseases. In the given pathway, PRNP is the starting point, initiating a cascade involving NMDA receptor subunits (GRIN1, GRIN2A-D), leading to calcium influx, mitochondrial calcium uptake via MCU, and subsequent mitochondrial permeability transition pore (MPTP) opening. This results in the release of cytochrome c (CYCS), activating APAF1 and caspases (CASP9, CASP3), ultimately causing apoptosis. This pathway is central to neuronal death. The misfolding of PRNP is directly linked to **Creutzfeldt-Jakob Disease (CJD)**, a rare, fatal prion disease characterized by rapid progression of neurological decline. The pathway highlights how PRNP dysfunction contributes to neuronal death via calcium dysregulation and apoptotic cascades, characteristic of CJD.\n\n\\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of this genomic pathway, plays a role in oxidative stress regulation. SOD1 catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen, thus mitigating oxidative damage. However, in the context of this pathway, SOD1 is linked to apoptosis regulation through interactions with BCL2, BAX, and BAK1, ultimately influencing cytochrome c release, APAF1 activation, and caspase-9 and -3 activation. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive loss of motor neurons. These mutations lead to toxic gain-of-function effects, disrupting cellular homeostasis and triggering apoptotic pathways. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that regulates apoptosis. SOD1, a copper/zinc superoxide dismutase, normally detoxifies reactive oxygen species. However, mutant SOD1 proteins gain toxic gain-of-function properties, leading to mitochondrial dysfunction and disruption of the intrinsic apoptosis pathway. This includes the release of cytochrome c from mitochondria via BAX and BAK1, activation of APAF1, CASP9, and ultimately CASP3, leading to cell death. Mutations in SOD1 are a well-documented cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by motor neuron loss. The toxic gain-of-function of mutant SOD1 disrupts cellular homeostasis and contributes to neuronal death. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described genomic pathway, is involved in apoptosis regulation. SOD1, a copper/zinc superoxide dismutase, normally detoxifies reactive oxygen species. Mutant SOD1 proteins, however, gain toxic gain-of-function properties, promoting neuronal death by disrupting mitochondrial function and activating the intrinsic apoptosis pathway. This leads to the release of cytochrome c, activating APAF1 and caspase-9, which in turn activates caspase-3 and triggers apoptosis. This pathway is critical in motor neuron degeneration. Mutations in SOD1 are a well-established cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The described pathway reflects the apoptotic mechanism through which mutant SOD1 contributes to ALS pathology.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, initiated by the MET proto-oncogene, plays a critical role in cell proliferation, survival, and migration. Activation of MET leads to the downstream signaling cascade involving GRB2, SOS, RAS, RAF, MEK, and ERK, ultimately resulting in the upregulation of CCND1, a key regulator of the cell cycle. Mutations or overexpression of MET can cause constitutive activation of this pathway, leading to uncontrolled cell proliferation. This contributes to the development of various cancers, including metastatic carcinomas. Specifically, aberrant MET signaling is strongly associated with the progression of non-small cell lung cancer (NSCLC), gastrointestinal stromal tumors (GISTs), and other malignancies. The activation of this pathway promotes tumor growth, invasion, and resistance to therapy. Thus, MET alterations are critical in the pathogenesis of NSCLC. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting from MET -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1. This pathway is critical for cell proliferation, survival, and differentiation. Activation of MET leads to the upregulation of CCND1, a key regulator of the cell cycle, promoting G1 phase progression. Overactivation of this pathway, often due to MET mutations or overexpression, drives uncontrolled cell growth. This contributes to the development of various cancers, particularly those involving tumor growth and metastasis. The MET pathway is frequently dysregulated in cancers such as non-small cell lung cancer, gastric cancer, and certain types of renal cell carcinoma. Therefore, the biological effect of this MET allele is the promotion of tumor growth and progression. \\boxed{Lung Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when mutated or overexpressed, activates the MET receptor tyrosine kinase, initiating a signaling cascade that includes GRB2, SOS, RAS, RAF, MEK, and ERK, ultimately leading to the upregulation of CCND1. This pathway is critical for cell proliferation, survival, and differentiation. Dysregulation of this pathway due to MET alterations results in uncontrolled cell growth and resistance to apoptosis. This contributes to the development and progression of cancers characterized by MET-driven oncogenesis. The most prominent disease associated with MET activation is non-small cell lung cancer (NSCLC), particularly in patients with MET exon 14 skipping mutations or MET amplifications. Additionally, MET alterations are implicated in other cancers, including gastric, papillary thyroid, and clear cell renal cell carcinomas. The activation of this pathway promotes tumor growth, metastasis, and poor prognosis. \\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase involved in ubiquitin-mediated proteolysis. Mutations in PRKN are a major cause of autosomal recessive Parkinson's disease. The pathway involving PRKN, MAO-A, and MAO-B suggests a link to dopamine metabolism. Parkin dysfunction leads to the accumulation of damaged mitochondria and proteins, contributing to neuronal loss in the substantia nigra. This process is exacerbated by the activity of monoamine oxidase enzymes, which metabolize dopamine. Impaired PRKN function disrupts quality control mechanisms, leading to neurodegeneration. This pathway is central to the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase critical for ubiquitin-mediated protein degradation. Mutations in PRKN lead to impaired protein quality control, contributing to the accumulation of misfolded proteins and mitochondrial dysfunction. This is directly associated with Parkinson's disease (PD), where PRKN mutations cause loss of function, disrupting neural homeostasis and increasing susceptibility to neurodegeneration. The pathway involving MAO (monoamine oxidase A and B) suggests a link to dopamine metabolism, as MAO enzymes degrade dopamine, and impaired regulation may contribute to neurotoxicity in PD. Thus, PRKN mutations are a major genetic cause of early-onset Parkinson's disease, highlighting its role in neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase that plays a critical role in protein quality control and mitophagy. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. In the given pathway, PRKN interacts with monoamine oxidases (MAO A and B), which metabolize dopamine. Dysfunction in PRKN leads to impaired ubiquitin-mediated degradation of damaged mitochondria, resulting in neuronal death, particularly in dopaminergic neurons. This contributes to the pathogenesis of Parkinson's disease. The loss of PRKN function disrupts dopamine metabolism and mitochondrial health, exacerbating neurodegeneration. Therefore, the biological effect of this PRKN allele is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to DNA repair, cell cycle regulation, and apoptosis. Mutations in TP53 disrupt these functions, leading to genomic instability and resistance to DNA damage. This contributes to the development and progression of various cancers. The listed genes (CDKN1A, GADD45, BAX, BAK1, DDB2, POLK) are downstream effectors of p53, mediating cell cycle arrest, DNA repair, and apoptosis. When TP53 is mutated, these genes are dysregulated, allowing damaged cells to survive and proliferate. This is a hallmark of many cancers. The most significant disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary cancer predisposition syndrome. TP53 mutations also contribute to a wide range of malignancies, including sarcomas, breast cancer, ovarian cancer, and brain tumors. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cell cycle regulation, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to genomic instability and uncontrolled cell proliferation. The listed genes\u2014CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK\u2014are downstream effectors of p53, mediating cell cycle arrest, DNA repair, and apoptosis. When TP53 is mutated, these genes are dysregulated, impairing the cell's ability to respond to DNA damage. This contributes to the development and progression of cancers characterized by genomic instability. The most significant disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary cancer predisposition syndrome. TP53 mutations are also frequently found in various malignancies, including breast, ovarian, bone, and brain cancers. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cell cycle regulation, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to loss of genomic stability. The listed genes\u2014CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK\u2014are downstream targets of p53, involved in cell cycle arrest, DNA repair, and apoptosis. Dysfunction in this pathway impairs the cell's ability to respond to DNA damage, promoting uncontrolled cell proliferation. This is a hallmark of cancer. Specifically, TP53 mutations are strongly associated with **Li-Fraumeni syndrome**, a hereditary disorder characterized by a high risk of multiple cancers, including sarcomas, breast cancer, brain tumors, and leukemias. Therefore, the biological effect of this TP53 allele is the development of **Li-Fraumeni syndrome**.\n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway begins with the **APP** gene, which encodes the amyloid beta precursor protein. Mutations in **APP** lead to the accumulation of **Abeta**, a key component in the formation of amyloid plaques. This contributes to **neurodegeneration** and is strongly associated with **Alzheimer\u2019s disease**. The subsequent cascade involves the release of **Ca\u00b2+** from the endoplasmic reticulum and mitochondria, leading to mitochondrial dysfunction, the permeabilization of the mitochondrial membrane (MPTP), and the release of **cytochrome c**, which activates the **apoptotic pathway** via **APAF1** and **caspase 9/3**, ultimately resulting in **cell death**. This pathway is central to the pathology of **Alzheimer\u2019s disease**, where it contributes to synaptic dysfunction, neuronal loss, and cognitive decline. The involvement of **APP** in this pathway highlights its critical role in **Alzheimer\u2019s disease**.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele, as shown in this genomic pathway, is the production of amyloid beta (Abeta), which initiates a cascade leading to mitochondrial calcium dysregulation, permeability transition pore (MPTP) opening, and subsequent release of cytochrome c, promoting apoptosis via caspase activation. This pathway is central to neurodegenerative processes. Mutations in APP are well-documented contributors to Alzheimer's disease, as they lead to the accumulation of toxic amyloid-beta plaques in the brain, disrupting cellular function and triggering neuronal apoptosis. The involvement of downstream molecules such as GRM5, GNAQ, PLCB, ITPR, MCU, and the apoptotic cascade underscores the role of APP in mitochondrial dysfunction and cell death, hallmark features of Alzheimer's disease. Thus, this pathway directly contributes to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele described in this genomic pathway is the production of amyloid-beta (Abeta), which initiates a cascade leading to mitochondrial dysfunction, calcium dysregulation, and ultimately apoptosis. This pathway is central to neurodegenerative processes, particularly those involving mitochondrial stress and cell death. The involvement of key players such as GRM5, GNAQ, PLCB, ITPR, MCU, and the mitochondrial permeability transition pore (MPTP) highlights the role of intracellular calcium imbalance and mitochondrial damage. The final effect is the activation of caspase-dependent apoptosis via APAF1 and CASP9, leading to neuronal death. This pathway is strongly associated with Alzheimer\u2019s disease, where the accumulation of Abeta and subsequent mitochondrial dysfunction contribute to neuronal loss and cognitive decline. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of infectious prions. In the given pathway, PRNP is the starting point, connecting to ryanodine receptors (RYR1-3) and inositol trisphosphate receptors (ITPR1-3), which regulate calcium release from the endoplasmic reticulum. This calcium influx is taken up by the mitochondrial calcium uniporter (MCU), leading to increased mitochondrial calcium (Ca2+ mito). Excess mitochondrial calcium can trigger the mitochondrial permeability transition pore (MPTP), causing mitochondrial damage and the release of cytochrome c (CYCS). This activates apoptotic pathways via APAF1 and CASP9, ultimately leading to CASP3 activation and apoptosis. This pathway is central to neurodegenerative diseases. The PRNP mutation is specifically linked to **Creutzfeldt-Jakob Disease (CJD)**, a rare, fatal brain disorder caused by prion protein misfolding. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the given pathway, PRNP is linked to RYR and ITPR, which regulate intracellular calcium release. This calcium flux is critical for mitochondrial function via MCU, leading to mitochondrial calcium overload. This overload can trigger the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS), which activates APAF1 and subsequently CASP9 and CASP3, leading to apoptosis. Mutations in PRNP, particularly those causing misfolding, are directly associated with Creutzfeldt-Jakob Disease (CJD), a fatal neurodegenerative disorder characterized by prion protein misfolding and subsequent neuronal damage. The pathway highlights the role of PRNP in calcium homeostasis and its disruption in disease progression.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the given pathway, PRNP is upstream of RYR and ITPR, which are calcium release channels in the sarcoplasmic reticulum. This calcium release activates the mitochondrial calcium uniporter (MCU), increasing mitochondrial calcium levels. Excess mitochondrial calcium can trigger the mitochondrial permeability transition pore (MPTP), leading to cytochrome c release. This activates the apoptotic pathway via APAF1, CASP9, and CASP3, resulting in cell death. This pathway is implicated in neurodegeneration. The PRNP mutation, particularly the methionine-to-valine substitution (MV), is a known risk factor for Creutzfeldt-Jakob disease (CJD), a fatal prion disease. \\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes protein ubiquitination and proteasomal degradation. SOD1, when misfolded or mutant, is associated with the aggregation of proteins marked with ubiquitin, leading to their improper degradation by the 26S proteasome. This process is critical in maintaining protein homeostasis. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The accumulation of misfolded SOD1 proteins disrupts cellular function, particularly in motor neurons, leading to their death. This pathway's dysfunction is a key contributor to the pathogenesis of ALS. Thus, the biological effect of this SOD1 allele is the development of $\\boxed{Amyotrophic Lateral Sclerosis (ALS)}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes protein ubiquitination and degradation via the 26S proteasome. SOD1 (superoxide dismutase 1) is an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations lead to the accumulation of misfolded SOD1 proteins, which can aggregate and disrupt cellular function, particularly in motor neurons. The involvement of the ubiquitin-proteasome system in this pathway suggests that impaired degradation of mutant SOD1 contributes to disease pathology. Therefore, the biological effect of this SOD1 allele is the contribution to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 (superoxide dismutase 1) gene is central to this genomic pathway, which involves ubiquitin-mediated protein degradation via the 26S proteasome. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. The pathway reflects the degradation of misfolded or damaged proteins, including mutant SOD1, which accumulates in ALS. The involvement of proteasome subunits (e.g., PSMA and PSMB) suggests impaired proteasomal function, contributing to neurodegeneration. Mutant SOD1 forms toxic aggregates, disrupts mitochondrial function, and induces oxidative stress, all hallmarks of ALS pathology. Therefore, the biological effect of the SOD1 allele in this pathway is the progression of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is involved in the NRG (Neuregulin) signaling pathway, which plays a critical role in neuronal development, myelination, and cell survival. ERBB4 is a receptor tyrosine kinase that binds Neuregulin ligands (NRG1-NRG4), activating downstream signaling cascades such as the MAPK and PI3K pathways. Mutations or dysregulation of ERBB4 can disrupt these pathways, leading to impaired neural development and connectivity. This contributes to neurodevelopmental disorders. Specifically, alterations in ERBB4 have been implicated in schizophrenia, where disrupted synaptic plasticity and neural circuitry are key features. The pathway's involvement in both developmental and adult brain functions makes ERBB4 a key player in psychiatric and neurological diseases. \\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cell signaling, particularly in neuronal development, myelination, and cell proliferation. The NRG (neuregulin) family of ligands binds to ERBB4, activating downstream signaling pathways such as the MAPK and PI3K/AKT pathways. Mutations or dysregulation of ERBB4 can disrupt these pathways, leading to impaired neural development and function. ERBB4 is implicated in several diseases, including certain types of cancer, such as non-small cell lung cancer and glioblastoma, due to its role in promoting cell survival and proliferation. However, its most significant disease association is in neurodevelopmental disorders. Mutations in ERBB4 are linked to schizophrenia and autism spectrum disorder (ASD), as they affect neural connectivity and synaptic plasticity. \\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is a key component of the NRG (Neuregulin) signaling pathway, which plays a crucial role in neural development, myelination, and cell survival. ERBB4 functions as a receptor tyrosine kinase that mediates signals from NRG1-4, promoting neurodevelopment and synaptic plasticity. Mutations or dysregulation of ERBB4 can disrupt these processes, contributing to neurological disorders. Specifically, alterations in ERBB4 have been implicated in schizophrenia, a psychiatric disorder characterized by disruptions in neural connectivity and cognition. ERBB4 variants are also associated with increased risk of gliomas and other neurodevelopmental conditions. The dysregulation of this pathway is linked to impaired neuronal development and function, making it a contributing factor to schizophrenia. \n\n\\boxed{Schizophrenia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, through its interaction with the pathway HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK, contributes to neurodegenerative processes. Mutations in HTT, particularly expansions of the CAG repeat, lead to the production of an unstable huntingtin protein, which disrupts cellular functions. This disrupts the MAPK signaling pathway, leading to neuronal death. This pathway is critical for stress responses and apoptosis. The disruption of this pathway is implicated in the pathogenesis of Huntington's disease. The accumulation of mutant huntingtin protein causes toxicity, leading to progressive degeneration of neurons, particularly in the striatum and cerebral cortex. This results in motor, cognitive, and psychiatric symptoms. Therefore, the biological effect of this HTT allele is the contribution to Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction leads to the accumulation of abnormal protein aggregates. This pathway, HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK, is involved in stress response and neuronal survival. Mutations in HTT, particularly CAG repeat expansions, result in the production of a toxic form of huntingtin, leading to neuronal degeneration. This is the genetic cause of Huntington's disease, a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The pathway's activation contributes to neuronal apoptosis through JNK-mediated signaling, exacerbating disease progression. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, when mutated, leads to the production of an abnormal huntingtin protein, which disrupts the neuronal pathway HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK. This disruption activates the c-Jun N-terminal kinase (JNK) signaling cascade, contributing to neuronal toxicity and apoptosis. This pathway is critical for neuronal survival and synaptic plasticity. The accumulation of mutant huntingtin protein causes progressive degeneration of neurons, particularly in the basal ganglia. This pathological process is the underlying mechanism of Huntington's disease, a neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. The mutation in HTT is inherited in an autosomal dominant manner, and the severity of the disease correlates with the length of the CAG repeat expansion in the HTT gene. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is central to the NRG (Neuregulin) signaling pathway, which plays a crucial role in neuronal development, myelination, and synaptic plasticity. ERBB4 is a receptor tyrosine kinase that binds Neuregulin ligands (NRG1\u20134), initiating downstream signaling cascades that regulate cell growth, differentiation, and survival. Mutations or dysregulation of ERBB4 can disrupt these processes, contributing to neurological disorders. Specifically, aberrant ERBB4 activity has been implicated in the pathogenesis of schizophrenia. This disorder is associated with impaired neural development and connectivity, which can result from disrupted NRG-ERBB4 signaling. Therefore, the biological effect of this ERBB4 allele is linked to the development of schizophrenia.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele, part of the NRG (Neuregulin) signaling pathway, plays a critical role in cellular processes such as differentiation, survival, and proliferation. Mutations or dysregulation in ERBB4 can disrupt this pathway, leading to aberrant signaling. This is particularly significant in neural development and myelination. ERBB4 is implicated in several diseases, including certain cancers like non-small cell lung cancer and breast cancer, where it can act as an oncogene. Additionally, ERBB4 has been linked to neurological disorders, such as schizophrenia and autism spectrum disorder, due to its role in brain development. Mutations in ERBB4 can also contribute to developmental disorders affecting the nervous system. One specific disease associated with ERBB4 dysfunction is \\boxed{Schizophrenia}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele plays a key role in the signaling pathway mediated by neuregulins (NRG1-4). ERBB4 is a receptor tyrosine kinase that, when activated by NRG ligands, initiates signaling cascades involved in cell proliferation, differentiation, and survival. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to various diseases. In particular, alterations in the ERBB4 pathway are implicated in neurodevelopmental disorders, including schizophrenia, due to its role in brain development and synaptic plasticity. Additionally, ERBB4 overactivation has been linked to certain cancers, such as non-small cell lung cancer and breast cancer, through enhanced cell growth and resistance to apoptosis. However, the most consistent and well-documented disease associated with ERBB4 dysfunction is \\boxed{Schizophrenia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase that plays a critical role in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with impaired ubiquitination and degradation of misfolded or damaged proteins, leading to the accumulation of toxic proteins in neurons. This dysfunction contributes to mitochondrial dysfunction, oxidative stress, and neurodegeneration. PRKN is particularly important in the degradation of mitochondria (mitophagy) and the removal of protein aggregates. Pathways involving MAO (monoamine oxidase) and DOPAL (dopamine \u03b2-hydroxylase) are also implicated in neurotransmitter metabolism and oxidative stress. Mutations in PRKN are strongly linked to Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. Therefore, the biological effect of pathogenic PRKN alleles is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase involved in ubiquitin-mediated degradation of proteins. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. In the given pathway, PRKN may influence the metabolism of dopamine through its interaction with monoamine oxidases (MAO-A and MAO-B), which break down monoamines like dopamine. Dysfunction in this pathway can lead to the accumulation of toxic dopamine metabolites, contributing to neurodegeneration. The loss of functional PRKN results in impaired protein quality control, leading to the accumulation of misfolded proteins and mitochondrial dysfunction, both of which are hallmarks of Parkinson's disease. Therefore, the biological effect of this PRKN allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase critical for mitochondrial quality control and protein degradation. Mutations in PRKN lead to loss of function, impairing the ubiquitination and degradation of damaged mitochondria and misfolded proteins. This results in the accumulation of dysfunctional mitochondria and oxidative stress, contributing to neuronal damage. PRKN mutations are a major cause of autosomal recessive Parkinson's disease. The pathway involving MAO enzymes (MAOA and MAOB) metabolizes dopamine and other monoamines, and dysfunction in this pathway can exacerbate oxidative stress and neurodegeneration. The combined disruption of PRKN and MAO pathways further supports the role of these genes in Parkinson's disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). In this pathway, SOD1 is upstream of BIP, which activates EIF2AK3. This leads to the phosphorylation of EIF2S1, inhibiting protein translation and activating ATF4, which in turn upregulates DDIT3. Mutant SOD1 proteins, particularly those with gain-of-toxic-function mutations, misfold and aggregate, disrupting cellular homeostasis. These aggregates trigger the unfolded protein response, leading to increased ER stress and neurodegeneration. The pathway's dysregulation contributes to neuronal death, particularly in motor neurons, which is a hallmark of ALS. Thus, the SOD1 allele's biological effect is central to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. SOD1, or superoxide dismutase 1, is a key enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are directly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway involving SOD1, BIP, EIF2AK3, EIF2S1, ATF4, and DDIT3 plays a role in cellular stress response and protein folding, which is disrupted in ALS. Mutant SOD1 proteins can misfold, aggregate, and cause toxicity, leading to motor neuron death. This contributes to the hallmark symptoms of ALS, including muscle atrophy and paralysis. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. This pathway is critical for cellular stress responses, particularly in protein folding and apoptosis regulation. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The misfolded SOD1 protein disrupts cellular homeostasis, leading to oxidative stress and neuronal death. The pathway's involvement in stress response and apoptosis further supports its role in ALS pathology. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase that plays a critical role in mitochondrial quality control and protein degradation via ubiquitin-proteasome pathways. Mutations in PRKN lead to impaired ubiquitination and degradation of damaged proteins, resulting in the accumulation of toxic aggregates. This dysfunction is a key contributor to neurodegeneration. Specifically, PRKN mutations are strongly associated with autosomal recessive Parkinson\u2019s disease (PD). The loss of functional parkin disrupts mitophagy and leads to neuronal loss in the substantia nigra, a hallmark of PD. Additionally, PRKN dysfunction has been implicated in other neurodegenerative disorders, but its most direct and well-documented association is with Parkinson\u2019s disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for mitochondrial quality control and protein degradation. Mutations in PRKN disrupt ubiquitin-mediated degradation of damaged proteins and mitochondrial maintenance, leading to the accumulation of dysfunctional proteins and impaired cellular homeostasis. This contributes to neurodegeneration. PRKN mutations are a key cause of early-onset Parkinson's disease, characterized by the loss of dopaminergic neurons in the substantia nigra. The pathway involving UBCH7/8 (E2 ligases) and SYPH1 (synuclein alpha interacting protein) further supports a role in ubiquitin-mediated degradation and synaptic function. Impaired PRKN function thereby promotes the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for ubiquitin-mediated protein degradation. Mutations in PRKN lead to impaired ubiquitination, disrupting protein quality control and mitochondrial homeostasis. This contributes to the accumulation of misfolded proteins and damaged mitochondria, which are hallmarks of neurodegenerative diseases. PRKN mutations are directly linked to autosomal recessive Parkinson's disease (PD), a disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The pathway involving UBCH7/8 and SYPH1 further supports the role of ubiquitin conjugation in this process. Dysfunction in this pathway impairs the clearance of toxic proteins such as alpha-synuclein, exacerbating neuronal damage. Thus, PRKN mutations are a key genetic contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN, also known as parkin, is an E3 ubiquitin ligase that plays a critical role in synaptic pruning and the degradation of damaged proteins. Mutations in PRKN are a major cause of autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and PAELR, is associated with ubiquitin-mediated protein degradation, which is essential for maintaining cellular homeostasis. Dysfunction in this pathway leads to the accumulation of toxic proteins and impaired mitochondrial function, both of which contribute to neurodegeneration. PRKN mutations disrupt this process, leading to neuronal death, particularly in the substantia nigra, a brain region affected in Parkinson's disease. Therefore, the biological effect of PRKN allele dysfunction is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN encodes parkin, an E3 ubiquitin ligase involved in mitochondrial quality control and proteasomal degradation. Mutations in PRKN lead to impaired ubiquitination and degradation of damaged mitochondria, resulting in the accumulation of dysfunctional mitochondria and increased oxidative stress. This contributes to neurodegeneration. PRKN mutations are a major cause of autosomal recessive Parkinson's disease, specifically PARK2. The pathway involving UBCH7/8 (E2 enzymes) and PAELR supports ubiquitin conjugation, essential for parkin-mediated protein degradation. Loss-of-function PRKN alleles disrupt this process, leading to neuronal death, particularly in dopaminergic neurons. This genetic defect is strongly associated with early-onset Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase that plays a critical role in mitochondrial quality control and protein degradation. Mutations in PRKN lead to impaired ubiquitination and proteasomal degradation, resulting in the accumulation of damaged proteins and dysfunctional mitochondria. This dysfunction is strongly associated with neurodegeneration. The pathway involving PRKN, along with UBCH7/8 and PAELR, is implicated in ubiquitin-mediated protein degradation. Loss-of-function mutations in PRKN are the most common genetic cause of autosomal recessive Parkinson\u2019s disease. These mutations disrupt the clearance of damaged mitochondria and aggregate-prone proteins, leading to neuronal death, particularly in dopaminergic neurons. Thus, the biological effect of PRKN allele dysfunction is the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade in cell proliferation and survival. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway, promoting uncontrolled cell growth. This dysregulation is strongly associated with various cancers. The most well-documented disease linked to BRAF mutations is melanoma, where the V600E mutation is present in approximately 50% of cases. Additionally, BRAF mutations contribute to other malignancies such as colorectal cancer, non-small cell lung cancer, and thyroid cancer. The persistent activation of MEK and ERK downstream of BRAF results in enhanced cell proliferation, resistance to apoptosis, and genomic instability, all of which drive tumor progression. Therefore, the biological effect of the BRAF allele is oncogenic, contributing to the development and progression of melanoma and other cancers.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele is part of the BRAF-MEK-ERK signaling pathway, which is critical for cell proliferation, survival, and differentiation. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the ERK pathway, promoting uncontrolled cell growth. This contributes to the development of various cancers. The most well-known disease associated with BRAF mutations is **melanoma**, where the V600E mutation is found in approximately 50% of cases. Additionally, BRAF mutations are implicated in other malignancies such as colorectal cancer, papillary thyroid cancer, and some lung and ovarian cancers. The persistent activation of the MAPK/ERK pathway due to BRAF mutations disrupts normal cellular regulation, driving oncogenesis. Therefore, the biological effect of the BRAF allele in this context is the promotion of tumor growth, particularly in **melanoma**.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele, specifically the V600E mutation, leads to constitutive activation of the BRAF protein, which drives the MAPK/ERK signaling pathway by continuously phosphorylating MEK and subsequently ERK. This results in uncontrolled cell proliferation, survival, and differentiation, contributing to tumor formation. This mutation is a key driver in several cancers, most notably melanoma, where it is present in approximately 50% of cases. Additionally, BRAF mutations are implicated in other malignancies such as colorectal cancer, non-small cell lung cancer, and thyroid cancer. The aberrant activation of this pathway promotes oncogenic transformation by enhancing cell growth and inhibiting apoptosis. The BRAF-V600E mutation is a well-established biomarker for targeted therapy with BRAF inhibitors. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor for saposins, which are essential for the activity of lysosomal enzymes involved in lipid metabolism. Mutations in PSAP lead to reduced production of functional saposins, impairing the activity of lysosomal enzymes such as GBA (beta-glucocerebrosidase), GBA2, and GALC. This results in the accumulation of glycolipids in lysosomes, leading to neurodegeneration. The most well-known disease associated with PSAP mutations is metachromatic leukodystrophy (MLD), a severe neurological disorder. MLD is caused by the deficiency of arylsulfatase A (ARSA), which is derived from prosaposin. However, PSAP mutations can also contribute to other lysosomal storage disorders, including Gaucher disease and Sandhoff disease, due to the shared involvement of GBA and GALC. The primary disease linked to PSAP is \\boxed{Metachromatic Leukodystrophy}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the proper folding and activity of lysosomal enzymes involved in sphingolipid metabolism. Mutations in PSAP lead to a deficiency in its derivative enzymes, including beta-glucosidase (GBA) and galactosylceramidase (GALC), which are critical for breaking down certain lipids. This dysfunction results in the accumulation of toxic lipid derivatives in lysosomes, leading to neurodegeneration. The most well-characterized disease associated with PSAP mutations is metachromatic leukodystrophy (MLD), a rare inherited metabolic disorder. MLD is characterized by progressive demyelination of the central and peripheral nervous system due to the buildup of sulfatides. The PSAP gene plays a central role in this condition, as its dysfunction impairs the activity of GBA and GALC, contributing to the pathogenesis of MLD.\n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP allele is involved in the metabolism of sphingolipids and is part of a pathway that includes GBA, GBA2, and GALC. Mutations in PSAP can lead to reduced production of prosaposin, a precursor for lysosomal enzymes. This disruption impairs the degradation of sphingolipids, leading to their accumulation in neurons. This accumulation is a hallmark of neuronal ceroid lipofuscinoses (NCLs), a group of inherited neurodegenerative disorders. Specifically, PSAP mutations contribute to a subtype of NCL known as **Jansen\u2019s disease** (also referred to as neuronal ceroid lipofuscinosis type 2, CLN2). This condition is characterized by progressive neurological decline, seizures, and vision loss. The dysfunction in this pathway underscores the critical role of PSAP in maintaining lysosomal enzyme activity and cellular homeostasis. \\boxed{Jansen's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein folding and ubiquitin-mediated proteolysis. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the formation of toxic protein aggregates, disrupting cellular function. This is the defining genetic cause of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3 connects glutamate signaling to calcium regulation and mitochondrial dysfunction, contributing to neuronal damage. The accumulation of mutant ataxin-3 impairs proteasomal function, leading to neuronal death, particularly in the cerebellum. This results in the clinical symptoms of SCA2. The disease is inherited in an autosomal dominant manner, and the severity correlates with the length of the polyglutamine expansion. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-mediated proteasomal degradation pathway. In the given pathway, ATXN3 is part of the IP3 receptor complex, which regulates intracellular calcium levels. Mutations in ATXN3 lead to the expansion of its polyglutamine tract, resulting in the formation of toxic protein aggregates. This is a hallmark of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The accumulation of mutant ataxin-3 disrupts cellular homeostasis, particularly in neurons, leading to oxidative stress, mitochondrial dysfunction, and neuronal death. The involvement of calcium signaling and mitochondrial pathways, as seen in the provided network, further supports the role of ATXN3 in neuronal vulnerability. Thus, the biological effect of the ATXN3 allele is the pathogenesis of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein folding and degradation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This pathogenic mechanism is central to Spinocerebellar Ataxia Type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3 is part of the calcium signaling cascade, where it interacts with ITPR1 and modulates calcium release from the endoplasmic reticulum. Dysregulation of this pathway contributes to neuronal dysfunction and cell death, hallmark features of SCA2. Therefore, the biological effect of the ATXN3 allele is the development of Spinocerebellar Ataxia Type 2.\n\n\\boxed{Spinocerebellar Ataxia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular responses to DNA damage and stress, regulating cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to loss of tumor suppression. This pathway includes genes like CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, all of which contribute to cell cycle regulation and DNA repair. When TP53 is mutated, these genes fail to function properly, allowing cells with damaged DNA to survive and divide, promoting genomic instability. This dysfunction is a hallmark of many cancers. The TP53 allele contributes to a wide range of cancers, most notably **Li-Fraumeni syndrome**, a hereditary cancer predisposition syndrome, and is also a key driver in **breast cancer**, **ovarian cancer**, **lung cancer**, and other solid tumors. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is a critical regulator of cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 disrupt its function, leading to impaired response to DNA damage and loss of tumor suppressor activity. This results in genomic instability and uncontrolled cell proliferation. Genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK are downstream targets of TP53, and their dysfunction further compromises DNA repair and apoptosis. The loss of TP53 function is strongly associated with a wide range of human cancers. Notably, TP53 mutations are among the most frequently altered genes in cancer, particularly in sarcomas, breast cancer, ovarian cancer, and lung cancer. The cumulative effect of TP53 dysfunction is the promotion of malignant transformation and tumor progression. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular responses to DNA damage and stress, regulating cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to loss of genomic stability. This contributes to uncontrolled cell proliferation and resistance to apoptosis, which are hallmarks of cancer. The listed genes (CDKN1A, GADD45, BAX, BAK1, DDB2, POLK) are downstream effectors of p53, involved in cell cycle regulation, DNA repair, and apoptosis. Dysregulation of this pathway is associated with various malignancies. The most well-known disease linked to TP53 mutations is Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome. TP53 mutations are also frequently observed in multiple cancers, including breast, ovarian, bone, and brain tumors. \\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating \u03b2-amyloid peptides. Mutations in PSEN1 are the most common cause of early-onset Alzheimer's disease (AD). The pathway described involves PSEN1 interacting with GSK3B, which regulates tau phosphorylation and neuronal survival, and kinesin proteins (KIF5A/B/C) and their light chain partners (KLC1-4), which are involved in intracellular transport. Disruption of this pathway leads to impaired protein clearance, neuronal dysfunction, and aggregation, contributing to neurodegeneration. These molecular alterations are central to the pathogenesis of Alzheimer's disease. The biological effect of pathogenic PSEN1 alleles is the increased risk and early onset of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) suggests a role in neurodegeneration through processes like protein trafficking and tau pathology. Impaired clearance of amyloid-beta and disrupted neuronal transport mechanisms contribute to neurotoxicity. These molecular disruptions are central to the pathogenesis of Alzheimer's disease. Therefore, the biological effect of this PSEN1 allele is the increased risk of developing Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating \u03b2-amyloid peptides. Mutations in PSEN1 are a primary cause of early-onset familial Alzheimer's disease (FAD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) suggests a role in neurodegeneration, as GSK3B is implicated in tau pathology and neuronal function. KIF5 and KLC proteins are involved in microtubule transport, essential for axonal transport and neuronal health. Dysregulation of this pathway contributes to the accumulation of toxic proteins and synaptic dysfunction, hallmark features of Alzheimer's disease. Thus, the PSEN1 allele is directly linked to the development of Alzheimer's disease. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS allele plays a key role in the cAMP signaling pathway, initiating a cascade involving ADCY, PKA, CREB, and ultimately POMC, which encodes proopiomelanocortin. Mutations in GNAS disrupt this pathway, leading to dysregulation of melanocortin hormone production, including ACTH. This results in hormonal imbalances, particularly affecting adrenal cortisol and melanocyte function. The most well-characterized disease associated with GNAS mutations is **McCune-Albright syndrome (MAS)**, characterized by fibrous dysplasia of bone, precocious puberty, and skin pigmentation changes. GNAS mutations also contribute to other disorders, including hypercortisolism and pituitary adenomas. These effects stem from aberrant activation or suppression of the Gs alpha subunit, disrupting normal hormonal signaling and cellular responses. \\boxed{McCune-Albright syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the alpha subunit of the stimulatory G protein (Gs\u03b1), which activates adenylate cyclase (ADCY) to increase cAMP levels. This leads to the activation of protein kinase A (PKA), which phosphorylates CREB, a transcription factor that promotes the expression of POMC, the precursor to ACTH. Mutations in GNAS can disrupt this pathway, leading to dysregulated cAMP signaling. This contributes to the development of pseudohypoparathyroidism, a disorder characterized by resistance to parathyroid hormone (PTH) due to impaired Gs\u03b1 function. Additionally, GNAS mutations are associated with primary hyperparathyroidism and other endocrine disorders. The most well-known disease linked to GNAS mutations is pseudohypoparathyroidism type 1a (PHP1a). \n\n\\boxed{Pseudohypoparathyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS allele plays a critical role in the cAMP signaling pathway, initiating a cascade involving adenylate cyclases (ADCY), cAMP, PKA, and CREB, ultimately influencing POMC expression. This pathway is central to the regulation of cortisol and melanocortin hormone production. Mutations in GNAS can lead to altered cAMP signaling, contributing to disorders of the hypothalamic-pituitary-adrenal (HPA) axis. Specifically, GNAS mutations are associated with **McCune-Albright syndrome**, characterized by fibrous dysplasia, endocrinopathy, and skin pigmentation abnormalities. This condition arises from somatic mutations in GNAS, leading to constitutive activation of the cAMP pathway and disrupted hormone regulation. The disease is marked by autonomous secretion of hormones such as ACTH and POMC-derived peptides, resulting in clinical manifestations like precocious puberty and adrenal hyperplasia. \\boxed{McCune-Albright syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex, which is essential for the proteolytic processing of amyloid precursor protein (APP). Mutations in PSEN1 are a well-documented cause of early-onset familial Alzheimer's disease (AD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin light chain proteins (KLC) suggests a role in intracellular transport and neuronal function, both of which are disrupted in AD. GSK3B, a downstream target of PSEN1, is involved in tau phosphorylation and amyloid-beta metabolism, both of which are pathological features of AD. Thus, the PSEN1 allele contributes to the molecular mechanisms underlying Alzheimer's disease by affecting key pathways in neurodegeneration and protein homeostasis. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are the most common genetic cause of early-onset familial Alzheimer's disease (FAD). The pathway described, PSEN1 \u2192 GSK3B -| (KIF5+KLC), reflects its role in modulating the activity of glycogen synthase kinase-3 beta (GSK3B), which is involved in tau phosphorylation and neurodegeneration. KIF5 and KLC proteins are involved in intracellular transport, suggesting a role in neuronal function and disease progression. Thus, mutations in PSEN1 disrupt these pathways, leading to the accumulation of toxic amyloid-\u03b2 and hyperphosphorylated tau, hallmark features of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). These mutations disrupt the normal function of the gamma-secretase complex, leading to increased production of toxic amyloid-beta42 peptides and reduced amyloid-beta40, promoting plaque formation in the brain. This pathological process contributes to neuronal dysfunction and neurodegeneration, hallmark features of Alzheimer's disease. The pathway also involves GSK3B, KIF5, and KLC proteins, which are implicated in intracellular transport and tau phosphorylation, further supporting the role of this pathway in disease progression. Thus, the PSEN1 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes the protein p16INK4a, which inhibits CDK4 and CDK6, preventing the phosphorylation of RB1. This keeps RB1 in its hypophosphorylated form, which represses E2F transcription factors, thereby halting cell cycle progression at the G1 phase. MDM2, which negatively regulates TP53, is inhibited by CDKN2A, leading to the stabilization and activation of TP53. Activated TP53 induces the expression of CDKN1A (p21), further suppressing cyclin D-CDK4/6 complexes and reinforcing G1 arrest. Loss or mutation of CDKN2A disrupts this checkpoint, leading to unchecked cell proliferation. This dysfunction is a key driver in several cancers, particularly melanoma, pancreatic cancer, and bladder cancer. The CDKN2A allele is a well-known tumor suppressor gene, and its mutation or inactivation is strongly associated with these diseases. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that negatively regulates the cell cycle by inhibiting CDK4/6 and preventing phosphorylation of the retinoblastoma protein (RB1). This inhibition leads to the retention of RB1 in its hypophosphorylated form, which in turn blocks the activity of E2F transcription factors, thereby suppressing the expression of genes required for S-phase entry. Mutations or loss-of-function in CDKN2A disrupt this regulatory mechanism, allowing uncontrolled cell proliferation. This contributes to the development of various cancers, most notably melanoma and pancreatic cancer. The pathway also involves MDM2, which promotes the degradation of TP53, further impairing the tumor suppressor function of p53. Together, these disruptions in the CDKN2A-MDM2-TP53 pathway lead to genomic instability and oncogenesis. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a potent inhibitor of CDK4/6, which are crucial for cell cycle progression. In the given pathway, CDKN2A negatively regulates MDM2, a ubiquitin ligase that targets TP53 for degradation. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its tumor-suppressive functions, including induction of CDKN1A and inhibition of cyclin D-CDK4/6 complexes. This leads to cell cycle arrest at G1. Loss or mutation of CDKN2A disrupts this regulatory network, allowing unchecked cell proliferation. This dysfunction is a hallmark of several cancers, particularly melanoma and pancreatic adenocarcinoma. CDKN2A mutations are also linked to familial melanoma syndromes. Thus, the biological effect of CDKN2A is tumor suppression, and its dysfunction contributes to **Melanoma**.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele, as part of the WNT signaling pathway, plays a critical role in regulating cell proliferation and differentiation. When mutated, it leads to the stabilization and accumulation of \u03b2-catenin, enhancing its transcriptional activity. This results in the aberrant activation of genes such as BIRC5, MYC, and CCND1, which drive uncontrolled cell growth. The dysregulation of this pathway is a hallmark of several cancers. Specifically, mutations in CTNNB1 are commonly associated with colorectal cancer, where they contribute to the development and progression of the disease by promoting oncogenic processes. Thus, the biological effect of this CTNNB1 allele is the promotion of uncontrolled cell proliferation, contributing to the development of colorectal cancer.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the WNT signaling pathway. CTNNB1 encodes \u03b2-catenin, a key mediator of WNT signaling. When mutated, CTNNB1 can lead to its stabilization and accumulation in the cytoplasm and nucleus, where it activates target genes such as BIRC5, MYC, and CCND1. This dysregulated signaling promotes cell proliferation and inhibits apoptosis, contributing to uncontrolled cell growth. These molecular changes are hallmarks of several cancers, particularly those involving aberrant WNT activation. The most well-documented disease associated with CTNNB1 mutations is colorectal cancer, where mutations in CTNNB1 are frequently observed and drive tumor progression. Therefore, the biological effect of this CTNNB1 allele is oncogenic, leading to the development of colorectal cancer.\n\n\\boxed{Colorectal cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the WNT signaling cascade. CTNNB1 encodes beta-catenin, a key mediator of WNT signaling. When stabilized, it translocates to the nucleus, where it activates TCF/LEF transcription factors, driving expression of downstream genes such as BIRC5, MYC, and CCND1. Mutations in CTNNB1 that prevent its degradation (e.g., mutations in AXIN1, APC, or GSK3B) lead to constitutive activation of WNT signaling. This dysregulation promotes uncontrolled cell proliferation and survival, contributing to tumorigenesis. The cumulative effect of this pathway activation is a hallmark of colorectal cancer, where CTNNB1 mutations are frequently observed. The persistent activation of this pathway disrupts normal cell cycle control and apoptosis, driving the development and progression of cancer. \\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 pathway is involved in calcium signaling, regulating the release of Ca\u00b2+ from the endoplasmic reticulum via ITPR channels, and its uptake into mitochondria through the MCU complex. This process is critical for mitochondrial function and apoptosis. Mutations in SIGMAR1 disrupt calcium homeostasis, leading to mitochondrial dysfunction and increased susceptibility to apoptosis. This contributes to neurodegenerative diseases, particularly Parkinson's disease, where SIGMAR1 mutations are associated with impaired mitochondrial calcium regulation, neuronal death, and alpha-synuclein pathology. The pathway's role in maintaining cellular energy balance and preventing oxidative stress further supports its involvement in neurodegeneration. Therefore, the biological effect of the SIGMAR1 allele is the contribution to Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 allele plays a role in regulating intracellular calcium homeostasis by modulating the inositol 1,4,5-trisphosphate receptor (ITPR) and mitochondrial calcium uniporter (MCU) pathways. This leads to altered mitochondrial calcium levels, which can trigger the mitochondrial permeability transition pore (MPTP) and release of cytochrome c (CYCS). This process is central to apoptosis and cellular stress responses. Mutations in SIGMAR1 have been implicated in neurodegenerative diseases, particularly Parkinson\u2019s disease, where disrupted calcium signaling and mitochondrial dysfunction contribute to neuronal death. The pathway highlights the role of SIGMAR1 in maintaining calcium balance and preventing mitochondrial dysfunction, making it a key player in neurodegeneration. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 pathway is involved in calcium signaling, regulating mitochondrial calcium uptake via MCU and the subsequent release of cytochrome c through the MPTP, which is essential for apoptosis. Mutations in SIGMAR1 disrupt this process, leading to impaired calcium homeostasis and increased mitochondrial permeability. This contributes to neuronal death and neurodegeneration. SIGMAR1 is particularly linked to Parkinson's disease, where it plays a role in oxidative stress, mitochondrial dysfunction, and dopaminergic neuron loss. The pathway's involvement in apoptosis and calcium regulation makes it a key player in neurodegenerative processes. Therefore, the biological effect of the SIGMAR1 allele is associated with the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele, as part of the described pathway, is involved in mitochondrial maintenance and apoptosis regulation. PINK1 is critical for mitophagy, the process by which damaged mitochondria are removed. When PINK1 is dysfunctional, mitochondrial quality control is impaired, leading to the accumulation of dysfunctional mitochondria. This disruption activates the intrinsic apoptosis pathway via the release of cytochrome c, facilitated by HTRA2 and TRAP1, leading to the activation of APAF1, CASP9, and ultimately CASP3, which results in cell death. Mutations in PINK1 are strongly associated with Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. The impairment in mitochondrial function and subsequent apoptosis contribute to neuronal degeneration. Therefore, the biological effect of this PINK1 allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is central to mitochondrial quality control and apoptosis. PINK1, when mutated, disrupts mitochondrial function by failing to stabilize the mitochondrial membrane potential and promote the recruitment of HTRA2 and TRAP1, which are critical for maintaining mitochondrial integrity. This disruption leads to the release of cytochrome c, activating APAF1, which in turn activates CASP9 and ultimately CASP3, initiating apoptosis. Mutations in PINK1 are strongly associated with Parkinson\u2019s disease, as they impair mitochondrial function and lead to neurodegeneration, particularly in dopaminergic neurons. The loss of PINK1 function results in the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal death, contributing to the pathogenesis of Parkinson\u2019s disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is critical for mitochondrial quality control and apoptosis regulation. PINK1, a mitochondrial kinase, phosphorylates HTRA2 and TRAP1, promoting the release of cytochrome c from mitochondria. This activates APAF1, leading to the formation of the apoptosome, which activates CASP9 and subsequently CASP3, resulting in apoptosis. Mutations in PINK1 disrupt this process, impairing mitochondrial function and preventing apoptosis. This contributes to neuronal loss, a hallmark of Parkinson's disease. PINK1 mutations are one of the most common genetic causes of inherited Parkinson's, underscoring its role in neurodegeneration. The pathway's dysfunction leads to the accumulation of damaged mitochondria and increased susceptibility to apoptotic cell death, particularly in dopamine-producing neurons. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and RNA processing. Mutations in ATXN3 lead to the expansion of a CAG trinucleotide repeat, resulting in the production of an abnormally long polyglutamine tract. This pathological expansion disrupts protein function and leads to neurodegeneration. The gene is part of a pathway involving autophagy-related proteins such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which are critical for autophagy, a cellular process that removes damaged proteins and organelles. Impaired autophagy due to ATXN3 mutations contributes to the accumulation of toxic protein aggregates. This process is closely linked to spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of motor coordination. The dysfunction of ATXN3 and its associated autophagy pathway is central to the pathogenesis of SCA2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, causing progressive neurodegeneration. This contributes to spinocerebellar ataxia type 2 (SCA2), a dominantly inherited disorder characterized by cerebellar ataxia, dysarthria, and cognitive decline. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy regulation, suggesting a role for ATXN3 in maintaining protein homeostasis. Impaired autophagy due to ATXN3 dysfunction may exacerbate neurodegeneration by promoting the accumulation of misfolded proteins. Thus, the ATXN3 allele contributes to the pathogenesis of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine tracts, resulting in the formation of toxic protein aggregates. This contributes to neurodegeneration by disrupting cellular function, particularly in the cerebellum. The presence of ATXN3 in a specific autophagy-related pathway (involving BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1) suggests a role in maintaining protein quality control through autophagy. Impaired autophagy due to ATXN3 dysfunction leads to the accumulation of misfolded proteins, exacerbating neuronal damage. This mechanism is central to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of coordination and motor control. The biological effect of the ATXN3 allele is therefore the induction of SCA2 through neurotoxic protein aggregation and impaired autophagy.\n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, when activated, promotes cell proliferation, survival, and migration. Activation of the MET gene, which encodes a receptor tyrosine kinase, can lead to uncontrolled cell growth by initiating downstream signaling through GRB2, SOS, RAS, RAF, MEK, and ERK, ultimately leading to increased expression of CCND1, a key regulator of the cell cycle. This pathway is frequently dysregulated in various cancers. Specifically, aberrant MET activation is associated with the development and progression of non-small cell lung cancer (NSCLC), hepatocellular carcinoma, and other malignancies. Mutations or amplifications in MET can drive tumor growth and resistance to therapy. Therefore, the biological effect of this MET allele is the promotion of oncogenic signaling, contributing to the development of NSCLC.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting from MET, leading through GRB2, SOS, RAS, RAF, MEK, and finally ERK to CCND1. This pathway is critical for cell proliferation, survival, and differentiation. Activation of MET can result in constitutive signaling, promoting uncontrolled cell growth. This contributes to diseases characterized by aberrant cell proliferation and tumor formation. Specifically, MET activation is associated with various cancers, including non-small cell lung cancer, renal cell carcinoma, and gastrointestinal stromal tumors. The downstream activation of CCND1, a cyclin that drives cell cycle progression, further supports unregulated cell division. Therefore, MET mutations or overexpression are linked to cancer development. \\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting with MET -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1. This pathway is central to cell proliferation, survival, and migration. Activation of MET leads to increased expression of CCND1, a key regulator of the cell cycle. Dysregulation of this pathway is associated with uncontrolled cell growth and tumor formation. Mutations or overexpression of MET can drive oncogenic transformation by constitutively activating downstream signaling. This contributes to the development of various cancers, including non-small cell lung cancer, gastric cancer, and renal cell carcinoma. Notably, MET mutations and amplifications are frequently observed in cancers such as non-small cell lung cancer (NSCLC), where MET-driven signaling promotes tumor progression and resistance to therapy. The activation of this pathway is a hallmark of several malignancies, making it a significant contributor to oncogenesis.\n\n\\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nCDKN2A encodes p16INK4a, a key inhibitor of CDK4/6, which are enzymes that drive the progression of cells through the G1 phase of the cell cycle by phosphorylating RB1. When CDKN2A is functional, it prevents the activation of RB1, thereby inhibiting E2F transcription factors that promote cell cycle progression. Loss or mutation of CDKN2A removes this inhibition, leading to unchecked cell proliferation. This pathway dysregulation is a hallmark of several cancers, particularly those involving uncontrolled cell growth. Mutations in CDKN2A are strongly associated with melanoma, and its inactivation is also commonly observed in pancreatic cancer, bladder cancer, and other malignancies. The loss of CDKN2A contributes to the development and progression of these diseases by promoting cell cycle progression and resisting tumor suppressor mechanisms. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nCDKN2A encodes the protein p16INK4a, which inhibits CDK4/6, preventing the phosphorylation of RB1. This inhibition blocks the release of E2F transcription factors, which are crucial for cell cycle progression. In the given pathway, CDKN2A acts as a tumor suppressor by suppressing the CDK4/6-cyclin D complex, thereby preventing RB1 phosphorylation and E2F activation. Loss or mutation of CDKN2A leads to unchecked cell proliferation. This is a key mechanism in several cancers, particularly those involving the RB1 pathway. The most well-known disease associated with CDKN2A dysfunction is pancreatic adenocarcinoma, but it is also implicated in melanoma, sarcomas, and other malignancies. \\boxed{Pancreatic Adenocarcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nCDKN2A encodes p16INK4a, a key inhibitor of CDK4/6, which are enzymes that phosphorylate RB1. In the given pathway, CDKN2A inhibits the CDK4/6-cyclin D complex, preventing RB1 phosphorylation and thereby blocking E2F-driven cell cycle progression. Loss or mutation of CDKN2A removes this inhibition, leading to RB1 phosphorylation, E2F activation, and unchecked cell proliferation. This dysregulation is a hallmark of uncontrolled cell growth, contributing to malignancies. CDKN2A mutations are strongly associated with various cancers, particularly melanoma, pancreatic adenocarcinoma, and some leukemias. The pathway disruption promotes tumor formation by allowing cells to progress through the cell cycle without proper control. Therefore, CDKN2A mutations contribute to \\boxed{Melanoma}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS-RAF-MEK-ERK signaling pathway, contributes to the activation of downstream effectors such as ERK and CCND1. This pathway is critical for cell proliferation, differentiation, and survival. Mutations in NRAS, particularly activating mutations, lead to constitutive activation of the MAPK/ERK cascade, promoting uncontrolled cell growth. This dysregulation is a hallmark of several cancers. Specifically, NRAS mutations are commonly found in melanoma, where they drive tumor progression by enhancing cell proliferation and inhibiting apoptosis. Additionally, NRAS mutations are associated with other malignancies, including non-small cell lung cancer and colorectal cancer. The persistent activation of this pathway due to NRAS mutations disrupts normal cellular regulation, leading to the development and progression of cancer. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> RAF -> MEK -> ERK -> CCND1 pathway, contributes to uncontrolled cell proliferation by activating the MAPK signaling cascade. This leads to increased expression of CCND1, a protein that drives cell cycle progression. Mutations in NRAS, particularly activating mutations, result in constitutive activation of this pathway, promoting tumor growth. This is a hallmark of several cancers, including melanoma, non-small cell lung cancer, and pancreatic cancer. NRAS mutations are particularly common in melanomas and certain leukemias. The persistent activation of the MAPK pathway due to NRAS mutation disrupts normal cell growth control, leading to the development and progression of these malignancies. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> RAF -> MEK -> ERK -> CCND1 pathway, contributes to uncontrolled cell proliferation by activating the MAPK signaling cascade. This leads to increased expression of CCND1, a gene that encodes cyclin D1, which promotes cell cycle progression. Mutations in NRAS, particularly activating mutations, result in constitutive activation of the MAPK pathway, driving cellular proliferation and inhibiting apoptosis. This dysregulation is a hallmark of several cancers. The most common disease associated with NRAS mutations is **Melanoma**, where activating mutations in NRAS are frequently observed and drive tumor growth. These mutations are also implicated in other malignancies such as bladder cancer, pancreatic cancer, and non-small cell lung cancer. The persistent activation of this pathway leads to oncogenic transformation and is a key driver in the development and progression of these diseases.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, contributes to the formation of the BCR-ABL fusion protein, which is a key driver in chronic myeloid leukemia (CML). This fusion protein results from a reciprocal translocation between chromosomes 9 and 22, creating the Philadelphia chromosome. The BCR-ABL oncogene constitutively activates the MAPK signaling pathway by initiating the BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK cascade. This leads to uncontrolled cell proliferation, resistance to apoptosis, and genomic instability. The continuous activation of this pathway promotes the transformation of hematopoietic cells into leukemic cells. Thus, the ABL1 allele contributes to the development of chronic myeloid leukemia. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or constitutively activated, leads to the continuous activation of the BCR-ABL oncoprotein. This results in the aberrant signaling through the downstream pathway: BCR-ABL \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This pathway is critical for cell proliferation, survival, and differentiation. Its dysregulation due to ABL1 activation promotes uncontrolled cell growth and resistance to apoptosis. This is a hallmark of chronic myeloid leukemia (CML), where the Philadelphia chromosome translocation fuses BCR to ABL1, creating a constitutively active BCR-ABL fusion protein. This leads to the activation of downstream signaling pathways, driving leukemogenesis. The disease is effectively targeted by tyrosine kinase inhibitors like imatinib. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, contributes to the development of chronic myeloid leukemia (CML). This occurs through the formation of the BCR-ABL fusion protein, which results from a reciprocal translocation between chromosomes 9 and 22, creating the Philadelphia chromosome. This abnormal protein has constitutive tyrosine kinase activity, leading to uncontrolled cell proliferation and inhibition of apoptosis. The downstream pathway, involving GRB2, SOS, RAS, RAF, MEK, and ERK, is continuously activated, promoting cell growth, survival, and differentiation. This persistent activation drives the transformation of hematopoietic cells into malignant ones. Thus, the biological effect of the ABL1 allele in this context is the initiation and progression of CML. \n\n\\boxed{Chronic myeloid leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitophagy, the selective degradation of damaged mitochondria. PRKN, also known as parkin, is an E3 ubiquitin ligase that interacts with MFN1 and MFN2, which are mitochondrial fusion proteins. This pathway is critical for maintaining mitochondrial quality control. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal damage. This contributes to neurodegenerative diseases. The most well-known disease associated with PRKN mutations is Parkinson's disease. Loss-of-function mutations in PRKN are a major genetic cause of early-onset Parkinson's disease, as they disrupt the removal of damaged mitochondria from neurons, particularly in the substantia nigra. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase that plays a critical role in mitophagy, the selective autophagic degradation of mitochondria. Its interaction with MFN1 and MFN2, which are mitochondrial outer membrane fusion proteins, underscores its role in mitochondrial quality control. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of damaged mitochondria and oxidative stress. This dysfunction is strongly associated with neurodegeneration. The most well-documented disease linked to PRKN mutations is Parkinson's disease. Loss-of-function mutations in PRKN are a major genetic cause of autosomal recessive Parkinson's disease, characterized by the loss of dopaminergic neurons in the substantia nigra. These mutations disrupt mitochondrial dynamics and contribute to neuronal death, highlighting PRKN's essential role in maintaining mitochondrial health and preventing neurodegeneration.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through the ubiquitination and degradation of mitofusins (MFN1 and MFN2), which are key proteins in mitochondrial fusion. Mutations in PRKN, which encodes the E3 ubiquitin ligase parkin, lead to impaired mitophagy, the selective degradation of damaged mitochondria. This disruption in mitochondrial quality control contributes to the accumulation of dysfunctional mitochondria, oxidative stress, and cellular dysfunction. These processes are implicated in neurodegenerative diseases. Specifically, PRKN mutations are a well-documented cause of Parkinson's disease, particularly in cases with early-onset and autosomal recessive inheritance. The loss of PRKN function disrupts the removal of damaged mitochondria, leading to neuronal death, especially in dopaminergic neurons. Therefore, the biological effect of this PRKN allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington's disease. The pathway involving HTT, CREB family members, and ATF4 suggests a role in transcriptional regulation, particularly in response to cellular stress. Mutations in HTT, such as expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long huntingtin protein, which gains toxic gain-of-function properties. This results in neuronal dysfunction and death, primarily in the striatum and cortex. The disease is characterized by progressive motor, cognitive, and psychiatric symptoms. The pathway highlights the involvement of transcription factors in modulating gene expression in response to HTT dysfunction, contributing to neurodegeneration. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutant form leads to the accumulation of abnormal protein aggregates. This is the primary cause of Huntington's disease, a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The pathway involving HTT, CREB family members, and ATF4 suggests a role in transcriptional regulation, which is disrupted in the disease. Mutations in HTT result in toxic gain-of-function effects, including disrupted neuronal signaling and synaptic dysfunction. These disruptions contribute to the hallmark neuronal loss in the striatum and cortex. The involvement of CREB and ATF4 indicates dysregulation of gene expression related to neuronal survival and stress responses. Thus, the HTT allele is directly associated with Huntington's disease. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction leads to the accumulation of misfolded protein aggregates. This is a hallmark of Huntington's disease, a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The pathway involving HTT, CREB family members, ATF4, and TAF4 suggests a role in transcriptional regulation, particularly in stress response and neuronal function. Mutations in HTT, specifically CAG trinucleotide repeats, result in the production of an abnormally long polyglutamine tract in the huntingtin protein, leading to its aggregation and toxicity. This process disrupts cellular homeostasis, ultimately causing neuronal death. The involvement of CREB and ATF4 in this pathway highlights the dysregulation of gene expression in response to cellular stress, a key mechanism in disease progression. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is central to mitochondrial quality control and apoptosis. PINK1, when mutated, impairs the recruitment of PRKN (parkin) to depolarized mitochondria, disrupting mitophagy and leading to the accumulation of damaged mitochondria. This dysfunction promotes the release of cytochrome c, activating APAF1 and CASP9, which triggers apoptosis via CASP3. This pathway is critical in preventing neurodegeneration. Mutations in PINK1 are strongly linked to Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. The dysfunction in PINK1-PRKN-BAX signaling leads to impaired mitochondrial homeostasis, oxidative stress, and neuronal death, contributing to disease progression. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is critical for mitochondrial quality control and apoptosis. PINK1 and PRKN (parkin) work together to ubiquitylate damaged mitochondria, targeting them for autophagy. If PINK1 is mutated, this process is impaired, leading to mitochondrial dysfunction and accumulation of damaged mitochondria. This disrupts the intrinsic apoptotic pathway, where BAX promotes cytochrome c release, activating APAF1 and CASP9, which in turn activate CASP3, leading to cell death. Mutations in PINK1 are associated with impaired mitophagy and increased neuronal vulnerability, contributing to neurodegeneration. This pathway is central to Parkinson's disease, where PINK1 mutations cause loss of dopaminergic neurons. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is critical for mitochondrial quality control and apoptosis. PINK1 activates PRKN (parkin), which ubiquitinates and targets damaged mitochondria for degradation. This process is essential for preventing the accumulation of dysfunctional mitochondria, which can lead to cellular stress and neurodegeneration. Mutations in PINK1 impair this pathway, disrupting mitochondrial homeostasis and leading to excessive apoptosis, particularly in neurons. This dysfunction is strongly associated with Parkinson\u2019s disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The PINK1-PRKN pathway thus plays a key role in maintaining neuronal survival, and its disruption contributes to the pathogenesis of Parkinson\u2019s disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene, also known as nucleoredoxin, is involved in redox regulation and has roles in cellular stress response and DNA repair. Its interaction with the DVL proteins, which are critical components of the Wnt signaling pathway, suggests a role in developmental processes and tissue homeostasis. Mutations in NXN may disrupt redox balance and Wnt signaling, contributing to impaired cellular function. This disruption has been implicated in several diseases, including neurodegenerative disorders and cancers. Specifically, alterations in the NXN allele have been associated with Parkinson's disease, where impaired redox regulation and disrupted Wnt signaling contribute to neuronal loss and disease progression. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN allele, which encodes nucleoredoxin, plays a role in redox regulation and cellular stress response. Its interaction with DVL proteins, which are key components of the Wnt signaling pathway, suggests a functional link between redox homeostasis and developmental processes. Mutations or dysregulation of NXN may disrupt this balance, leading to impaired signaling and cellular dysfunction. This pathway is critical for processes such as cell proliferation, differentiation, and tissue polarity. Disruption of this pathway has been implicated in various diseases, including cancer and neurodegenerative disorders. Specifically, alterations in the NXN-DVL pathway have been associated with **colorectal cancer** due to its role in regulating cell growth and apoptosis. Therefore, the biological effect of this NXN allele is linked to **colorectal cancer**.\n\n\\boxed{Colorectal cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein with thioredoxin-like activity, involved in redox regulation and cellular stress responses. Its interaction with DVL (dishevelled) proteins, which are key components of the Wnt signaling pathway, suggests a role in modulating this pathway. Mutations in NXN may disrupt redox homeostasis and Wnt signaling, contributing to developmental abnormalities. Specifically, disruptions in this pathway have been implicated in neural tube defects. The NXN allele's effect on redox balance and Wnt signaling likely impairs proper neural development. Therefore, the biological effect of this NXN allele is associated with spina bifida. \n\n\\boxed{Spina bifida}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). In this pathway, SOD1 is the starting point, with its dysfunction leading to increased production of reactive oxygen species. This oxidative stress triggers the unfolded protein response via HSPA5 (BIP) and ATF6, ultimately leading to the upregulation of DDIT3, a gene involved in cell cycle arrest and apoptosis. Mutant SOD1 proteins are prone to misfolding and aggregation, which further exacerbates cellular stress and neurotoxicity. These mechanisms contribute to motor neuron degeneration, a hallmark of ALS. Thus, the biological effect of the SOD1 allele in this pathway is the induction of oxidative and endoplasmic reticulum stress, ultimately driving neurodegeneration. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, leading to decreased expression of DDIT3. SOD1 is a key enzyme in the detoxification of reactive oxygen species. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The dysfunction of this pathway may contribute to oxidative stress and neuronal damage, hallmark features of ALS. Thus, the biological effect of this SOD1 allele is the disruption of cellular stress response mechanisms, leading to neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 negatively regulates BIP, which in turn inhibits ATF6. ATF6 is a key transcription factor that promotes the unfolded protein response (UPR) by upregulating DDIT3, a gene involved in cellular stress response and apoptosis. Mutations in SOD1, particularly in the context of familial amyotrophic lateral sclerosis (fALS), lead to the production of toxic SOD1 protein aggregates. These aggregates disrupt mitochondrial function, cause oxidative stress, and induce ER stress, ultimately leading to motor neuron death. The pathway described highlights how SOD1 dysfunction contributes to ER stress and neuronal damage, which are central to the pathogenesis of ALS. The biological effect of the SOD1 allele is therefore the induction of neurodegeneration through impaired protein homeostasis and increased apoptosis. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein quality control. Mutations in ATXN3, specifically expansions of the polyglutamine tract, cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. In the provided pathway, ATXN3 is linked to the IP3-Ca\u00b2+ signaling cascade, suggesting its role in modulating intracellular calcium levels, which are critical for neuronal function. Dysregulation of this pathway due to ATXN3 mutations likely contributes to neuronal dysfunction and degeneration observed in SCA2. Therefore, the biological effect of the ATXN3 allele is the development of \\boxed{Spinocerebellar ataxia type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein folding and degradation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This dysfunction disrupts neuronal integrity and leads to progressive neurodegeneration. The pathway involving ATXN3 is associated with the dysregulation of calcium signaling, mitochondrial function, and apoptosis, all of which contribute to neuronal death. This genetic alteration is specifically linked to spinocerebellar ataxia type 2 (SCA2), a hereditary neurological disorder characterized by cerebellar degeneration, ataxia, and motor dysfunction. The disruption of calcium homeostasis through the mitochondrial pathway, as described, underlies the pathophysiology of this condition. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in ubiquitin-dependent proteasomal degradation. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the accumulation of dysfunctional ataxin-3, disrupting protein clearance and causing neuronal toxicity. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3 intersects with calcium signaling and mitochondrial dysfunction, which are critical in neuronal health. The accumulation of mutant ataxin-3 impairs the clearance of misfolded proteins, leading to oxidative stress and cell death, particularly in the cerebellum. This results in the clinical features of SCA2. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele plays a critical role in the VHL-RBXCullin ubiquitin ligase complex, which targets hypoxia-inducible factors (HIFs) for degradation. When VHL is dysfunctional, this complex fails to degrade HIF-1\u03b1, leading to its stabilization and activation. This results in the upregulation of downstream genes such as VEGFA, CXCL8, GLUT1, and EPO, promoting angiogenesis, inflammation, and erythropoiesis. This pathway is disrupted in VHL-haploinsufficient states, contributing to the development of clear cell renal cell carcinoma (ccRCC). The loss of VHL function leads to uncontrolled cell proliferation and tumor formation, particularly in the kidneys. The presence of VHL mutations is a hallmark of ccRCC, making it a key driver in this disease. \\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, in the context of the described pathway, is part of the VHL-RBX1-Elongin C/B-CUL2 E3 ubiquitin ligase complex, which targets hypoxia-inducible factors (HIFs) for proteasomal degradation. When VHL is mutated, this complex is destabilized, leading to the stabilization of HIF-1\u03b1 and HIF-2\u03b1. This results in the aberrant activation of HIF target genes such as VEGFA, CXCL8, GLUT1, and EPO, promoting angiogenesis, inflammation, and erythropoiesis. This dysregulation is a hallmark of clear cell renal cell carcinoma (ccRCC), where VHL loss causes constitutive HIF activation. The pathway also links to other HIF-dependent diseases, but the most characteristic and well-documented is ccRCC. \n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in ubiquitin-dependent protein degradation. Mutations in VHL disrupt this complex, leading to stabilization of hypoxia-inducible factors (HIFs), such as EPAS1 and ARNT. This results in constitutive activation of genes like VEGFA, CXCL8, GLUT1, and EPO, which drive angiogenesis, inflammation, and erythropoiesis. This dysfunctional pathway is a hallmark of clear cell renal cell carcinoma (ccRCC), where VHL inactivation leads to uncontrolled cell growth and tumor formation. The pathway's dysregulation also contributes to other cancers, but ccRCC is the most well-characterized disease associated with VHL mutations. \\boxed{Clear cell renal cell carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to oncogenic signaling by constitutively activating PI3K, leading to increased PIP3 and subsequent activation of AKT. This inhibits BAD, preventing apoptosis and promoting cell survival and proliferation. Mutations in NRAS, similar to KRAS, result in gain-of-function, driving uncontrolled cell growth. This pathway is critical in several cancers, particularly those of hematopoietic origin. The most common disease associated with NRAS mutations is **Melanoma**, where activating mutations in NRAS are frequently observed. These mutations drive tumor progression by enhancing cell survival and resistance to apoptosis. NRAS mutations are also implicated in other cancers such as lung, colorectal, and bladder cancers, but their prevalence is highest in melanoma. Therefore, the biological effect of this NRAS allele is the promotion of oncogenic growth, contributing to **Melanoma**.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to oncogenic signaling by activating the PI3K-AKT axis. This leads to the inhibition of BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. Mutations in NRAS, such as activating mutations, result in constitutive activation of the MAPK and PI3K pathways, driving uncontrolled cell growth. This mechanism is commonly observed in cancers characterized by RAS pathway activation. The most well-known disease associated with NRAS mutations is **melanoma**, particularly in cases where NRAS is mutated in conjunction with other genetic alterations. NRAS mutations are also implicated in other cancers, including non-small cell lung cancer, colon cancer, and certain leukemias. However, melanoma is the most prominent and well-documented disease linked to NRAS mutations in this pathway. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K/AKT signaling cascade. This pathway is critical for cell survival, proliferation, and growth. Mutations in NRAS, like in KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This results in resistance to apoptosis and uncontrolled cell growth. Such alterations are commonly found in cancers characterized by RAS addiction. The most well-documented disease associated with NRAS mutations is **Melanoma**, particularly in cases with BRAF wild-type mutations. These mutations drive tumorigenesis by promoting cell survival and proliferation, making NRAS a key oncogenic driver in melanoma. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this genomic pathway is the production of amyloid-beta (Abeta), which is a key component in the pathogenesis of Alzheimer's disease. The pathway shows the progression from APP to Abeta, then to PPID, and onward through mitochondrial proteins such as VDACs and SLC25 family members, ultimately involving CYCS (cytochrome c). This suggests a role in mitochondrial dysfunction and oxidative stress, both of which are linked to neurodegeneration. The accumulation of Abeta leads to the formation of plaques in the brain, neuronal damage, and cognitive decline, hallmarks of Alzheimer's disease. Therefore, this pathway contributes to the development of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is associated with the production of amyloid-beta (Abeta), a key protein in the pathogenesis of neurodegenerative diseases. The pathway starts with the cleavage of the amyloid beta precursor protein (APP) to produce Abeta, which then interacts with peptidylprolyl isomerase D (PPID) and leads to the generation of mitochondrial permeability transition pores (MPTP) through voltage-dependent anion channel (VDAC) proteins. This disrupts mitochondrial function, leading to the release of cytochrome c (CYCS) and subsequent apoptosis. This pathway is central to Alzheimer's disease, where the accumulation of Abeta and mitochondrial dysfunction contribute to neuronal death. The involvement of SLC25A family proteins further supports mitochondrial dysfunction. Therefore, this pathway contributes to the development of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this genomic pathway is the production of amyloid-beta (Abeta), which is a key component in the pathogenesis of neurodegenerative diseases. The pathway describes the conversion of APP to Abeta, which then interacts with PPID and other mitochondrial proteins, ultimately affecting mitochondrial function by involving MPTP (mitochondrial permeability transition pore) and CYCS (cytochrome c). This disruption leads to mitochondrial dysfunction and oxidative stress, contributing to neuronal damage. Mutations or dysregulation in this pathway are strongly associated with Alzheimer's disease, where the accumulation of Abeta plaques and mitochondrial impairments are central features. The involvement of VDACs and SLC25A genes further underscores the role of mitochondrial dysfunction in disease progression. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving ubiquitination and proteasome-mediated protein degradation. SOD1, a copper/zinc superoxide dismutase, is primarily involved in antioxidant defense. When mutated, it gains toxic gain-of-function properties, leading to misfolding and aggregation. This disrupts normal cellular processes, particularly in neurons, by promoting proteotoxic stress and impairing protein clearance. The accumulation of misfolded SOD1 proteins contributes to neuronal death, a hallmark of neurodegenerative diseases. This pathway is specifically associated with amyotrophic lateral sclerosis (ALS), where mutant SOD1 forms are found in affected motor neurons. The involvement of DERL1, ubiquitin genes (UBA52, UBB, UBC), and proteasome subunits (PSMA, PSMB, PSMC, PSMD) underscores the role of ubiquitin-proteasome system dysfunction in disease progression. Mutant SOD1 disrupts proteostasis, leading to neurodegeneration. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is linked to a pathway involving protein ubiquitination and proteasomal degradation. SOD1, a copper/zinc superoxide dismutase, is primarily involved in antioxidant defense. However, mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive degeneration of motor neurons. The pathway involves DERL1, ubiquitination (via UBA52, UBB, UBC), and proteasomal degradation through 26S proteasome subunits (e.g., PSMA and PSMB proteins). Mutant SOD1 can misfold, aggregate, and disrupt proteasomal function, leading to neuronal toxicity. This misfolded protein impairs proteasomal degradation, contributing to protein accumulation and neurodegeneration. The connection between SOD1 dysfunction and proteasomal stress underscores its role in ALS pathogenesis. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in the aggregation of superoxide dismutase 1, a copper-zinc containing enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. Mutations in SOD1 lead to misfolding and aggregation of the protein, which is toxic to motor neurons. This pathological process is a key contributor to the degeneration of motor neurons, leading to a neurodegenerative disorder. The pathway involving DERL1, ubiquitination, and proteasomal degradation highlights the failure in protein quality control, further exacerbating the accumulation of misfolded SOD1. This mechanism is central to the development of a specific neurodegenerative disease characterized by progressive motor neuron loss. The biological effect of the SOD1 allele is therefore the induction of a fatal, hereditary motor neuron disease. \\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (AD). These mutations lead to increased production of toxic amyloid-beta oligomers, which aggregate into plaques in the brain, contributing to neuronal dysfunction and death. The pathway described involves calcium dysregulation via the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channel (VDAC), leading to mitochondrial permeability transition pore (MPTP) opening, cytochrome c release, and activation of the intrinsic apoptosis pathway via APAF1 and caspases 9, 3, and 7. This apoptotic cascade further exacerbates neurodegeneration. Thus, PSEN1 mutations contribute to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating \u03b2-amyloid peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (AD). These mutations disrupt proteolytic processing, leading to accumulation of toxic \u03b2-amyloid plaques in the brain, which is a hallmark of AD. The pathway described involves calcium dysregulation through the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channel (VDAC), contributing to mitochondrial dysfunction and apoptosis via the intrinsic pathway, mediated by cytochrome c release, APAF1, CASP9, and ultimately CASP3 and CASP7. This cascade leads to neuronal death, reinforcing the role of PSEN1 mutations in neurodegeneration. The biological effect of the PSEN1 allele is therefore a significant contribution to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of toxic amyloid-\u03b242, which aggregates into plaques in the brain, triggering neurodegeneration. The pathway described involves calcium dysregulation through the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channels (VDACs), leading to mitochondrial dysfunction, cytochrome c release, and activation of the intrinsic apoptosis pathway via APAF1 and CASP9. This ultimately results in neuronal death. Therefore, the biological effect of the PSEN1 allele is the contribution to **Alzheimer's disease**.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele, specifically mutations in FLT3, leads to constitutive activation of the FMS-like tyrosine kinase 3 receptor. This results in continuous signaling through the STAT5 pathway, promoting uncontrolled cell proliferation and survival. The activation of PIM1 and PIM2 further enhances this oncogenic process by phosphorylating and stabilizing key proteins involved in cell cycle progression and resistance to apoptosis. These molecular alterations are strongly associated with the development and progression of acute myeloid leukemia (AML). FLT3 mutations are among the most common genetic aberrations in AML, contributing to disease aggressiveness and poor prognosis. Therefore, the biological effect of this FLT3 allele is the promotion of leukemic transformation. \\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele in this genomic pathway contributes to the activation of STAT5, leading to the upregulation of PIM1 and PIM2. This pathway is critical for cell survival, proliferation, and differentiation. Mutations in FLT3, particularly internal tandem duplications (ITDs) or mutations in the tyrosine kinase domain, lead to constitutive activation of the receptor, resulting in uncontrolled signaling. This dysregulation is strongly associated with acute myeloid leukemia (AML). FLT3 mutations are among the most common genetic alterations in AML, particularly in cases with poor prognosis. The persistent activation of STAT5 and PIM1/2 promotes leukemia cell survival and resistance to therapy. Therefore, the biological effect of this FLT3 allele is the promotion of leukemic transformation, contributing to the development of acute myeloid leukemia.\n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele, specifically mutations in the FLT3 gene, contribute to the development of acute myeloid leukemia (AML). FLT3 is a receptor tyrosine kinase that plays a key role in cell survival and proliferation. Mutations in FLT3, particularly internal tandem duplications (ITDs) or point mutations in the tyrosine kinase domain (TKD), result in constitutive activation of the kinase, leading to uncontrolled cell growth. This activation triggers downstream signaling through the STAT5 pathway, which in turn activates PIM1 and PIM2, further promoting cell survival and proliferation. These molecular events drive leukemic transformation by disrupting normal hematopoiesis and promoting the survival of abnormal blasts. Consequently, FLT3 mutations are strongly associated with AML, particularly in the context of poor prognosis and resistance to therapy.\n\n\\boxed{Acute Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 pathway described involves a signaling cascade starting with LRRK2, leading to the release of cytochrome c (CYCS), activation of APAF1, and subsequent activation of caspase 9 (CASP9) and caspase 3 (CASP3). This cascade is central to apoptosis. Mutations in LRRK2 are well-documented in Parkinson's disease (PD), where they contribute to neurodegeneration. LRRK2 is a key gene in PD, with mutations increasing the risk of developing the disease. The pathway described is consistent with apoptosis dysregulation seen in PD, where excessive or impaired cell death in dopaminergic neurons contributes to disease progression. Therefore, the biological effect of the LRRK2 allele in this context is associated with increased risk of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 pathway described involves a signaling cascade starting with LRRK2, which leads to the release of cytochrome c (CYCS), activation of APAF1, and subsequent activation of caspase 9 (CASP9) and caspase 3 (CASP3). This pathway is central to apoptosis. Mutations in LRRK2 are well-documented in Parkinson's disease, where they contribute to neurodegeneration by disrupting mitochondrial function and promoting neuronal apoptosis. The involvement of cytochrome c and caspase activation suggests that LRRK2 mutations may enhance apoptotic cell death in dopaminergic neurons, leading to progressive loss of these neurons, a hallmark of Parkinson's. Thus, the biological effect of this LRRK2 allele is the promotion of apoptosis, contributing to the development of \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway LRRK2 \u2192 CYCS \u2192 APAF1 \u2192 CASP9 \u2192 CASP3 represents a key apoptotic cascade. LRRK2, a serine/threonine kinase, modulates mitochondrial function and apoptosis. Mutations in LRRK2 are well-documented in Parkinson's disease (PD). The pathway highlights LRRK2's role in regulating cytochrome c release from mitochondria, which activates APAF1 and promotes caspase-9 and caspase-3 activation, leading to apoptosis. Dysregulated LRRK2 activity can disrupt this balance, increasing neuronal cell death, a hallmark of PD. Thus, the LRRK2 allele contributes to the pathogenesis of \\boxed{Parkinson's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **CACNA1A** gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neurotransmitter release and neuronal excitability. Mutations in **CACNA1A** are associated with **familial hemiplegic migraine (FHM)**, a rare inherited form of migraine with brainstem symptoms and hemiparesis. These mutations disrupt calcium homeostasis, leading to impaired regulation of neuronal activity and increased susceptibility to migraine attacks. The pathway described, involving extracellular calcium and the calcium channel, highlights the role of **CACNA1A** in modulating calcium influx into neurons, which is essential for normal synaptic function. Dysregulation of this process contributes to the pathophysiology of **familial hemiplegic migraine**. \n\n\\boxed{Familial hemiplegic migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel. This subunit is critical for calcium influx into neurons, playing a key role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with episodic ataxia type 2 (EA2), a neurological disorder characterized by intermittent loss of coordination. These mutations typically result in reduced calcium channel function, leading to impaired neurotransmission and neuronal hyperexcitability. In addition to EA2, CACNA1A mutations are linked to other conditions such as familial hemiplegic migraine and certain forms of cerebral cortical atrophy. The altered calcium signaling disrupts normal neural function, contributing to the clinical manifestations of these diseases. Thus, the CACNA1A allele contributes to episodic ataxia type 2.\n\n\\boxed{Episodic Ataxia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, which is critical for neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with a range of neurological disorders, most notably familial hemiplegic migraine (FHM), a form of migraine with aura. These mutations disrupt calcium homeostasis, leading to aberrant neuronal activity and vascular responses. Additionally, CACNA1A mutations have been linked to cerebellar ataxia, episodic ataxia type 2, and in some cases, sudden sensorineural hearing loss. The pathway involving extracellular calcium and the \u03b11A subunit underscores its role in calcium signaling, which is fundamental to synaptic transmission and neuronal function. Dysregulation of this pathway contributes to the pathophysiology of these neurological conditions. \\boxed{Familial Hemiplegic Migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in protein misfolding and aggregation. In the given pathway, SNCA interacts with BIP (binding immunoglobulin protein), a chaperone involved in the unfolded protein response (UPR) in the endoplasmic reticulum (ER). ERN1, a key sensor of the UPR, activates XBP1, a transcription factor critical for ER homeostasis. Mutations or overexpression of SNCA disrupt this pathway, leading to ER stress and impaired protein folding. This contributes to neurodegeneration by promoting alpha-synuclein aggregation, a hallmark of Parkinson\u2019s disease. The disruption of the ER stress response further exacerbates neuronal damage, linking SNCA dysfunction to Parkinson\u2019s disease pathology. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson\u2019s disease. In the given pathway, SNCA is upstream of BIP (binding immunoglobulin protein), which is involved in ER stress responses. ERN1 (IRE1) activates XBP1, a key transcription factor in the unfolded protein response. Dysregulation of this pathway, particularly increased alpha-synuclein, contributes to ER stress and neuronal dysfunction. Accumulation of alpha-synuclein leads to the formation of Lewy bodies, a hallmark of Parkinson\u2019s disease. Mutations or overexpression of SNCA are strongly associated with familial and sporadic forms of Parkinson\u2019s. Thus, the SNCA allele contributes to the development of Parkinson\u2019s disease through its role in ER stress and protein misfolding. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes \u03b1-synuclein, a protein involved in synaptic function. In the given pathway, SNCA interacts with HSPA5 (Binding Immunoglobulin Protein), which is central to the unfolded protein response in the endoplasmic reticulum. ERN1 (IRE1) activates XBP1, a transcription factor crucial for ER stress response. Mutations in SNCA, particularly in the context of ER stress, are strongly associated with the aggregation of \u03b1-synuclein, leading to neurodegeneration. This contributes to Parkinson\u2019s disease, where \u03b1-synuclein misfolding and aggregation form Lewy bodies, a hallmark of the disease. The pathway highlights the role of ER stress in disease progression. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for protein quality control and mitochondrial homeostasis. Mutations in PRKN lead to impaired ubiquitin-mediated degradation of damaged proteins and dysfunctional mitochondria. This contributes to neurodegeneration by promoting the accumulation of toxic proteins and oxidative stress. The pathway involving PRKN, along with UBCH7/8 and PAELR, is central to ubiquitin-mediated proteolysis. Loss-of-function mutations in PRKN are a major cause of autosomal recessive Parkinson\u2019s disease (PD). These mutations disrupt the clearance of misfolded proteins, leading to neuronal loss in the substantia nigra. PRKN mutations account for approximately 10-15% of early-onset PD cases. The resulting neurodegeneration is characterized by dopaminergic neuron loss and Lewy body formation. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for protein degradation via the ubiquitin-proteasome system. Mutations in PRKN lead to impaired ubiquitination, disrupting protein quality control and mitochondrial function. This contributes to the accumulation of damaged proteins and dysfunctional mitochondria, which are hallmarks of neurodegenerative diseases. Specifically, PRKN mutations are a major cause of autosomal recessive Parkinson's disease. Loss of parkin function results in the accumulation of alpha-synuclein and other toxic proteins, neuronal dysfunction, and dopaminergic neuron loss. Mutations in PRKN are also associated with other Parkinsonism-related phenotypes. Therefore, the biological effect of PRKN allele dysfunction is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for protein quality control and mitophagy. Mutations in PRKN lead to impaired ubiquitin-mediated degradation of damaged mitochondria, resulting in mitochondrial dysfunction and neuronal death. This contributes to neurodegenerative diseases. The pathway involving UBCH7/8 (E2 enzymes) and PRKN is central to ubiquitin-mediated proteolysis. Loss-of-function mutations in PRKN are a well-documented cause of autosomal recessive Parkinson's disease. These mutations disrupt the ubiquitin-proteasome system and mitochondrial homeostasis, leading to progressive dopaminergic neuron loss. Therefore, the biological effect of this PRKN allele is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the aggregation of alpha-synuclein, which is a hallmark of Lewy body formation in Parkinson's disease. The pathway includes genes related to the proteasome, which is responsible for degrading misfolded or damaged proteins. Impaired proteasome function, as indicated by the involvement of multiple proteasome subunits (PSMA and PSMB), can result in the accumulation of toxic alpha-synuclein aggregates. This dysfunction contributes to neuronal death in Parkinson's disease. Therefore, the SNCA allele is directly associated with the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson\u2019s disease. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein, forming Lewy bodies, which are a hallmark of Parkinson\u2019s disease. The pathway includes genes involved in proteasome function, which is essential for protein degradation. Impaired proteasome activity, as indicated by the involvement of multiple proteasome subunits (PSMA and PSMB), may contribute to the aggregation of alpha-synuclein, exacerbating neurodegeneration. This interplay between SNCA and proteasome dysfunction highlights a key mechanism in Parkinson\u2019s disease pathology. The biological effect of the SNCA allele is therefore the promotion of protein misfolding and aggregation, leading to neuronal toxicity and the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in protein misfolding and aggregation. Its interaction with the 26S proteasome, which includes subunits like PSMA and PSMB, suggests a role in proteasomal degradation. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein, contributing to the formation of Lewy bodies. This process is a hallmark of Parkinson's disease. The involvement of the proteasome pathway underscores impaired protein quality control, a key factor in neuronal dysfunction. Thus, the SNCA allele is strongly associated with Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN2 are associated with early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of toxic amyloid-\u03b242, which aggregates into plaques in the brain, a hallmark of Alzheimer's. The pathway described involves calcium dysregulation through the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channel (VDAC), leading to mitochondrial dysfunction, cytochrome c release, and activation of caspases, ultimately contributing to neuronal apoptosis. This underscores the role of PSEN2 in neurodegeneration and its contribution to Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN2 are associated with early-onset familial Alzheimer's disease. In the provided pathway, PSEN2 is part of a network involving calcium homeostasis and apoptosis. Dysfunctional PSEN2 leads to increased production of toxic amyloid-\u03b2, disrupting neuronal function and contributing to neurodegeneration. This aligns with its role in Alzheimer's disease pathology, where impaired calcium regulation and mitochondrial dysfunction trigger apoptosis via the intrinsic pathway, involving cytochrome c release, APAF1, and caspase activation. Thus, the biological effect of PSEN2 mutations is the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN2 are associated with early-onset Alzheimer's disease (AD). In the given pathway, PSEN2 is a starting point, influencing intracellular calcium dynamics via RYR3 and MCU, leading to mitochondrial dysfunction and apoptosis through the mitochondrial permeability transition pore (MPTP) and cytochrome c release, ultimately activating caspases like CASP9, CASP3, and CASP7. This cascade contributes to neuronal apoptosis, a key mechanism in AD pathology. Therefore, the biological effect of the PSEN2 allele is the contribution to the development of \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutant form is associated with Huntington's disease. In the provided pathway, HTT is part of the signaling cascade initiated by glutamate through GRM5, leading to Ca\u00b2+ influx via the mitochondrial calcium uniporter (MCU) and subsequent mitochondrial dysfunction. Mutations in HTT, particularly expansions of the CAG trinucleotide repeat, result in the production of an abnormally long huntingtin protein, which forms toxic aggregates. This leads to neuronal dysfunction and death, especially in the striatum and cortex. The resulting pathological process is characterized by progressive motor, cognitive, and psychiatric decline. Thus, the HTT allele contributes to Huntington's disease. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington's disease. In this pathway, HTT is part of the IP3 receptor complex, which regulates calcium release from the endoplasmic reticulum. Mutations in HTT, particularly the CAG trinucleotide repeat expansion, lead to the production of an abnormally long and toxic huntingtin protein. This misfolded protein disrupts cellular calcium homeostasis, mitochondrial function, and neuronal survival, ultimately triggering apoptosis via the mitochondrial pathway involving cytochrome c, APAF1, and caspase activation. The accumulation of mutant HTT leads to neurodegeneration, particularly in the striatum and cortex, resulting in the clinical features of Huntington's disease. The pathway highlights the role of HTT in calcium signaling and its critical contribution to disease progression. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington's disease. In this pathway, HTT is part of the IP3 receptor complex, which regulates calcium release from the endoplasmic reticulum. Mutations in HTT, specifically expansions of the CAG repeat in the coding region, lead to the production of an abnormal, toxic form of huntingtin. This protein disrupts cellular processes, including calcium homeostasis, mitochondrial function, and neuronal survival. The resulting dysfunction triggers apoptosis via the intrinsic mitochondrial pathway, characterized by the release of cytochrome c, activation of caspases, and ultimately neuronal death. This pathological process is the primary cause of Huntington's disease, a neurodegenerative disorder marked by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can cause neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a regulatory interaction where PRNP may modulate NOTCH1 signaling. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob disease (CJD), a rare, rapidly progressive, and fatal neurodegenerative disorder. These mutations lead to the conversion of normal prion protein (PrP^C) into the disease-associated form (PrP^Sc), triggering cellular damage and neurodegeneration. The interaction with NOTCH1 may influence cell fate and differentiation, potentially contributing to the pathogenesis. Thus, the biological effect of this PRNP allele is the development of Creutzfeldt-Jakob disease. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction between prion protein signaling and the NOTCH1 receptor, which is involved in cell differentiation and development. Mutations in PRNP, particularly those leading to misfolding or aggregation of the prion protein, are most famously associated with Creutzfeldt-Jakob Disease (CJD), a rapidly progressive and fatal brain disorder. This disease is caused by the conversion of normal prion protein (PrP^C) into an infectious, disease-associated form (PrP^Sc). The interaction with NOTCH1 may influence cellular processes that contribute to neuronal damage. Therefore, the biological effect of this PRNP allele is the contribution to \\boxed{Creutzfeldt-Jakob Disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of infectious prions. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction between the prion protein and the NOTCH1 receptor, which plays a role in cell differentiation and signaling. Mutations in PRNP, particularly those that alter the conformation of the prion protein, are most famously associated with Creutzfeldt-Jakob Disease (CJD), a rare, fatal neurodegenerative disorder. These mutations can cause abnormal prion protein accumulation, leading to neuronal damage and progressive dementia. This pathway contributes to the pathogenesis of CJD, a form of sporadic or inherited prion disease. The interaction with NOTCH1 may modulate cell signaling pathways that are disrupted in neurodegeneration. \\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin protein turnover. This gene is part of a pathway involving ubiquitin-related proteins (UB(chain), UBA52, UBB, UBC) and free ubiquitin. UCHL1's primary function is to deubiquitinate proteins, regulating protein stability and cellular processes. Mutations in UCHL1 are associated with impaired ubiquitin metabolism, leading to the accumulation of misfolded proteins. This contributes to neurodegenerative processes. The most well-documented disease linked to UCHL1 dysfunction is Parkinson's disease, where reduced UCHL1 activity is implicated in the pathogenesis of Lewy body formation and neuronal loss. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin-proteasome system regulation. Its role in the pathway UB(chain) // UCHL1* // UB(free) suggests it modulates ubiquitin processing and protein degradation. Mutations in UCHL1 are associated with impaired protein homeostasis, leading to neurodegeneration. Specifically, UCHL1 mutations contribute to Parkinson's disease by disrupting lysosomal function and promoting alpha-synuclein aggregation. This disruption impairs neuronal survival, particularly in the substantia nigra. Thus, the UCHL1 allele is implicated in the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin metabolism. Its role in the ubiquitin-proteasome system is critical for protein quality control. Mutations in UCHL1 can disrupt this process, leading to the accumulation of misfolded or damaged proteins. This is particularly relevant in neurodegenerative diseases where protein aggregation is a hallmark. The pathway involving UB(chain), UCHL1, and UB(free) reflects the dynamic regulation of ubiquitin conjugation and deconjugation. Impaired UCHL1 function contributes to the pathogenesis of Parkinson's disease, as it is associated with the accumulation of alpha-synuclein and other toxic proteins in affected neurons. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally catalyzes the conversion of superoxide radicals into hydrogen peroxide. Mutations in SOD1 lead to the production of toxic protein aggregates, which contribute to motor neuron degeneration. This pathway includes genes involved in axonal transport and dynein-mediated motility, such as DCTN1-DCTN6, ACTR1A, ACTR1B, and various DNAH and DNAI genes, all of which are critical for intracellular transport. Dysfunction in this pathway disrupts the clearance of toxic proteins and impair axonal transport, exacerbating neuronal damage. This results in the progressive loss of motor neurons, leading to the clinical features of ALS. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally breaks down superoxide radicals, protecting cells from oxidative stress. Mutations in SOD1 disrupt its function, leading to toxic gain-of-function effects in motor neurons. These mutations cause misfolding and aggregation of the SOD1 protein, which contributes to neurodegeneration. The pathway includes dynactin subunits and dynein proteins, which are involved in intracellular transport and neuronal function. Dysfunction in this pathway impairs axonal transport, leading to motor neuron death. This genetic pathway is directly linked to the development of ALS, a fatal neurodegenerative disorder characterized by the progressive loss of motor neurons. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally detoxifies reactive oxygen species. Mutations in SOD1 disrupt its function, leading to protein misfolding and aggregation, which are toxic to motor neurons. These aggregates interfere with cellular processes, including protein degradation and mitochondrial function, ultimately causing neuronal death. The pathway involving SOD1, dynactin subunits, and dynein-related proteins is critical for axonal transport and cellular homeostasis. Impairment of this network contributes to neurodegeneration. Mutations in SOD1 account for approximately 10-20% of familial ALS cases. The accumulation of misfolded SOD1 protein is a key pathological feature of the disease. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 suggests a link between oxidative stress and endoplasmic reticulum (ER) stress. SOD1 encodes superoxide dismutase 1, an enzyme that converts superoxide radicals into hydrogen peroxide. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway's involvement of ATF6 and DDIT3 indicates a response to ER stress, which is also observed in ALS. The accumulation of misfolded proteins and oxidative stress, driven by mutant SOD1, leads to neuronal death. Therefore, the biological effect of this SOD1 allele is the contribution to amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). In the given pathway, SOD1 is upstream of BIP and ATF6, which regulate DDIT3. Mutations in SOD1 lead to misfolded proteins and endoplasmic reticulum (ER) stress, triggering the unfolded protein response via ATF6 and increasing DDIT3 expression. This contributes to neuronal dysfunction and degeneration. SOD1 mutations are a well-established genetic cause of familial ALS, a neurodegenerative disease characterized by progressive loss of motor neurons. The pathway highlights how SOD1 dysfunction disrupts protein homeostasis, leading to neurotoxicity. Thus, the biological effect of the SOD1 allele is the development of amyotrophic lateral sclerosis. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, ultimately affecting DDIT3. SOD1 is a key enzyme that catalyzes the dismutation of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The altered pathway suggests a disruption in cellular stress responses, particularly the unfolded protein response, which is critical for maintaining endoplasmic reticulum homeostasis. This dysfunction contributes to neuronal death, a hallmark of ALS. Thus, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or aberrantly activated, contributes to the development of chronic myeloid leukemia (CML). This occurs through the formation of the BCR-ABL oncogene via a chromosomal translocation (t(9;22)), which results in the constitutive activation of the ABL1 tyrosine kinase. This leads to uncontrolled cell proliferation and survival by activating downstream signaling pathways, including the RAS-RAF-MEK-ERK cascade. This pathway promotes cell growth, inhibits apoptosis, and drives tumorigenesis. The continuous activation of these pathways disrupts normal hematopoiesis, leading to the accumulation of immature myeloid cells. The most notable clinical manifestation is CML, characterized by the presence of the Philadelphia chromosome. Targeted therapies such as tyrosine kinase inhibitors (e.g., imatinib) have significantly improved outcomes for patients with this disease. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, contributes to the formation of the BCR-ABL oncoprotein, which drives uncontrolled cell proliferation by constitutively activating the downstream RAS-RAF-MEK-ERK signaling pathway. This leads to genomic instability and transformation of cells, promoting malignancy. The most well-known disease associated with this pathway is chronic myeloid leukemia (CML), caused by the Philadelphia chromosome translocation t(9;22), which fuses BCR to ABL1. This fusion protein acts as a constitutively active tyrosine kinase, disrupting normal cellular regulation and leading to leukemic transformation. Other diseases, such as some cases of acute lymphoblastic leukemia (ALL), may also involve BCR-ABL. \\boxed{Chronic myeloid leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or aberrantly activated, leads to the constitutive activation of the BCR-ABL oncoprotein. This results in uncontrolled tyrosine kinase activity, which drives the downstream signaling cascade involving GRB2, SOS, RAS, RAF, MEK, and ERK. This pathway is crucial for cell proliferation, survival, and differentiation. The persistent activation of this pathway promotes uncontrolled cell growth and resistance to apoptosis, leading to the development of cancer. Specifically, the most well-known disease associated with this pathway is Chronic Myeloid Leukemia (CML). The hallmark of CML is the Philadelphia chromosome, which results from a chromosomal translocation (t(9;22)) that fuses the ABL1 gene with the BCR gene, creating the BCR-ABL fusion protein. This fusion protein is a potent driver of leukemic transformation. \\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, when mutated, leads to constitutive activation of the KIT receptor tyrosine kinase, which initiates the downstream signaling cascade: KIT \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This results in uncontrolled cell proliferation and survival, contributing to the development of various cancers. Specifically, mutations in KIT are strongly associated with gastrointestinal stromal tumors (GISTs), which arise from the interstitial cells of Cajal. These tumors are characterized by the presence of activating mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA). The continuous activation of the MAPK pathway due to KIT mutations promotes tumor growth and resistance to apoptosis. Therefore, the biological effect of the KIT allele mutation is the promotion of GISTs, a type of sarcoma. \\boxed{Gastrointestinal Stromal Tumors}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is critical for cell survival, proliferation, and differentiation. Mutations in KIT, particularly activating mutations, lead to constitutive activation of the KIT receptor tyrosine kinase, resulting in uncontrolled signaling downstream through GRB2, SOS, RAS, and the RAF-MEK-ERK cascade. This leads to dysregulated cell growth and survival. Such mutations are strongly associated with mast cell disorders, including mastocytosis and systemic mastocytosis, as well as gastrointestinal stromal tumors (GISTs). KIT mutations are also implicated in other cancers, such as certain leukemias and melanomas. The most characteristic disease linked to KIT mutations is **mast cell leukemia** and **systemic mastocytosis**, which are driven by constitutive KIT signaling. These conditions are marked by the accumulation of mast cells in tissues, leading to inflammation and organ dysfunction. \\boxed{Systemic Mastocytosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is critical in cell survival, proliferation, and differentiation. Mutations in KIT, particularly gain-of-function mutations, lead to constitutive activation of the KIT receptor tyrosine kinase, driving continuous downstream signaling through GRB2, SOS, RAS, and the MAPK/ERK cascade. This uncontrolled signaling promotes unregulated cell growth and survival, contributing to the development of malignancies. Specifically, constitutive KIT activation is a hallmark of mast cell disorders, such as mastocytosis, and is also implicated in gastrointestinal stromal tumors (GISTs). In these diseases, KIT mutations often result in tumor formation by sustaining proliferative and anti-apoptotic signals. The most well-known association is with GISTs, where KIT mutations are frequently found. \\boxed{Gastrointestinal Stromal Tumors}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele in this pathway plays a critical role in cell cycle regulation by phosphorylating the retinoblastoma protein (RB1). This phosphorylation inactivates RB1, releasing E2F transcription factors, which drive the expression of genes necessary for DNA synthesis and cell division. Mutations or overexpression of CDK4 can lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation. This dysregulation is a hallmark of several cancers, particularly those involving excessive cell growth. CDK4 overactivity is frequently observed in cancers such as breast, lung, and melanoma, and is often associated with poor prognosis. The aberrant activation of the CDK4-RB1-E2F pathway contributes to the development and progression of these malignancies. Thus, the biological effect of the CDK4 allele is the promotion of cell proliferation, contributing to \\boxed{Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele in this pathway plays a critical role in cell cycle regulation by phosphorylating RB1, which inhibits its ability to suppress E2F transcription factors. This leads to the activation of E2F, promoting cell proliferation. Mutations or overexpression of CDK4 can disrupt this regulatory mechanism, resulting in unchecked cell division. This dysregulation is a hallmark of several cancers. Specifically, alterations in CDK4 are strongly associated with melanoma, where amplification or mutations in CDK4 contribute to tumor progression by driving cell cycle entry and inhibiting cellular senescence. Additionally, CDK4 dysregulation is implicated in other malignancies such as lung and breast cancers. The pathway described is central to the G1/S transition of the cell cycle, and its disruption is a key driver in oncogenesis. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the interaction between cyclins (CCND1-3) and CDK4, leading to the phosphorylation and inactivation of the tumor suppressor RB1. This inactivation releases E2F transcription factors, promoting cell cycle progression from G1 to S phase. The CDK4 allele, when mutated or overexpressed, enhances this process, driving uncontrolled cell proliferation. This dysregulation is a hallmark of several cancers. The most notable disease associated with CDK4 pathway activation is **small cell lung cancer (SCLC)**, where amplification or mutation of CDK4 contributes to tumor growth. Additionally, CDK4 overactivity is implicated in **melanoma**, **breast cancer**, and **prostate cancer**, where it supports cell cycle progression and resistance to apoptosis. Thus, the biological effect of the CDK4 allele is the promotion of uncontrolled cell division, contributing to **small cell lung cancer**.\n\n\\boxed{Small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene plays a critical role in autophagy and protein quality control. In the context of the provided pathway, SQSTM1 interacts with components of the mitochondrial quality control network, including PINK1 and PRKN, which are involved in Parkinson's disease (PD) pathogenesis. Mutations or dysfunction in SQSTM1 can impair autophagy, leading to the accumulation of damaged proteins and organelles, including mitochondria. This disruption contributes to neurodegeneration. SQSTM1 mutations are linked to autosomal recessive early-onset Parkinsonism, characterized by progressive motor dysfunction. The gene's role in ubiquitin-mediated degradation and autophagy makes it a key player in PD. Dysfunction in SQSTM1 impairs the clearance of damaged mitochondria and protein aggregates, promoting neuronal loss. Thus, SQSTM1 dysfunction is a contributing factor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene plays a critical role in autophagy and protein degradation through its interaction with PINK1 and PRKN in the mitochondrial pathway. Mutations in SQSTM1 can disrupt this pathway, leading to impaired mitophagy and accumulation of damaged mitochondria. This dysfunction is linked to the pathogenesis of Parkinson's disease. SQSTM1 contributes to the ubiquitin-proteasome system and autophagy, and its dysfunction can result in the aggregation of misfolded proteins and neurotoxicity. Mutations in SQSTM1 have been associated with autosomal recessive Parkinsonism, a form of Parkinson's disease characterized by premature onset and progression. Therefore, the biological effect of SQSTM1 mutations is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component in the autophagy pathway, involved in the ubiquitin-proteasome system and the recruitment of damaged proteins for degradation. In the context of the provided pathway, SQSTM1 interacts with PINK1 and PRKN, which are critical in mitochondrial quality control. Mutations in SQSTM1 can disrupt this process, leading to the accumulation of damaged proteins and mitochondrial dysfunction. This contributes to neurodegenerative processes. Specifically, SQSTM1 mutations are strongly associated with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. The dysfunction of SQSTM1 impairs autophagy and proteostasis, exacerbating neuronal stress and contributing to disease progression. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway involves the production of amyloid-beta (Abeta), which initiates apoptosis via the FAS and mitochondrial pathways. This leads to the activation of caspases (CASP8, CASP9, CASP3) and the release of cytochrome c (CYCS), promoting cell death. This process is central to neurodegeneration. The accumulation of Abeta is a hallmark of Alzheimer's disease, where it disrupts neuronal function and triggers apoptotic pathways, contributing to cognitive decline and neuronal loss. Therefore, the APP allele's activity in this pathway is directly linked to the pathogenesis of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele, as depicted in the pathway, involves the production of amyloid beta (Abeta), which initiates a cascade leading to the activation of caspases and mitochondrial apoptosis. This pathway is central to neuronal cell death. Accumulation of Abeta is a hallmark of Alzheimer's disease, where it contributes to neurodegeneration by promoting apoptosis and oxidative stress. The pathway's progression from APP to cytochrome c release and caspase activation underscores its role in neurotoxicity. Mutations in APP can increase Abeta production or reduce its clearance, exacerbating the pathological process. This pathway is therefore strongly linked to the development and progression of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele involves the initiation of a pro-apoptotic pathway. APP is processed to produce amyloid-beta (Abeta), which triggers the Fas receptor, leading to activation of FADD and caspase-8. This initiates the intrinsic mitochondrial apoptotic pathway via BID, BAX, and BAK1, resulting in the release of cytochrome c and activation of APAF1 and caspase-9, ultimately leading to caspase-3 activation and cell death. This pathway is central in neuronal apoptosis. Mutations in APP that increase amyloid-beta production are strongly associated with the accumulation of toxic plaques in the brain, a hallmark of Alzheimer's disease. The disruption of apoptotic regulation via this pathway contributes to neurodegeneration. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is critical for cell survival, proliferation, and differentiation. Mutations in KIT, such as gain-of-function mutations, lead to constitutive activation of downstream effectors like PI3K and AKT. This results in the inhibition of BAD, a pro-apoptotic protein, thereby promoting cell survival. This pathway is dysregulated in several cancers. Specifically, mutations in KIT are commonly associated with gastrointestinal stromal tumors (GISTs), where activating mutations in KIT drive uncontrolled cell growth. Additionally, KIT mutations can contribute to other malignancies, including certain leukemias and mast cell disorders. The constitutive activation of the KIT-PI3K-AKT axis disrupts normal apoptotic signaling, leading to tumor progression. \\boxed{Gastrointestinal Stromal Tumor}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, through its activation of the PI3K-AKT-BAD pathway, promotes cell survival by inhibiting BAD, a pro-apoptotic protein. This leads to resistance to apoptosis and uncontrolled cell proliferation. Mutations in KIT, particularly gain-of-function mutations, result in constitutive activation of the KIT receptor tyrosine kinase, driving downstream signaling. This pathway is critical in hematopoietic cell development and is frequently dysregulated in cancers. The biological effect of an activating KIT allele is the promotion of tumor growth and survival. This contributes to the development of gastrointestinal stromal tumors (GISTs), which are highly dependent on KIT signaling. \\boxed{GIST}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is critical for cell survival and proliferation. Activation of KIT, through mutations or overexpression, leads to constitutive signaling downstream via PI3K, resulting in increased PIP3 and subsequent activation of AKT. This suppresses BAD, preventing apoptosis. Mutations in KIT, such as activating mutations in the KIT gene, are commonly associated with gastrointestinal stromal tumors (GISTs). These mutations lead to uncontrolled cell growth and tumor formation. The involvement of other genes like PIK3CA, PIK3CB, PIK3CD, AKT1/2/3, and BAD further supports the role of this pathway in tumor progression. The persistent activation of this pathway promotes cell survival and resistance to apoptosis, contributing to the development and progression of GISTs. \\boxed{GIST}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described genomic pathway, contributes to neurodegenerative disease. SOD1 encodes superoxide dismutase 1, an enzyme that normally detoxifies reactive oxygen species. Mutations in SOD1 can lead to gain-of-toxic-function, disrupting cellular homeostasis and triggering apoptosis via the mitochondrial pathway. The pathway shows SOD1 interacting with BCL2, which normally inhibits apoptosis, but mutated SOD1 can promote the release of cytochrome c (CYCS) from mitochondria, activating APAF1 and caspase-9 (CASP9), ultimately leading to caspase-3 (CASP3) activation and cell death. This apoptotic cascade is implicated in motor neuron loss. Mutations in SOD1 are a well-established cause of **Amyotrophic Lateral Sclerosis (ALS)**, a fatal neurodegenerative disorder.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a signaling pathway that regulates apoptosis. SOD1, a copper/zinc superoxide dismutase, normally detoxifies reactive oxygen species. However, mutant SOD1 proteins, particularly those associated with gain-of-toxic-function, disrupt cellular homeostasis and mitochondrial function. This leads to the activation of the intrinsic apoptotic pathway via BCL2 inhibition, release of cytochrome c (CYCS), and subsequent activation of APAF1, CASP9, and CASP3. This cascade results in neuronal apoptosis, particularly in motor neurons. This pathway is critically linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. Mutations in SOD1 are a well-documented cause of familial ALS. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that regulates apoptosis. SOD1, an antioxidant enzyme, when mutated, leads to the dysfunction of the apoptotic network. This disruption affects the balance between pro-apoptotic (BAX, BAK1) and anti-apoptotic (BCL2) factors, leading to the release of cytochrome c (CYCS) and activation of APAF1, CASP9, and ultimately CASP3. This cascade promotes cell death, particularly in neurons. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive degeneration of motor neurons. The accumulation of misfolded SOD1 protein contributes to neuronal death through the activation of apoptotic pathways. Therefore, the biological effect of this SOD1 allele is the promotion of apoptosis, contributing to the pathogenesis of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, specifically the gene *MEN1*, encodes menin, a tumor suppressor protein that functions as a scaffold in various signaling pathways, including those involving KMT2A and CDKN1B/CDKN2C. Mutations in *MEN1* lead to loss of function of menin, disrupting cell cycle regulation and apoptosis. This contributes to uncontrolled cell proliferation and tumor formation. The pathway involves KMT2A, a histone methyltransferase, and CDKN1B and CDKN2C, which are cyclin-dependent kinase inhibitors. The disruption of this pathway is associated with multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome characterized by tumors in multiple endocrine glands, including parathyroid, pituitary, and pancreatic neuroendocrine tumors. \\boxed{Multiple Endocrine Neoplasia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 gene encodes menin, a tumor suppressor protein that plays a critical role in regulating gene expression through interactions with chromatin-modifying enzymes like KMT2A. The pathway described involves MEN1 and KMT2A, which together modulate the expression of CDKN1B and CDKN2C\u2014key cyclin-dependent kinase inhibitors that control cell cycle progression. Mutations in MEN1 disrupt this regulatory network, leading to uncontrolled cell proliferation. This is central to Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary syndrome characterized by tumors in multiple endocrine glands, including parathyroid, pancreatic, and pituitary glands. The loss-of-function mutations in MEN1 result in impaired tumor suppression, contributing to the development of neuroendocrine tumors and other malignancies. \\boxed{Multiple Endocrine Neoplasia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, when mutated, leads to the loss of function of the MEN1 gene, which encodes the menin protein. Menin is a tumor suppressor that plays a critical role in regulating cell cycle progression and apoptosis by interacting with various transcription factors, including KMT2A, and modulating the expression of cyclin-dependent kinase inhibitors such as CDKN1B and CDKN2C. The genetic interaction described implies that the loss of MEN1 disrupts these regulatory pathways, promoting uncontrolled cell growth. This contributes to the development of multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome characterized by the formation of tumors in multiple endocrine organs. The pathway disruption leads to increased cell proliferation and decreased differentiation, driving the pathogenesis of MEN1 syndrome. \n\n\\boxed{Multiple Endocrine Neoplasia Type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a critical role in the Wnt signaling pathway. The pathway described involves the degradation of \u03b2-catenin (CTNNB1) by a complex including APC, GSK3B, AXIN1, and AXIN2. When APC is mutated or inactivated, this degradation is impaired, leading to the accumulation of \u03b2-catenin. This results in its nuclear translocation and activation of TCF/LEF transcription factors, driving the expression of oncogenes such as BIRC5, MYC, and CCND1. This dysregulation promotes uncontrolled cell proliferation and inhibition of apoptosis, which are hallmarks of cancer. Mutations in APC are among the earliest and most common genetic alterations in colorectal cancer. Therefore, the biological effect of this APC allele is the promotion of tumorigenesis, and it contributes to \\boxed{Colorectal Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a central role in the WNT signaling pathway. The pathway described involves the degradation of CTNNB1 (\u03b2-catenin) by a complex including APC, GSK3B, and AXIN, preventing its nuclear accumulation. When APC is mutated or inactivated, this degradation is impaired, leading to \u03b2-catenin stabilization and nuclear translocation. This activates TCF/LEF transcription factors, driving the expression of downstream genes like BIRC5, MYC, and CCND1, which promote cell proliferation and inhibit apoptosis. These molecular changes are hallmarks of uncontrolled cell growth. Mutations in APC are a key driver in colorectal carcinogenesis, as they disrupt the balance of cell proliferation and apoptosis. Therefore, the biological effect of the APC allele mutation is the promotion of colorectal cancer.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a critical role in the WNT signaling pathway. The pathway described involves the inhibition of \u03b2-catenin degradation by the APC complex (GSK3B, AXIN, and APC), allowing CTNNB1 to accumulate and translocate to the nucleus, where it activates TCF/LEF transcription factors. This leads to the upregulation of genes such as BIRC5, MYC, and CCND1, which are associated with cell proliferation and survival. Mutations in APC, particularly loss-of-function mutations, disrupt this regulation, leading to unchecked cell growth. This is a hallmark of colorectal cancer, where APC mutations are among the most common genetic alterations. The accumulation of \u03b2-catenin and activation of downstream oncogenes drive tumorigenesis. Therefore, the biological effect of the APC allele is the promotion of uncontrolled cell proliferation, contributing to the development of colorectal cancer.\n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in the pathway leading to protein ubiquitination and degradation via the 26S proteasome. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. The accumulation of misfolded or aggregated SOD1 proteins, due to impaired proteasomal degradation, contributes to neuronal toxicity. This pathway includes ubiquitin ligases such as DERL1 and components of the proteasome complex, including PSMA and PSMB subunits, which are essential for protein degradation. The disruption of this pathway in SOD1 mutant models leads to the accumulation of toxic protein species and eventual cell death. Therefore, the biological effect of the SOD1 allele in this context is the induction of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes DERL1, ubiquitination, and proteasomal degradation. SOD1, when misfolded or mutated, leads to the accumulation of toxic protein aggregates, which is a hallmark of neurodegenerative diseases. Specifically, mutations in SOD1 are well-documented as a cause of Amyotrophic Lateral Sclerosis (ALS). The pathway involves ubiquitination of SOD1, leading to its recognition and degradation by the 26S proteasome. Impairment in this process results in the accumulation of mutant SOD1, which contributes to neuronal damage and cell death. This pathway is critical for protein homeostasis, and its dysfunction directly links to the pathogenesis of ALS. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving protein ubiquitination and proteasomal degradation. SOD1, when misfolded or mutated, leads to the accumulation of dysfunctional protein aggregates, impairing proteasomal function. This process is critical in neurodegenerative diseases. Mutations in SOD1 are well-documented as a cause of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder characterized by the progressive degeneration of motor neurons. The pathway described, involving DERL1, ubiquitin ligases, and proteasome subunits, highlights the role of protein quality control in preventing neurodegeneration. Impaired proteasomal degradation due to SOD1 dysfunction leads to toxic protein accumulation, contributing to neuronal death. Therefore, the biological effect of the SOD1 allele in this pathway directly contributes to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway involving SOD1 includes dynactin subunits and dynein proteins, which are essential for intracellular transport and neuronal function. Dysfunctional SOD1 can lead to protein misfolding, oxidative stress, and neurotoxicity, ultimately contributing to motor neuron degeneration. The inclusion of these transport-related genes suggests a role in maintaining cellular homeostasis and proper axonal transport, which is crucial for neuronal survival. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally neutralizes free radicals. Mutations in SOD1 disrupt its function, leading to toxic gain-of-function effects in motor neurons. These mutations cause protein misfolding, aggregation, and oxidative stress, ultimately resulting in neuronal death. The pathway includes genes involved in axonal transport, such as dynactin subunits (DCTN1-6), actin-related proteins (ACTR1A, ACTR1B, ACTR10), and dynein axonemal heavy and light chains (DNAH1-DNAH12, DNAI1, DNAI2, DNALI1, DNAL1, DNAL4). Dysfunction in this pathway impairs intracellular transport, contributing to neuronal degeneration. SOD1 mutations are a well-established genetic cause of familial ALS, and they are linked to disease onset and progression. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented as a cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway described includes genes involved in axonal transport and dynein motor function, which are critical for neuronal health. SOD1 interacts with these components, and mutant SOD1 proteins can disrupt axonal transport, leading to neurotoxicity. This disruption contributes to the pathogenesis of ALS. Therefore, the biological effect of mutant SOD1 is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. The pathway SNCA \u2192 VMAT2 suggests a regulatory relationship where alpha-synuclein may influence vesicular monoamine transporter 2 (VMAT2), which is critical for the storage of monoamines in synaptic vesicles. Accumulation of misfolded alpha-synuclein is a hallmark of Parkinson's disease, leading to the formation of Lewy bodies and neuronal dysfunction. Mutations or overexpression of SNCA increase the risk of developing Parkinson's disease by promoting the aggregation of alpha-synuclein and disrupting dopamine homeostasis. This contributes to the progressive degeneration of dopaminergic neurons in the substantia nigra, a key feature of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. The pathway SNCA \u2192 VMAT2 highlights a regulatory relationship where SNCA influences VMAT2, a vesicular monoamine transporter. Mutations in SNCA, particularly those leading to abnormal aggregation of alpha-synuclein, are strongly associated with the pathogenesis of Parkinson's disease. These mutations contribute to the formation of Lewy bodies, a hallmark of the disease. The interaction with VMAT2 may affect dopamine storage and release, exacerbating neurodegeneration. Thus, the SNCA allele contributes to the development of Parkinson's disease by promoting toxic protein aggregation and disrupting monoamine transport. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA (synuclein alpha) gene is involved in the pathogenesis of Parkinson's disease. SNCA encodes alpha-synuclein, a protein that misfolds and aggregates in neurons, leading to the formation of Lewy bodies, a hallmark of Parkinson's disease. The interaction with VMAT2 (vesicular monoamine transporter 2), as indicated by the network definition SNCA* -| VMAT2, suggests a role in the transport of monoamines, such as dopamine, into synaptic vesicles. Mutations or overexpression of SNCA can disrupt this process, contributing to neuronal dysfunction and neurodegeneration. The accumulation of misfolded alpha-synuclein is strongly associated with the progression of Parkinson's disease. Therefore, the biological effect of this SNCA allele is the promotion of neurodegeneration and the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate, which activates carbamoyl-phosphate synthase 1 (CPS1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing urea synthesis and causing the accumulation of ammonia. This results in hyperammonemia, a life-threatening condition. NAGS mutations are associated with Hartnup disease, a rare autosomal recessive disorder characterized by impaired amino acid transport and neurologic symptoms due to ammonia toxicity. The disruption of this pathway contributes to the pathophysiology of Hartnup disease. \n\n\\boxed{Hartnup disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme activates carbamoyl phosphate synthetase I (CPS1), which is essential for ammonia detoxification. Mutations in NAGS lead to reduced CPS1 activity, causing hyperammonemia. This results in NAGS deficiency, a rare autosomal recessive disorder characterized by elevated blood ammonia levels, neurological symptoms, and potential liver dysfunction. The disrupted pathway impairs urea synthesis, leading to toxic ammonia accumulation. This condition is associated with neurological complications, including developmental delays, seizures, and in severe cases, coma or death. NAGS deficiency is classified as a urea cycle disorder. \n\n\\boxed{NAGS deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the synthesis of carbamoyl phosphate in the urea cycle. This enzyme activates CPS1, which is essential for converting ammonia into urea. Mutations in NAGS lead to reduced CPS1 activity, impairing urea cycle function. This results in hyperammonemia, a condition characterized by elevated ammonia levels in the blood, which can cause neurological damage. The specific disease associated with NAGS mutations is **hyperammonemia due to N-acetylglutamate synthase deficiency**, a rare inborn error of metabolism. This disorder typically presents in infancy with symptoms such as seizures, lethargy, and developmental delay. The primary treatment involves managing ammonia levels through dietary restrictions and medications. \\boxed{Hyperammonemia due to N-acetylglutamate synthase deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway involving SOD1 \u2192 BIP \u2192 ERN1 \u2192 XBP1 highlights its role in oxidative stress and the unfolded protein response. Mutant SOD1 proteins gain toxic gain-of-function properties, leading to neurotoxicity and motor neuron death. This pathway is central to the pathogenesis of ALS, linking oxidative stress and endoplasmic reticulum stress in disease progression. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1* allele is part of a pathway involving SOD1 \u2192 BIP \u2192 ERN1 \u2192 XBP1. SOD1 encodes superoxide dismutase 1, an enzyme that detoxifies reactive oxygen species. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive degeneration of motor neurons. The pathway involves the unfolded protein response (UPR), with ERN1 (IRE1) activating XBP1, a transcription factor that promotes ER stress adaptation. SOD1 mutations disrupt this pathway, leading to ER stress, protein misfolding, and neuronal toxicity. This disruption is a key mechanism in ALS pathogenesis. The connection between SOD1 and ALS is well-established, making this pathway critical in the disease's progression. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is part of a pathway involving SOD1 \u2192 BIP \u2192 ERN1 \u2192 XBP1. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to contribute to neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). These mutations lead to the accumulation of misfolded proteins, disrupting cellular homeostasis and triggering the unfolded protein response via the ERN1-XBP1 pathway. This cascade results in oxidative stress, endoplasmic reticulum (ER) stress, and neuronal death, hallmarks of ALS. The involvement of HSPA5 (a chaperone protein) further supports ER stress and protein misfolding. Therefore, the SOD1 allele, when mutated, contributes to the pathogenesis of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, drives oncogenic signaling by constitutively activating PI3K, leading to increased PIP3 and subsequent AKT activation. This suppresses BAD, preventing apoptosis and promoting cell survival and proliferation. Mutations in NRAS, particularly gain-of-function mutations, disrupt normal GTPase regulation, leading to sustained signaling through the PI3K-AKT pathway. This contributes to uncontrolled cell growth and resistance to apoptosis, hallmarks of cancer. NRAS mutations are commonly found in diseases such as melanoma, non-small cell lung cancer, and colorectal cancer. Specifically, NRAS mutations are a key driver in **melanoma**, where they occur in approximately 10-20% of cases, often in conjunction with BRAF mutations. These mutations contribute to tumor initiation and progression by enhancing cell survival and proliferation.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This disruption of apoptosis promotes uncontrolled cell proliferation and survival, key drivers of cancer. NRAS mutations are frequently found in melanoma, where they drive oncogenic transformation by activating the MAPK and PI3K pathways. This leads to increased cell growth, resistance to apoptosis, and angiogenesis, all hallmarks of malignant progression. Therefore, NRAS mutations are strongly associated with melanoma. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. This pathway is critical for cell survival, proliferation, and growth. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD and prevents apoptosis. This promotes uncontrolled cell growth and survival, hallmark features of cancer. NRAS mutations are commonly found in cancers such as melanoma, non-small cell lung cancer, and colorectal cancer. The persistent activation of this pathway disrupts normal cellular regulation, leading to oncogenesis. Therefore, NRAS mutations are strongly associated with the development of **melanoma** and other malignancies driven by RAS pathway activation.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cell cycle regulation, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to genomic instability and impaired tumor suppression. The listed genes\u2014CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK\u2014are downstream targets of p53, involved in cell cycle arrest, DNA repair, and apoptosis. When TP53 is mutated, these genes are not properly activated, allowing cells with damaged DNA to survive and proliferate. This contributes to uncontrolled cell growth and tumorigenesis. The most significant disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary cancer syndrome characterized by an increased risk of multiple cancers, including sarcomas, breast cancer, osteosarcoma, and leukemias. TP53 mutations are also common in various sporadic cancers, making it one of the most critical tumor suppressor genes.\n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular stress response, DNA repair, and apoptosis. Mutations in TP53 disrupt its function, leading to impaired response to DNA damage and loss of cell cycle control. This results in genomic instability and resistance to apoptosis, promoting tumor development. The listed genes\u2014CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK\u2014are downstream effectors of p53, involved in cell cycle arrest, DNA repair, and apoptosis. Dysfunction in this pathway is a hallmark of cancers characterized by genomic instability and evasion of apoptosis. The most prominent disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary cancer syndrome with high risk of multiple malignancies, including breast, osteosarcoma, and brain tumors. TP53 mutations also contribute to sporadic cancers such as lung, ovarian, and bladder cancer. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is a critical regulator of cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to genomic instability and loss of tumor suppressor activity. This pathway includes genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which collectively mediate cell cycle arrest, DNA repair, and apoptosis in response to DNA damage. Dysfunction in this pathway is a hallmark of many cancers. Specifically, TP53 mutations are strongly associated with Li-Fraumeni syndrome, a hereditary disorder that increases the risk of multiple cancers, including sarcomas, breast cancer, brain tumors, and leukemias. The TP53 allele contributes to tumorigenesis by impairing the cell's ability to respond to DNA damage and undergo programmed cell death. \\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, plays a critical role in cellular protection against oxidative stress and mitochondrial dysfunction. Mutations in PARK7 are associated with impaired protein degradation and increased susceptibility to neurodegeneration. In the context of the provided pathway (PARK7 \u2192 TP53 \u2192 DUSP1), the dysfunction of PARK7 can lead to compromised regulation of the tumor suppressor TP53 and downstream phosphatase DUSP1, which modulates MAPK signaling. This disruption contributes to neuronal death and is a key factor in Parkinson's disease. PARK7 mutations are linked to autosomal recessive Parkinsonism, characterized by dopaminergic neuron loss and motor impairments. The loss of PARK7 function disrupts cellular homeostasis, leading to the hallmark features of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1*, plays a critical role in oxidative stress response and protein degradation. Its interaction with TP53 and regulation of DUSP1 suggest involvement in cellular stress response and apoptosis. Mutations in PARK7 are associated with increased susceptibility to Parkinson's disease, as they impair its protective functions, leading to mitochondrial dysfunction and neurodegeneration. The pathway highlights PARK7's role in maintaining cellular homeostasis, and its dysfunction contributes to neuronal loss observed in Parkinson's. Therefore, the biological effect of this PARK7 allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1*, encodes a protein involved in cellular protection against oxidative stress and is critical for mitochondrial function. Mutations in PARK7 are associated with impaired protein degradation, leading to the accumulation of misfolded proteins and subsequent neurotoxicity. This contributes to the pathogenesis of Parkinson's disease. The pathway involving PARK7, TP53, and DUSP1 suggests a role in stress response and apoptosis regulation. Specifically, dysfunction in PARK7 disrupts the regulation of TP53 and DUSP1, which are key in cell survival and stress adaptation. This cascade ultimately leads to neuronal death, a hallmark of Parkinson's disease. Therefore, the biological effect of the PARK7 allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade. This results in uncontrolled cell growth and inhibition of apoptosis. Specifically, activating mutations in FGFR3 are strongly associated with the development of **bladder urothelial carcinoma**, particularly **papillary urothelial neoplasm with low malignant potential (PUNLMP)** and **non-muscle-invasive bladder cancer (NMIBC)**. These mutations drive pathological proliferation of urothelial cells, contributing to tumor formation and progression. FGFR3 mutations are also implicated in **achondroplasia**, a form of skeletal dysplasia, but the context of the pathway and the presence of oncogenic signaling suggest a role in bladder cancer. \\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell growth and differentiation. Mutations in FGFR3 can lead to constitutive activation of the downstream signaling cascade, including RAS, RAF, MEK, and ERK, ultimately increasing MYC activity. This dysregulation promotes uncontrolled cell proliferation and can contribute to oncogenesis. Specifically, activating mutations in FGFR3 are associated with **bladder cancer**, particularly **bladder urothelial carcinoma**. These mutations result in continuous signaling, driving tumor progression. FGFR3 mutations are also linked to **achondroplasia**, a form of dwarfism, but in the context of oncogenic signaling, they are most notably connected to **bladder cancer**. The activation of the RAS-ERK-MYC axis through FGFR3 mutations leads to increased cell survival, proliferation, and resistance to apoptosis, hallmark features of cancer. \\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cellular growth and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade. This results in uncontrolled cell proliferation and survival. In particular, mutations in FGFR3 are strongly associated with skeletal dysplasias, most notably achondroplasia, the most common form of short-limbed disproportionate dwarfism. These mutations typically involve missense changes, such as the G380R substitution, which impair the receptor's ability to terminate signaling properly, leading to persistent activation of the pathway. This abnormal signaling disrupts endochondral ossification, resulting in the characteristic short stature and rhizomelia seen in achondroplasia. \\boxed{Achondroplasia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when activated, initiates a signaling cascade: RET \u2192 PI3K \u2192 PIP3 \u2192 AKT \u2192 MTOR. This pathway is critical for cell growth, survival, and metabolism. Mutations in RET, particularly gain-of-function mutations, lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation. This is a hallmark of cancer. Specifically, RET activation is strongly associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome characterized by medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenomas. RET mutations also contribute to other cancers, including certain lung and renal tumors. The dysregulated PI3K/AKT/MTOR pathway drives tumor progression by enhancing cell survival, angiogenesis, and resistance to apoptosis. Therefore, RET mutations are a key driver in MEN2 and related malignancies.\n\n\\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, disrupts the RET protein's function, which is critical for cell signaling in developmental processes such as neural crest cell migration and kidney development. In the given pathway, RET activates PI3K, leading to downstream activation of AKT and MTOR, which regulate cell growth, survival, and metabolism. Mutations in RET are associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary cancer syndrome. These mutations drive uncontrolled cell proliferation and tumor formation, particularly in the thyroid, parathyroid, and adrenal glands. The dysregulated PI3K-AKT-MTOR pathway contributes to the oncogenic potential of RET mutations, promoting tumor growth and metastasis. \\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase, initiating the signaling cascade: RET \u2192 PI3K \u2192 PIP3 \u2192 AKT \u2192 MTOR. This pathway is critical for cell survival, growth, and metabolism. Dysregulation of this pathway due to RET mutations results in uncontrolled cell proliferation and inhibition of apoptosis, contributing to tumorigenesis. This is most notably associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome characterized by medullary thyroid carcinoma and parathyroid and adrenal tumors. RET mutations are also implicated in other cancers, including small cell lung cancer and certain gastrointestinal tumors. The activation of the PI3K-AKT-MTOR pathway due to RET dysfunction promotes tumor growth and resistance to apoptosis, making it a key driver in these malignancies. \\boxed{Multiple Endocrine Neoplasia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 (profilin 1) is a key regulator of actin dynamics, binding to monomeric actin and promoting its incorporation into filamentous actin structures. Mutations in PFN1 disrupt this process, leading to impaired cytoskeletal organization. This contributes to neurological disorders, particularly those involving synaptic function and axonal transport. PFN1 mutations are strongly associated with Charcot-Marie-Tooth disease type 2A (CMT2A), a hereditary motor and sensory neuropathy characterized by progressive muscle weakness and sensory loss. The disease results from defective actin filament formation, affecting nerve conduction. Thus, the biological effect of a pathogenic PFN1 allele is the disruption of actin polymerization, leading to CMT2A.\n\n\\boxed{Charcot-Marie-Tooth disease type 2A}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 encodes profilin 1, a protein that binds to monomeric actin and promotes its polymerization into filamentous actin. This process is essential for cytoskeletal dynamics, including cell motility, division, and intracellular transport. Mutations in PFN1 disrupt this process, leading to impaired actin filament formation and stability. This contributes to neurodevelopmental disorders, particularly affecting the brain. One such disease is **Familial Hemiplegic Paroxysmal Torticollis (FHPT)**, a rare genetic disorder characterized by episodic head-turning movements and motor dysfunction. PFN1 mutations are associated with disrupted neural development and function, leading to these symptoms. The pathway involving actin monomers, profilin 1, and filamentous actin is critical for neuronal integrity, and its disruption underlies the pathogenesis of this condition. \n\n\\boxed{Familial Hemiplegic Paroxysmal Torticollis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 (profilin 1) is involved in the regulation of actin dynamics by binding to monomeric actin and promoting its polymerization into filamentous actin. Mutations in PFN1 can disrupt this process, leading to impaired cellular functions reliant on actin filaments, such as cytoskeletal organization, cell motility, and intracellular transport. One well-documented disease associated with PFN1 mutations is **Meynert\u2013Graham\u2013Hutchinson syndrome**, also known as **spastic paraplegia type 11 (SPG11)**. This is a rare neurodegenerative disorder characterized by progressive lower limb weakness, spasticity, and cognitive decline. The dysfunction in actin regulation due to PFN1 mutations leads to neuronal degeneration, contributing to the clinical manifestations of the disease. \n\n\\boxed{Meynert\u2013Graham\u2013Hutchinson syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves PSEN1 and PSEN2, which are crucial for gamma-secretase activity. Mutations in PSEN1 are well-documented in familial Alzheimer's disease (AD). These mutations lead to impaired proteolytic processing of amyloid precursor protein (APP), resulting in the accumulation of toxic amyloid-beta plaques in the brain. This accumulation is a hallmark of AD and contributes to neuronal dysfunction and degeneration. The downstream events, including mitochondrial calcium dysregulation via MCU and VDACs, lead to mitochondrial stress, cytochrome c release, and activation of the intrinsic apoptotic pathway via APAF1 and CASP9, ultimately resulting in caspase-mediated cell death. Therefore, the PSEN1 allele contributes to Alzheimer's disease.  \n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), leading to the production of \u03b2-amyloid peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). These mutations disrupt normal proteolytic processing, increasing \u03b2-amyloid production and aggregation, which contributes to amyloid plaque formation in the brain. This pathological accumulation triggers neuroinflammation, synaptic dysfunction, and neuronal death. The pathway described highlights the connection between PSEN1 dysfunction and calcium dysregulation via the mitochondrial permeability transition pore (MPTP), leading to apoptosis through the activation of CASP9, CASP3, and CASP7. These events collectively contribute to neuronal loss observed in Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in Notch and amyloid precursor protein (APP) cleavage. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to impaired \u03b3-secretase function, resulting in increased production of amyloid-\u03b2 peptides, particularly the toxic A\u03b242 species. This contributes to the formation of amyloid plaques, a hallmark of Alzheimer's disease. Additionally, PSEN1 mutations can disrupt calcium homeostasis by affecting mitochondrial function and apoptosis pathways, as indicated by the genomic pathway involving MCU, MPTP, and CASP3/CASP7. These disruptions further exacerbate neuronal dysfunction and cell death. The cumulative effects of these molecular alterations directly contribute to the pathogenesis of Alzheimer's disease. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is critical for mitochondrial quality control through the ubiquitination and degradation of damaged mitochondria via the autophagy process (mitophagy). Mutations in PRKN lead to impaired mitophagy, resulting in mitochondrial dysfunction and neuronal death. This pathway is particularly important in neurons, where mitochondrial dysfunction contributes to neurodegeneration. Mutations in PRKN are associated with Parkinson's disease, specifically in cases linked to early-onset Parkinson's. The disruption of the PRKN-PLCG1-IP3-ITPR-Ca2+ pathway impairs calcium homeostasis and mitochondrial dynamics, further exacerbating neuronal damage. Thus, the biological effect of pathogenic PRKN alleles is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through ubiquitin-mediated degradation of damaged mitochondria, a process known as mitophagy. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and increased oxidative stress. This contributes to neuronal damage and degeneration. The most well-documented disease associated with PRKN mutations is Parkinson's disease. Loss-of-function mutations in PRKN are a major genetic cause of inherited Parkinson's, particularly in familial cases. These mutations disrupt the clearance of damaged mitochondria in dopaminergic neurons, leading to neurodegeneration. Therefore, the biological effect of this PRKN allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is a key component of the ubiquitin-proteasome system, involved in mitochondrial quality control and protein degradation. Mutations in PRKN lead to impaired ubiquitination, resulting in the accumulation of damaged mitochondria and neuronal dysfunction. This pathway involves PLCG1, IP3, and ITPR, which regulate intracellular calcium levels. Disruption of this pathway disrupts calcium homeostasis, contributing to neuronal death. These mechanisms are central to Parkinson's disease, where PRKN mutations cause loss of dopaminergic neurons. PRKN mutations are associated with early-onset Parkinson's disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose aberrant expression due to an expanded CAG repeat leads to the accumulation of toxic protein aggregates. This results in neuronal degeneration, particularly in the basal ganglia. The pathway involving HTT, UQCRFS1, CYTB, CYC1, and other components of complex III is critical for the electron transport chain and ATP production. Disruption of this pathway impairs mitochondrial function, contributing to neurodegeneration. The most well-known disease associated with HTT mutations is Huntington's disease, a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. The HTT allele with expanded CAG repeats is the primary genetic cause of this condition. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein implicated in Huntington's disease. Mutations in HTT, specifically expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long polyglutamine tract in the huntingtin protein. This results in protein misfolding, aggregation, and neurotoxicity, particularly in the striatum and cerebral cortex. These pathological changes cause progressive neurodegeneration, leading to motor dysfunction, cognitive decline, and psychiatric symptoms. The pathway involving HTT, UQCRFS1, CYTB, CYC1, and other components of complex III is critical for mitochondrial electron transport and ATP production. Disruption of this pathway contributes to mitochondrial dysfunction and oxidative stress, exacerbating neuronal damage. Thus, the HTT allele is directly linked to Huntington's disease. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction leads to Huntington's disease. The pathway described involves components of complex III in the electron transport chain, including genes like UQCRFS1, CYTB, CYC1, and others, which are critical for mitochondrial function. The HTT protein interacts with complex III, suggesting a role in mitochondrial energy production. Mutations in HTT, particularly CAG trinucleotide expansions, result in toxic huntingtin aggregates, disrupting mitochondrial function and causing neuronal death. This primarily affects the basal ganglia, leading to progressive motor, cognitive, and psychiatric deficits. Huntington's disease is a neurodegenerative disorder characterized by these symptoms. The involvement of HTT in mitochondrial pathways underscores its role in energy metabolism and neuronal survival. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, as part of the RET-RAS-RAF-MEK-ERK pathway, is critical in cellular signaling involved in growth, differentiation, and survival. Mutations in RET can lead to constitutive activation of this pathway, driving uncontrolled cell proliferation. This is particularly associated with cancers arising from neural crest-derived tissues. The most notable disease linked to RET mutations is Multiple Endocrine Neoplasia Type 2 (MEN2), characterized by tumors in multiple endocrine glands. RET mutations also contribute to medullary thyroid carcinoma (MTC), which is a key component of MEN2. Additionally, RET aberrations are implicated in other cancers, including lung and breast cancers, through activation of downstream RAS and RAF components. The biological effect of RET mutations is thus oncogenic, promoting tumor formation and progression. \\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase, which initiates the RET-RAS-RAF-MEK-ERK signaling pathway. This pathway is critical for cell proliferation, survival, and differentiation. Mutations in RET are associated with multiple endocrine neoplasia type 2 (MEN2), a hereditary cancer syndrome. These mutations result in tumor formation in various endocrine glands, including the thyroid, parathyroid, and adrenal medulla. RET mutations also contribute to medullary thyroid carcinoma (MTC), which is the hallmark tumor of MEN2. Additionally, RET alterations have been implicated in other cancers, such as lung and kidney tumors. Overall, RET mutations drive uncontrolled cell growth and are a key factor in the development of MEN2 and associated malignancies. \n\n\\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, activates the RET receptor tyrosine kinase, initiating the RET-RAS-RAF-MEK-ERK signaling pathway. This pathway is crucial for cell proliferation, differentiation, and survival. Mutations in RET can lead to constitutive activation of this pathway, promoting uncontrolled cell growth. This contributes to the development of multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome characterized by medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid adenoma. RET mutations are also implicated in other cancers, including certain lung and renal tumors. The most common RET mutations associated with MEN2 are found in exons 10, 11, and 12. These mutations result in gain-of-function effects, leading to increased signaling through the MAPK pathway, which drives tumorigenesis. \\boxed{Multiple Endocrine Neoplasia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PI3K* -> PIP3 -> AKT -> MTOR -> S6K pathway is a central regulator of cell growth, survival, and metabolism. Mutations in PIK3CA, which encodes the catalytic subunit of phosphatidylinositol-3 kinase (PI3K), lead to constitutive activation of the PI3K-AKT-MTOR signaling axis. This results in increased protein synthesis, cell proliferation, and resistance to apoptosis. Such dysregulation is a hallmark of several cancers. The most prominent disease associated with PIK3CA mutations is **Breast Cancer**, where these mutations are frequently observed and contribute to tumor progression by promoting cell survival and metastasis. Additionally, PIK3CA mutations are also implicated in **Colorectal Cancer**, **Endometrial Cancer**, and **Lung Cancer**, among others. These mutations drive oncogenic processes by enhancing the PI3K-AKT-MTOR pathway, making them important targets for therapeutic intervention. \\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol-3 kinase (PI3K), a key enzyme in the PI3K-AKT-MTOR signaling pathway. Mutations in PIK3CA, such as activating mutations, lead to constitutive activation of this pathway, resulting in increased downstream signaling through PIP3, AKT, and MTOR. This dysregulation promotes cell survival, proliferation, and resistance to apoptosis. Such aberrant signaling is implicated in the development and progression of various cancers. Specifically, PIK3CA mutations are commonly found in cancers such as breast cancer, colorectal cancer, endometrial cancer, and non-small cell lung cancer. These mutations contribute to tumor growth and therapeutic resistance. Therefore, the biological effect of a pathogenic PIK3CA allele is the promotion of oncogenic signaling, contributing to the development of \\boxed{Breast Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol-3-kinase (PI3K), a key enzyme in the PI3K-AKT-MTOR signaling pathway. Mutations in PIK3CA, such as activating mutations, lead to constitutive activation of this pathway, promoting cell survival, proliferation, and resistance to apoptosis. This dysregulated signaling is implicated in multiple human cancers. The pathway described (PI3K* -> PIP3 -> AKT -> MTOR -> S6K) is central to cell growth and metabolism. Mutations in PIK3CA are commonly found in cancers such as breast, colorectal, endometrial, and bladder cancer. These mutations drive tumor progression by enhancing protein synthesis and cell cycle progression. Thus, the biological effect of a pathogenic PIK3CA allele is oncogenic activity, contributing to the development and progression of cancer.\n\n\\boxed{Breast Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase that plays a critical role in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN lead to loss of function, impairing the degradation of damaged proteins and mitochondrial quality control. This contributes to the accumulation of dysfunctional proteins and mitochondrial dysfunction, which are hallmarks of neurodegenerative diseases. Specifically, PRKN mutations are strongly associated with autosomal recessive Parkinson's disease. The pathway involving UBCH7/8 (E2 enzymes) and alpha-Synuclein (SNCA) further supports this connection, as impaired ubiquitination and protein clearance are central to the pathogenesis of Parkinson's. Therefore, the biological effect of this PRKN allele is the disruption of protein homeostasis, leading to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with impaired neuronal function and the accumulation of toxic proteins. This contributes to neurodegeneration. Specifically, PRKN mutations are a major cause of autosomal recessive Parkinson's disease. The pathway includes UBCH7/8 (E2 conjugating enzymes) and alpha-Synuclein (SNCA), which is known to aggregate in Parkinson's. The loss of PRKN function disrupts ubiquitin-mediated degradation of alpha-Synuclein and other proteins, leading to neuronal dysfunction and cell death. This pathway is critical for maintaining proteostasis in neurons. The biological effect of PRKN allele dysfunction is therefore a key contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase that plays a critical role in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN lead to loss of function, impairing the clearance of damaged proteins and mitochondria. This contributes to the accumulation of toxic proteins and mitochondrial dysfunction, which are hallmarks of neurodegenerative diseases. PRKN mutations are a well-documented cause of autosomal recessive Parkinson's disease. The involvement of SNCA (alpha-synuclein) further supports a link to Parkinson's, as alpha-synuclein misfolding and aggregation are key features of the disease. Therefore, the PRKN allele contributes to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in mitochondrial quality control. PINK1 and PRKN (parkin) work together in a pathway that regulates mitochondrial integrity by ubiquitinating damaged mitochondria, marking them for degradation via autophagy. Mutations in PINK1 or PRKN disrupt this process, leading to the accumulation of dysfunctional mitochondria, which is toxic to neurons. This dysfunction is strongly associated with neurodegeneration. Specifically, mutations in PINK1 are a known cause of Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. The PINK1-PRKN pathway is critical for maintaining mitochondrial health, and its disruption contributes to the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is critical for mitochondrial quality control. PINK1 and PRKN (parkin) form a key pathway in mitophagy, the selective degradation of damaged mitochondria. PINK1 stabilizes on depolarized mitochondria and recruits PRKN, leading to ubiquitination of mitochondrial proteins and subsequent autophagic removal of dysfunctional mitochondria. Mutations in PINK1 disrupt this process, leading to mitochondrial dysfunction and accumulation of damaged mitochondria. This contributes to neuronal loss, a hallmark of Parkinson's disease. MFN1 and MFN2, which mediate mitochondrial fusion, also play a role in maintaining mitochondrial network integrity. Defects in this pathway are strongly associated with hereditary forms of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in mitochondrial quality control. PINK1 encodes a serine/threonine kinase that plays a critical role in maintaining mitochondrial integrity by phosphorylating Parkin (PRKN), an E3 ubiquitin ligase. This phosphorylation primes Parkin for translocation to damaged mitochondria, where it promotes mitophagy, the selective degradation of dysfunctional mitochondria. Mutations in PINK1 disrupt this process, leading to the accumulation of damaged mitochondria and cellular stress. This dysfunction is strongly linked to neurodegeneration. The pathway also involves MFN1 and MFN2, which are crucial for mitochondrial fusion. Together, these genes contribute to Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex, which plays a key role in the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). The pathway described, involving PSEN1 \u2192 GSK3B and interaction with KIF5+KLC proteins, suggests a connection between presenilin function, glycogen synthase kinase 3 beta (GSK3B), and microtubule transport. Impaired PSEN1 function disrupts APP processing, leading to increased amyloid-beta production and aggregation, which contributes to neurodegeneration. This pathway is central to the pathogenesis of Alzheimer's disease. The biological effect of pathogenic PSEN1 alleles is therefore the promotion of Alzheimer's disease through altered proteolytic processing and downstream neurotoxic effects. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) suggests a role in neurodegeneration through altered protein processing and transport. Disruption of this pathway leads to the accumulation of toxic amyloid-\u03b2 plaques and tau tangles, hallmark features of Alzheimer's disease. The biological effect of pathogenic PSEN1 alleles is therefore the promotion of neurotoxicity and cognitive decline, contributing directly to the development of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the proteolytic processing of amyloid precursor protein (APP). Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease. The pathway described involves PSEN1 interacting with GSK3B, a kinase involved in neuronal function and tau phosphorylation, and modulating the activity of KIF5 (kinesin family member 5) and KLC (kinesin light chain) proteins, which are crucial for intracellular transport. Dysfunction in this pathway disrupts protein trafficking and clearance, contributing to neurodegeneration. These molecular alterations are central to the pathogenesis of Alzheimer's disease. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). The pathway involves PSEN1 regulating GSK3B, a kinase involved in neuronal survival and amyloidogenesis. The interaction with KIF5 (kinesin family member 5) and KLC (kinesin light chain) suggests roles in axonal transport, which is disrupted in neurodegenerative diseases. These interactions highlight a connection between protein trafficking and the accumulation of pathological proteins. Therefore, the PSEN1 allele contributes to the pathogenesis of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). The pathway described highlights PSEN1's interaction with GSK3B, a kinase involved in neurodegenerative processes, and its association with kinesin family members (KIF5A/B/C) and kinesin light chains (KLC1-4), which are essential for intracellular transport. Dysregulation of this pathway likely impairs neuronal function and protein trafficking, contributing to the pathogenesis of Alzheimer's disease. The accumulation of toxic protein fragments, such as amyloid-beta and tau, is a hallmark of this condition. Therefore, the biological effect of PSEN1 mutations is the disruption of essential cellular processes, leading to neurodegeneration. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating \u03b2-amyloid peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). The pathway described\u2014PSEN1 \u2192 GSK3B -| (KIF5+KLC)\u2014highlights its role in regulating GSK3B, a kinase involved in neurodegeneration, and its interaction with kinesin proteins and light chains, which are involved in intracellular transport and neuronal function. Dysregulation of this pathway contributes to neuronal dysfunction and amyloid accumulation, hallmark features of Alzheimer's disease. Therefore, the biological effect of PSEN1 mutations is the disruption of critical neurodegenerative pathways, leading to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. In the given pathway, PRKN interacts with UBCH7/8 (E2 conjugating enzymes) and PAELR, suggesting a role in ubiquitination processes. Dysfunction in this pathway leads to impaired protein clearance, mitochondrial dysfunction, and neuronal death. This contributes to the pathogenesis of Parkinson's disease. Mutations in PRKN reduce its E3 ligase activity, disrupting quality control mechanisms and leading to neurodegeneration. The involvement of PRKN in ubiquitin-dependent degradation highlights its critical role in maintaining cellular homeostasis. Therefore, PRKN mutations contribute to Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase critical for ubiquitin-mediated protein degradation. Mutations in PRKN are associated with autosomal recessive Parkinson\u2019s disease. The pathway involving PRKN, along with UBCH7/8 and PAELR, is involved in ubiquitin conjugation and proteasomal degradation. Impaired PRKN function leads to the accumulation of misfolded proteins and mitochondrial dysfunction, contributing to neuronal death. This is a key mechanism in Parkinson\u2019s disease. The loss of functional PRKN disrupts quality control mechanisms, leading to neurodegeneration. Thus, mutations in PRKN directly contribute to Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN, also known as parkin, is an E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and PAELR, is implicated in protein quality control and mitochondrial function. Loss-of-function mutations in PRKN impair mitophagic clearance of damaged mitochondria, leading to neuronal dysfunction and degeneration. This contributes to the pathogenesis of Parkinson's disease. The biological effect of a pathogenic PRKN allele is the disruption of ubiquitin-mediated proteolysis, resulting in the accumulation of toxic proteins and mitochondrial dysfunction, which are key features of Parkinson's disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta (Abeta), which activates NMDA receptors (via GRIN subunits). Excessive NMDA receptor activation causes an influx of calcium ions (Ca2+), which are taken up by mitochondria through the mitochondrial calcium uniporter (MCU) and other proteins like VDAC and SLC25 family members. This mitochondrial calcium overload triggers the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating apoptosis. This pathway is central to neurodegeneration. The accumulation of Abeta and subsequent calcium dyshomeostasis are hallmarks of Alzheimer's disease. Therefore, this APP allele contributes to \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele, as described in the pathway, is the production of amyloid-beta (Abeta), which triggers a cascade involving NMDA receptors (GRIN1, GRIN2A-D), mitochondrial calcium influx via MCU and VDAC channels, leading to mitochondrial dysfunction, release of cytochrome c (CYCS), and ultimately neuronal cell death. This pathway is central to the pathogenesis of Alzheimer's disease. The accumulation of Abeta disrupts calcium homeostasis, activates glutamatergic toxicity, and initiates mitochondrial stress, culminating in apoptosis. This process is closely linked to the progressive neurodegeneration observed in Alzheimer's. Therefore, the APP allele contributes to the development of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the progression from the amyloid beta precursor protein (APP) to the formation of amyloid-beta, which activates NMDA receptors (GRIN1, GRIN2A-D). This leads to an influx of calcium ions (Ca2+), which are transported into mitochondria via the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channels (VDAC1-3), as well as solute carriers (SLC25A4, SLC25A5, SLC25A6, SLC25A31). Excess mitochondrial calcium triggers the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS), leading to apoptosis. This pathway is central to neurodegeneration. The accumulation of amyloid-beta and subsequent mitochondrial dysfunction are hallmarks of Alzheimer\u2019s disease. The APP allele contributes to the pathogenesis of Alzheimer\u2019s disease by promoting amyloid-beta production and subsequent neuronal injury. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO (thyroid peroxidase) enzyme plays a critical role in the synthesis of thyroid hormones by catalyzing the organification of iodide onto tyrosine residues in thyroglobulin (TG), forming monoiodo- and diiodotyrosine (MIT and DIT). These compounds are then coupled to form triiodothyronine (T3) and thyroxine (T4). Mutations in the TPO gene can lead to impaired iodide oxidation and hormone synthesis, resulting in congenital hypothyroidism. This condition occurs when the thyroid gland fails to produce adequate thyroid hormones, leading to developmental delays and metabolic dysfunction if left untreated. The most common disease associated with TPO dysfunction is **congenital hypothyroidism**, which can be caused by genetic defects in TPO, among other factors. \\boxed{Congenital hypothyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO (thyroid peroxidase) allele is critical for thyroid hormone synthesis. TPO catalyzes the organification of iodide onto tyrosine residues in thyroglobulin (TG), forming monoiodotyrosine (MIT) and diiodotyrosine (DIT). These intermediates then couple to form triiodothyronine (T3) and thyroxine (T4), the thyroid hormones. Mutations in TPO disrupt this process, leading to impaired hormone production. This results in hypothyroidism, where the thyroid gland fails to produce adequate hormones. TPO defects are a key cause of **Congenital Hypothyroidism**, a condition that can lead to developmental delays and metabolic disorders if untreated. This disease is often detected through newborn screening and managed with thyroid hormone replacement. \\boxed{Congenital Hypothyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe thyroid peroxidase (TPO) enzyme plays a critical role in thyroid hormone synthesis by catalyzing the organification of iodide onto tyrosine residues in thyroglobulin, forming monoiodo- (MIT) and diiodotyrosine (DIT) residues. These residues then couple to form triiodothyronine (T3) and thyroxine (T4). Mutations in the TPO gene can impair this process, leading to reduced thyroid hormone production. This deficiency results in hypothyroidism, where the thyroid gland fails to produce sufficient hormones. A specific mutation in TPO is a known cause of congenital hypothyroidism, which can lead to developmental delays if untreated. The most well-documented disease associated with TPO dysfunction is **Hashimoto's thyroiditis**, an autoimmune disorder where TPO antibodies attack the thyroid gland, causing inflammation and hypofunction. \\boxed{Hashimoto's thyroiditis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate, which is a potent activator of carbamoyl-phosphate synthase I (CPS1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing ammonia detoxification. This results in hyperammonemia, a condition characterized by elevated blood ammonia levels. The accumulation of ammonia can cause severe neurological symptoms, including seizures, encephalopathy, and developmental delays. NAGS deficiency is an autosomal recessive disorder that contributes to congenital urea cycle disorders. It is associated with neonatal-onset hyperammonemia and can lead to morbidity and mortality if untreated. The primary disease linked to NAGS mutations is \\boxed{Neonatal Hyperammonemia}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate from acetyl-CoA and glutamate, which is essential for the activation of carbamoyl phosphate synthetase I (CPS1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing ammonia detoxification. This results in hyperammonemia, a condition characterized by elevated blood ammonia levels. The specific disease associated with NAGS mutations is **N-acetylglutamate synthase deficiency**, a rare genetic disorder that causes neurological symptoms due to toxic ammonia accumulation. This condition is typically autosomal recessive and can lead to severe neurological complications if untreated. \\boxed{N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme essential for the urea cycle. This enzyme catalyzes the conversion of glutamine to N-acetylglutamate, which activates carbamoyl phosphate synthetase I (CPS1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced CPS1 activation, impairing urea synthesis and causing the accumulation of ammonia. This results in hyperammonemia, a condition characterized by elevated ammonia levels in the blood, which can be neurotoxic. The most common disease associated with NAGS mutations is **N-acetylglutamate synthase deficiency**, a rare inherited disorder that typically presents in infancy with seizures, developmental delay, and hyperammonemic encephalopathy. This disorder is a form of urea cycle disorder. \\boxed{N-acetylglutamate synthase deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 are the genetic cause of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process critical for protein quality control and stress response. Impaired autophagy due to ATXN3 dysfunction leads to the accumulation of misfolded proteins and neuronal toxicity, contributing to the pathogenesis of SCA2. This condition results in cerebellar degeneration and motor impairment. The biological effect of the ATXN3 allele, particularly in the context of this pathway, is central to the development and progression of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and transcriptional regulation. Mutations in ATXN3 are associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The gene is part of a pathway involving autophagy-related proteins such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which suggests a role in autophagy regulation. Dysfunction in this pathway may contribute to the accumulation of misfolded proteins, a common feature in neurodegenerative diseases. The specific expansion of CAG repeats in ATXN3 leads to the production of an abnormal ataxin-3 protein, which disrupts cellular processes and leads to neuronal degeneration. This genetic mutation is directly linked to SCA2, highlighting the critical role of ATXN3 in maintaining neuronal function and preventing disease.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and transcription. Mutations in ATXN3 cause Huntington's disease-like symptoms, specifically spinocerebellar ataxia type 2 (SCA2). This condition is characterized by progressive degeneration of the cerebellum and brainstem, leading to motor dysfunction. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is related to autophagy, a cellular process critical for protein quality control. Dysfunction in this pathway can impair autophagy, leading to the accumulation of misfolded proteins and neuronal death. This contributes to the pathogenesis of SCA2. The expansion of CAG repeats in ATXN3 is the primary genetic cause of this disease. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a critical signaling cascade in cell proliferation and survival. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway, driving uncontrolled cell growth. This contributes to the development and progression of various cancers. The involvement of BRAF in this pathway is strongly associated with melanoma, where the V600E mutation is found in approximately 50% of cases. Additionally, BRAF mutations are implicated in other malignancies, including colorectal, lung, and thyroid cancers. The persistent activation of MEK and ERK downstream of BRAF results in increased cell division, resistance to apoptosis, and promotion of tumor angiogenesis. Thus, BRAF mutations are a key driver in melanoma and other cancers, making them important targets for therapeutic intervention. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele, specifically mutations in the BRAF gene, contribute to the activation of the MAPK/ERK signaling pathway by promoting the phosphorylation and activation of downstream proteins such as MEK and ERK. This leads to increased cell proliferation, survival, and differentiation. Mutations in BRAF, particularly the V600E substitution, are commonly found in melanoma, where they drive uncontrolled cell growth and tumor progression. These mutations disrupt the normal regulation of cell cycle control, leading to the development and progression of melanoma. Additionally, BRAF mutations have been implicated in other cancers, including colorectal, lung, and thyroid cancers. The dysregulation of this pathway is a key driver in the pathogenesis of these malignancies. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade in cell proliferation and survival. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway by enhancing the kinase activity of BRAF. This results in uncontrolled cell growth and resistance to apoptosis. The persistent activation of MEK and ERK downstream of BRAF promotes tumorigenesis. This pathway is frequently dysregulated in various cancers. The most well-known disease associated with BRAF mutations is **melanoma**, where BRAF mutations are found in approximately 50% of cases. These mutations contribute to oncogenic transformation by driving proliferation and inhibiting apoptosis. Additionally, BRAF mutations are also implicated in other malignancies such as colorectal cancer, thyroid carcinoma, and non-small cell lung cancer. The biological effect of this BRAF allele is the promotion of malignant cell growth through sustained activation of the MAPK signaling pathway. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The SMO allele, when activated, leads to the inhibition of SUFU, allowing the GLI family of transcription factors (GLI1, GLI2, GLI3) to activate downstream targets. This pathway is critical for embryonic development, cell proliferation, and tissue patterning. Mutations or dysregulation of SMO can result in constitutive activation of the Hh pathway, leading to uncontrolled cell growth. This contributes to several diseases, most notably Basal Cell Carcinoma (BCC), a type of skin cancer. SMO mutations are frequently found in BCC, where they drive tumor progression by enhancing Hedgehog signaling. Additionally, aberrant SMO activity has been implicated in other cancers, such as medulloblastoma and certain sarcomas. Thus, the biological effect of a pathogenic SMO allele is the promotion of uncontrolled cell proliferation, contributing to the development of Basal Cell Carcinoma.\n\n\\boxed{Basal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The pathway definition indicates SMO activates GLI transcription factors, which regulate genes such as GLI1, PTCH, HHIP, and WNTs. Mutations in SMO, particularly gain-of-function mutations, lead to constitutive activation of the Hh pathway, promoting uncontrolled cell proliferation. This aberrant signaling is implicated in various cancers, most notably basal cell carcinoma (BCC), the most common human malignancy. Additionally, SMO mutations are associated with medulloblastoma and other central nervous system tumors. Inhibition of SMO, such as with vismodegib, is a therapeutic strategy in these diseases. Thus, constitutive activation of SMO contributes to tumor development by driving proliferation and suppressing differentiation. \\boxed{Basal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The pathway definition indicates that SMO interacts with SUFU and KIF7, and activates GLI transcription factors, which regulate downstream genes such as BMP2/4, HHIP, GLI1, PTCH, and WNT family members. Mutations in SMO, particularly gain-of-function mutations, lead to constitutive activation of the Hh pathway. This dysregulation contributes to uncontrolled cell proliferation and tissue overgrowth. In humans, such mutations are strongly associated with basal cell carcinoma (BCC), the most common type of skin cancer. Additionally, SMO mutations have been implicated in other malignancies, including medulloblastoma and certain sarcomas. The hallmark of SMO-driven cancers is the loss of normal growth control due to persistent Hh signaling. \\boxed{Basal Cell Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele involves the cleavage of APP to produce amyloid-beta (Abeta), a key component in the formation of plaques in the brain. This process is central to the pathogenesis of Alzheimer's disease. The pathway described, APP \u2192 Abeta \u2192 CxIV \u2192 H2O, reflects the involvement of APP in amyloid-beta production, which is neurotoxic and leads to neuronal damage. The presence of various COX subunits suggests a potential link to mitochondrial dysfunction, which is also implicated in Alzheimer's disease. The accumulation of Abeta disrupts cellular homeostasis, leading to synaptic dysfunction and neuronal loss. Thus, this pathway is directly associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele involves the production of amyloid beta (Abeta), a key component in the pathogenesis of Alzheimer's disease. The pathway shows APP being converted into Abeta, which can aggregate and form plaques in the brain, a hallmark of Alzheimer's. The involvement of multiple COX subunits suggests a potential link between mitochondrial function and the pathophysiology of the disease, as mitochondrial dysfunction is associated with neurodegeneration. The accumulation of Abeta disrupts cellular homeostasis, leading to neuronal damage and cognitive decline. This pathway is central to the development of Alzheimer's disease, where abnormal Abeta accumulation contributes to synaptic dysfunction and neuronal death. Therefore, the biological effect of this APP allele is the promotion of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele is the production of amyloid-beta (Abeta) peptides through the sequential cleavage of the APP protein. This process is central to the pathogenesis of Alzheimer's disease. The accumulation of Abeta plaques in the brain is a hallmark of Alzheimer's, leading to neuronal dysfunction and cognitive decline. The pathway described, APP -> Abeta -> CxIV -> H2O, reflects the cleavage of APP and the subsequent processing of Abeta, which can aggregate and form toxic plaques. The involvement of cytochrome c oxidase subunits suggests a link between mitochondrial dysfunction and Abeta toxicity, further contributing to neurodegeneration. Therefore, this pathway is strongly associated with Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cell growth, differentiation, and survival. It is activated by ligands such as neuregulins (NRG1-NRG4). Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to various diseases. Specifically, alterations in ERBB4 have been implicated in cancer, particularly in breast, lung, and ovarian cancers, where it promotes tumor progression. Additionally, ERBB4 is involved in neural development, and its dysfunction has been linked to neurological disorders such as schizophrenia and autism spectrum disorder. However, the most well-documented disease associated with ERBB4 is cancer. \\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in signaling pathways involved in cell proliferation, differentiation, and survival. The NRG (neuregulin) family of ligands binds to ERBB4, activating downstream signaling cascades such as the MAPK and PI3K/AKT pathways. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to uncontrolled cell growth and tumorigenesis. Specifically, altered ERBB4 activity has been implicated in the development and progression of various cancers, including non-small cell lung cancer (NSCLC), glioblastoma, and certain breast cancers. Additionally, ERBB4 has been associated with neurodevelopmental disorders due to its role in nervous system development. However, its most well-documented pathological contribution is in cancer. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is involved in the NRG (neuregulin) signaling pathway, which plays a critical role in neuronal development, myelination, and cell survival. ERBB4, as a receptor tyrosine kinase, mediates signals from NRG ligands, influencing processes such as axon guidance and synaptic plasticity. Mutations or dysregulation in ERBB4 can disrupt these processes, contributing to neurological disorders. Specifically, aberrant ERBB4 activity has been linked to schizophrenia, a neurodevelopmental disorder characterized by impairments in cognition, emotion regulation, and social behavior. Altered ERBB4 signaling may affect neural circuitry and synaptic function, contributing to the pathophysiology of schizophrenia. Thus, the biological effect of this ERBB4 allele is associated with increased risk of \\boxed{Schizophrenia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 pathway involves ATXN1, which encodes ataxin-1, a protein associated with transcriptional regulation. The network shows ATXN1 interacts with RORA and KAT5, influencing genes such as ITPR1, SLC1A6, and GRM1. Mutations in ATXN1 are known to cause spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of coordination. The expanded CAG repeats in ATXN1 lead to dysfunctional ataxin-1, disrupting calcium homeostasis and synaptic transmission, which contributes to neuronal degeneration. This pathway's dysregulation is central to the pathogenesis of SCA1. The involvement of RORA and KAT5 suggests epigenetic and transcriptional dysregulation in disease progression. Therefore, the biological effect of this ATXN1 allele is the development of \\boxed{Spinocerebellar ataxia type 1}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene encodes ataxin-1, a protein involved in transcriptional regulation. The pathway indicates that ATXN1 interacts with RORA and KAT5, influencing the expression of ITPR1, SLC1A6, and GRM1, which are involved in neuronal signaling and ion homeostasis. Mutations in ATXN1 are well-documented in Spinocerebellar Ataxia Type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of motor coordination. Expansion of the CAG repeat in ATXN1 leads to the production of an abnormally long polyglutamine tract in ataxin-1, resulting in protein misfolding, aggregation, and neuronal toxicity, particularly in cerebellar Purkinje cells. This genetic mutation disrupts normal neuronal function and contributes to the hallmark symptoms of SCA1. \\boxed{Spinocerebellar Ataxia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene encodes ataxin-1, a protein involved in transcriptional regulation and RNA processing. The pathway indicates that ATXN1 interacts with RORA and KAT5, leading to the regulation of ITPR1, SLC1A6, and GRM1, which are involved in calcium signaling, glutamate transport, and metabotropic glutamate receptor function. Mutations in ATXN1, particularly expansions of the CAG repeat, lead to the production of an abnormally long ataxin-1 protein, resulting in neuronal dysfunction. This is the underlying cause of \\boxed{Spinocerebellar ataxia type 1 (SCA1)}, a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The disease results from the toxic gain-of-function of the mutant ATXN1 protein, leading to neuronal death in the cerebellum and other brain regions."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in regulating the p53 tumor suppressor pathway. CDKN2A encodes for p14ARF, which inhibits MDM2, a protein that normally degrades TP53. By preventing MDM2-mediated degradation of TP53, CDKN2A ensures proper activation of TP53, which in turn upregulates CDKN1A, a G1-phase cell cycle inhibitor. CDKN1A, along with cyclin D1/2/3 and CDK4/6, inhibits RB1, preventing E2F-driven transcription of S-phase genes. Loss or mutation of CDKN2A disrupts this regulatory network, leading to unchecked cell proliferation. This pathway dysfunction is a key driver in several cancers. The most well-known disease associated with CDKN2A mutations is **Melanoma**, as well as other cancers like Pancreatic Cancer and Prostate Cancer. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that inhibits cyclin-dependent kinases, including CDK4 and CDK6, by binding to them and preventing their activation. It also interacts with MDM2, which normally targets TP53 for degradation. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its tumor-suppressive functions. Mutations in CDKN2A disrupt this regulatory network, leading to loss of TP53 function and unchecked cell proliferation. This contributes to uncontrolled cell growth and genomic instability. CDKN2A mutations are strongly associated with melanoma, particularly in the context of familial melanoma and melanoma susceptibility syndromes. They also play a role in other cancers, such as breast and pancreatic cancer, but are most prominently linked to melanoma. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of CDK4 and CDK6, which are essential for cell cycle progression. In the given pathway, CDKN2A negatively regulates MDM2, which normally targets TP53 for degradation. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its tumor suppressive functions, including induction of CDKN1A and inhibition of cyclin D-CDK4/6 complexes. This ultimately leads to cell cycle arrest. Loss or mutation of CDKN2A disrupts this regulatory network, allowing unchecked cell proliferation and evasion of apoptosis. This contributes to the development of various cancers, particularly those with impaired p53 pathways. The most significant disease associated with CDKN2A dysfunction is melanoma, but it is also implicated in pancreatic cancer, sarcomas, and other malignancies. \\boxed{Melanoma}"]]